imiquimod has been researched along with Disease Models, Animal in 506 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.40) | 18.2507 |
| 2000's | 12 (2.37) | 29.6817 |
| 2010's | 240 (47.43) | 24.3611 |
| 2020's | 252 (49.80) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Chen, C; Dai, L; Liu, J; Liu, L; Pan, Y; Sui, Q; Sun, H; Sun, L; Wen, X; You, Y; Yuan, H | 1 |
| Dou, H; Hou, Y; Kong, W; Li, D; Li, J; Liang, J; Lu, L; Pan, Y; Wang, J; Wang, T; Xia, X | 1 |
| Chen, S; Chen, X; Lin, Z; Xi, L; Zheng, Y; Zhou, Q | 1 |
| Amento, E; Kang, GJ; Kaur, M; Mechanic, J; Ravikumar, P; Welihinda, A; Yadav, S | 1 |
| Egawa, S; Ito, M; Kamata, M; Mizukawa, I; Shimizu, T; Tada, Y; Takeshima, R; Uchida, H; Watanabe, A | 1 |
| Asahina, R; Chow, Z; Dainichi, T; Egawa, G; Ishida, Y; Kabashima, K; Kitoh, A; Miyake, T; Nomura, T; Okuno, T; Otsuka, M; Yokomizo, T | 1 |
| Abdollahifar, MA; Dehpour, AR; Haddadi, NS; Hedayatyanfard, K; Kazemi, K; Shayan, M; Shokrian Zeini, M; Solaimanian, S | 1 |
| Bassaganya-Riera, J; Chauhan, J; Hontecillas, R; Leber, A; Maturavongsadit, P; Tubau-Juni, N | 1 |
| Bai, Q; Chan, CKW; Choi, CHJ; Choi, PC; Han, R; Ho, LWC; Lee, LKC | 1 |
| Choi, YA; Jang, YH; Jeong, GS; Kang, J; Kim, N; Kim, SH; Lee, S | 1 |
| Kang, J; Khang, D; Kim, N; Kim, SH; Kwon, TK; Lee, S | 1 |
| Chen, C; Chen, X; Chen, Z; Dou, X; Huang, C; Huang, H; Huang, X; Jian, X; Jiang, B; Li, Z; Liu, X; Ren, X; Shen, C; Yang, L; Yu, B; Zhong, W | 1 |
| Vinardell, MP | 1 |
| Fang, H; Li, C; Lu, Z; Ma, L; Shao, S; Wang, G; Xue, K | 1 |
| Agócs, R; Dobosy, P; Kemény, L; Németh, I; Pajtók, C; Pap, D; Szabó, AJ; Szebeni, B; Tulassay, T; Vannay, Á; Veréb, Z; Veres-Székely, A | 1 |
| Abdellatif, AAH; Abdulmonem, WA; Al Rugaie, O; Alhumaydhi, FA; Aljasir, M; Aljohani, ASM; AlKhowailed, MS; Alnuqaydan, AM; Alsagaby, SA; Alsuhaibani, SA; Alwashmi, ASS; Babiker, AY; Elsheikh, SY; Hegazy, AMS; Mousa, AM; Seleem, HS; Soliman, KEA; Yosof, MYR | 1 |
| Iida, K; Ishikawa, J; Iwamoto, T; Iwata, A; Kageyama, T; Makita, S; Nakajima, H; Suto, A; Suzuki, K; Tanaka, S; Yabe, Y; Yokota, M | 1 |
| Blauvelt, A; Boki, H; Kimura, T; Miyagaki, T; Okochi, H; Sato, S; Suga, H; Sugaya, M | 1 |
| Jiang, J; Kuai, L; Li, B; Li, X; Liu, T; Luo, Y; Ru, Y; Song, J; Sun, X; Xing, M; Zhang, H | 1 |
| Chen, Y; He, Y; Li, W; Ma, Y; Shangguan, Y; Zhao, Y | 1 |
| Alalaiwe, A; Chuang, SY; Fang, JY; Huang, TH; Lin, CF; Nguyen, TMH; Wang, PW | 1 |
| Di, T; Fu, J; Guo, J; Guo, X; Li, P; Liu, Q; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J | 1 |
| Deng, M; Li, S; Li, X; Luo, S; Su, Y; Tan, S; Tang, G; Wu, R; Zhang, P; Zhang, Q; Zhang, S; Zhang, X; Zhao, M; Zhu, Y | 1 |
| Chen, D; Gao, J; Guo, W; Jiang, X; Ke, B; Lai, Y; Ma, H; Shao, F; Sun, Y; Wu, Z; Xu, Q; Yan, W; Zhu, Y | 1 |
| Gangwar, RS; Gudjonsson, JE; Ward, NL | 1 |
| Assani, I; Chen, L; Huang, RZ; Jin, Q; Kang, YY; Li, Y; Liao, ZX; Lv, SM; Su, M; Sun, B; Wang, CG; Wang, DZ; Wang, JW; Wang, MX; Wu, XZ; Zhao, SF | 1 |
| Chen, Z; Di, T; Li, P; Lv, J; Wang, Y; Xu, J; Yang, H; Zhou, T | 1 |
| Cao, G; Cao, Z; Liu, Z; Shi, Y; Sun, R; Xu, Q; Yang, N; Zhang, C | 1 |
| Chen, X; Li, B; Li, HJ; Li, W; Li, X; Liu, L; Lu, Y; Sun, XY; Ze, K; Zhou, YQ | 1 |
| Han, D; Li, F; Lu, S; Meng, L; Mou, K; Wang, B; Xu, J; Zhang, W; Zhao, Y; Zhou, Y; Zhu, W | 1 |
| Chen, J; Dang, E; Fang, H; Li, Q; Ma, J; Pang, B; Qiao, H; Qiao, P; Shao, S; Sun, Z; Wang, G; Wang, L; Xue, K; Yu, C | 1 |
| Du, JC; Han, X; Liu, XH; Yan, Y; Zhang, F; Zhu, R | 1 |
| Chen, N; Li, L; Tian, C; Xia, Z; Yang, S; Zhang, G | 1 |
| Cui, J; Li, W; Sun, H; Zhai, S; Zhang, P; Zhao, Y | 1 |
| Assmann, JC; Morrison, PJ; Mrowietz, U; Schwaninger, M; Suhrkamp, I; Wettschureck, N | 1 |
| Lin, X; Liu, Q; Qian, J; Tang, J; Xie, Q; Xiong, S; Zhou, Z | 1 |
| Guo, H; Li, M; Liu, H | 1 |
| Aljuffali, IA; Fang, JY; Huang, JR; Lin, CF; Tseng, CH; Yang, SH | 1 |
| Chung, JH; Jo, SJ; Kim, EJ; Kim, SJ; Kim, TG; Lee, Y; Ohn, J; Suh, JH | 1 |
| Agostini, SBN; Alves, CO; Bernardes, MTCP; Carvalho, FC; da Silva, LP; Gonçalves, RV; Novaes, RD; Pereira, GR | 1 |
| Rasool, M; Srikanth, M | 1 |
| Cheng, LY; Deng, Y; Feng, XY; Guo, DJ; Guo, WJ; Hua, L; Li, FL; Liu, X; Wang, Y; Xi, RF; Ze, K; Zhu, JY; Zhu, SJ | 1 |
| Dang, N; Fan, H; Huang, S; Li, X; Liu, N; Ma, G; Qin, L; Wang, J; Yang, T; Zhang, P | 1 |
| Fang, X; Li, W; Ling, S; Liu, X; Luo, Y; Wang, A; Xu, B; Yao, X; Zhang, S; Zhou, Y; Zong, W | 1 |
| Im, DS; Koh, JM; Son, SE | 1 |
| Du, Z; Gu, H; Huang, J; Li, C; Liu, G; Shi, Y; Xu, Y; Zhang, L; Zhou, W | 1 |
| Alani, R; Ali, D; Ardianto, C; Ayoub, R; Goh, KW; Jarrar, Q; Jilani, J; Moshawih, S | 1 |
| Goto, H; Habe, K; Iida, S; Kondo, M; Matsushima, Y; Naka, M; Nakai, Y; Nishii, M; Yamanaka, K | 1 |
| Ahmad, SF; Al-Harbi, NO; Alanazi, AZ; Alasmari, F; Alharbi, M; Alhazzani, K; Almutairi, M; Alqahtani, F; Alqarni, SA; Ibrahim, KE; Nadeem, A | 1 |
| Bieler, T; Daiber, A; Karbach, S; Keller, K; Knopp, T; Kropp, A; Lagrange, J; Molitor, M; Münzel, T; Rauh, M; Ringen, J; Sies, K; Titze, J; Waisman, A; Wenzel, P; Wild, J | 1 |
| Correa Atella, G; Donato-Trancoso, A; Romana-Souza, B | 1 |
| Adachi, A; Egawa, G; Gunzer, M; Honda, T; Hossain, MR; Ikuta, K; Kabashima, K; Kanameishi, S; Komine, M; Miyake, T; Ohtsuki, M; Takimoto, R | 1 |
| Bansal, AK; Parmar, PK; Rohit, A; Sharma, N; Wasil Kabeer, S | 1 |
| Chen, LC; Cheng, YP; Guo, JW; Liu, CY | 1 |
| Cho, H; Hwang, ES; Je, JH; Jeon, Y; Jeong, MG; Kang, J; Lee, K; Song, J | 1 |
| Chen, XY; Landeck, L; Man, XY; Wang, P; Wang, ZY; Xu, F; Yan, BX; Zheng, M; Zhou, Y | 1 |
| Chen, Z; Hu, L; Lei, X; Li, S; Liu, J; Liu, Y; Song, Z; Wei, Z; Xiang, R; Yang, Y | 1 |
| Guo, M; Lai, R; Lei, Q; Xian, D; Xian, L; Xu, J; Yang, Y; Zhao, Y; Zhong, J | 1 |
| Dashti, M; Haghnnavaz, N; Moghadam, M; Pordel, S; Rezaee, M; Sankian, M; Shobeiri, SS | 1 |
| Chen, X; Kuang, Y; Li, J; Liu, N; Liu, P; Peng, C; Yan, B; Yi, X; Zhu, W | 1 |
| Chen, Y; Li, X; Song, S; Wang, Y; Zhu, J | 1 |
| Cai, Y; Chen, L; Ding, C; Hu, X; Li, X; Liu, N; Qin, H; Rouchka, EC; Tieri, D; Wang, L; Xu, Q; Xue, F; Yan, J; Zheng, J | 1 |
| Arakawa, Y; Arita, T; Asai, J; Katoh, N; Masuda, K; Nakamura, K | 1 |
| Abe, T; Hida, T; Ichimiya, S; Ikegami, I; Inoue, KI; Kamada, Y; Kamekura, R; Kamiya, S; Kamiya, T; Kobayashi, K; Sato, T; Takaki, H; Uhara, H; Yanagi, M | 1 |
| Bai, Y; Cao, L; Chen, S; Chen, W; Fan, W; Ge, H; Li, B; Li, Z; Liu, M; Luo, S; Mao, Y; Shen, J; Sun, L; Wang, D; Wang, Y; Yong, L; Yu, Y; Zhang, C; Zhang, R; Zhen, Q | 1 |
| Chen, Z; Gao, WQ; Hao, W; Lin, J; Tang, J; Wang, L; Xu, H; Yang, M; You, Q; Zhao, X | 1 |
| Wu, X; Xiang, S; Xiang, Y | 1 |
| Di, T; Feng, F; Hu, X; Li, P; Meng, Y; Qi, C; Wang, Y; Zhang, X; Zhao, J; Zhao, N | 1 |
| Daien, CI; King, NJC; Macia, L; Mielle, J; Moore, RJ; Ni, D; Pinget, GV; Simpson, S; Stanley, D; Taitz, J; Tan, JK | 1 |
| Chen, J; He, L; Liu, L; Niu, Y; Qi, H; Qin, S; Yu, S | 1 |
| AAl-Haidari, R; Ah Mostafa, M; Alhaddad, A; N Al Busaidi, H; Samman, W; Samuel Kelechi, M; Sarkar, D; Sm, F | 1 |
| He, L; Li, C; Li, M; Qiao, P; Shao, S; Wang, G; Wang, Z; Zhang, J; Zhang, K; Zhang, Y | 1 |
| Huang, C; Huang, F; Li, B; Lin, D; Wang, S; Xu, C; Zhang, T | 1 |
| Carlos, ECDS; Cristovão, GA; Ribeiro, BCS; Romana-Souza, B; Silva, AA | 1 |
| Li, M; Liu, C; Liu, S; Lu, J; Tang, J; Zhou, X; Zhu, L | 1 |
| Jiang, C; Li, H; Qi, Q; Zhou, Y; Zou, W | 1 |
| Dai, C; Guo, X; Jiang, F; Wang, J; Wu, X; Yin, Q | 1 |
| Chen, Y; Chikazawa, S; Ichimasu, N; Katagiri, K; Kobayashi, K; Suzuki, S | 1 |
| Hou, JJ; Jia, HY; Qiu, HY; Wu, Y; Zhang, MD; Zhou, ML | 1 |
| Huang, J; Jin, H; Wang, Y | 1 |
| Bai, D; Cheng, X; Hao, J; Li, Q; Lu, F; Sun, T; Zhang, B; Zhang, Y | 1 |
| Li, W; Yang, C; Yang, W | 1 |
| Duan, J; Duan, R; Gao, S; Li, J; Li, X; Ma, X; Qin, Y; Shi, R; Zhang, L; Zhao, R | 1 |
| Chang, YH; Chen, HY; Chuang, JH; Li, FA; Li, SC; Lin, TK; Liou, CW; Shen, FC; Sheu, JJ; Su, YJ; Wang, PW; Weng, SW | 1 |
| Huo, R; Li, H; Shen, B; Sheng, H; Shu, J; Sun, H; Sun, Y; Zhai, T; Zhang, J | 1 |
| Li, H; Wang, J; Wang, S; Xiong, Y; Zhou, X | 1 |
| Abram, CL; Bevilacqua, D; Cassatella, MA; Caveggion, E; Cestari, T; Constantin, G; Costa, S; De Sanctis, F; Donini, M; Dusi, S; Gasperini, S; Girolomoni, G; Lonardi, S; Lowell, CA; Pettinella, F; Rodegher, P; Scapini, P; Tagliaro, F; Ugel, S; Vermi, W; Zenaro, E | 1 |
| Cui, H; Guo, H; Li, S; Li, X; Li, Y; Li, Z; Nandakumar, KS | 1 |
| Asaji, M; Chang, J; Hattori, H; Higo, T; Hikoso, S; Ichi, I; Inui, H; Ito, K; Kamada, Y; Kanno, K; Koseki, M; Nishida, M; Nishihara, S; Ohama, T; Okada, T; Okuzaki, D; Omatsu, T; Ono, M; Saga, A; Saibara, T; Sakata, Y; Tanaka, K; Yamashita, S; Zhu, Y | 1 |
| Chen, C; Chen, M; Chen, X; Hou, G; Kuang, Y; Li, J; Li, L; Lin, L; Liu, P; Peng, C; Su, J; Yan, B; Zhu, W | 1 |
| Chenyang, W; Fushida, N; Hamaguchi, Y; Horii, M; Ikawa, Y; Kitano, T; Komuro, A; Matsushita, T; Nakabori, I; Sawada, K; Xibei, J | 1 |
| Bhavana, V; Chary, PS; Mehra, NK; Pardhi, E; Singh, SB; Sulthana, S | 1 |
| Li, K; Nandakumar, KS; Ou, J; Wang, T; Wu, H | 1 |
| Lian, LH; Nan, JX; Wu, YL; Yang, HX; Zhan, ZY; Zhang, ZH | 1 |
| Christensen, PKF; Hansen, AK; Høyer-Hansen, MH; Koch, J; Larsen, J; Martel, BC; Skov, S | 1 |
| Ando, M; Fukuyama, T; Iwashita, N; Kushiro, M; Takagi, Y; Yamaguchi, H | 1 |
| Li, H; Li, X; Lin, N; Liu, L; Lu, Y; Luo, D; Sun, X; Wang, J; Yin, C; Zhang, M; Zhou, Y | 1 |
| Egusa, C; Harada, K; Hayakawa, K; Maeda, T; Okubo, Y | 1 |
| Chen, X; Lei, Y; Liu, Y; Lyu, C; Yang, Y; Ye, Y; Zhang, T; Zhou, X | 1 |
| Burnet, M; Cloos, N; Cruces, S; Fischer, T; Geiger, J; Geiger, S; Guezguez, J; Guse, JH; Keppler, M; Laufer, S; Martorelli, M; Riexinger, L; Sandri, TL; Schwamborn, A; Späth, N; Straß, S | 1 |
| Chodaczek, G; Kupczyk, P; Makarec, A; Makuch, S; Woźniak, M; Ziółkowski, P | 1 |
| Chang, YC; Chen, CH; Chen, PJ; Chen, SH; Fang, SY; Hwang, TL; Tsai, SC; Tsai, YF; Tseng, HH; Wang, YH | 1 |
| Choi, JH; Jung, SY; Kim, DW; Lee, KA; Park, S; Park, SH | 1 |
| Chen, X; He, Y; Huang, X; Jia, H; Liu, T; Shan, W; Sun, R; Yang, Q | 1 |
| Abdallah, OY; Atia, NM; El-Aal, SAA; Ibrahim, SSA; Reda, AM; Shahine, Y; Sheta, E | 1 |
| Chen, C; Chen, M; Chen, X; Kuang, Y; Li, J; Li, L; Liu, P; Peng, C; Su, J; Yan, B; Zhou, Y; Zhu, W | 1 |
| Chen, X; Chu, C; Han, J; Huang, X; Li, X; Lin, Z; Wang, F; Xiong, Y; Xu, R | 1 |
| Bang, J; Bareja, R; Desman, G; Ding, W; Elemento, O; Eljalby, M; Granstein, RD; Miller, LS; Reilly, MD; Vyas, NS; You, J; Yusupova, M; Zippin, JH | 1 |
| Li, G; Li, L; Li, S; Li, X; Wu, F | 1 |
| Cai, X; Du, J; Gao, W; Gong, H; Lu, H; Xiao, H; Xu, J; Yang, Y | 1 |
| Liu, Q; Ren, C; Wang, D; Wang, Q; Zhang, H | 1 |
| Jiang, Y; Lai, Y; Lu, S; Wang, L | 1 |
| Al Rudaisat, M; Amanullah, M; Chen, S; Chen, X; Cheng, H; Hua, C; Liang, Q; Song, Y; van der Veen, S; Wang, X; Zhou, C | 1 |
| Amalia, SN; Baral, H; Fujiwara, C; Hosoi, M; Inoue, Y; Ishikawa, M; Kosaka, K; Motegi, SI; Ogino, S; Sekiguchi, A; Shibasaki, K; Torii, R; Uchiyama, A; Yamazaki, S; Yokoyama, Y | 1 |
| Lin, J; Lin, P; Lu, YY; Shi, HY | 1 |
| Chen, S; Ding, K; Huang, H; Huang, T; Lv, W; Ma, S; Rong, Z; Wang, X; Yang, B; Zhang, X; Zheng, B; Zhong, Y | 1 |
| Feng, S; Guo, D; Guo, T; Li, A; Li, S; Li, Y; Wang, B; Wang, Q; Yin, S | 1 |
| Han, X; Li, P; Lin, Y; Liu, X; Xie, X; Zhang, L | 1 |
| Fu, D; Fu, X; Hu, H; Li, J; Li, M; Song, X; Tian, Z; Wang, Q; Yan, D; Yang, Z; Zheng, S | 1 |
| Antal, D; Bai, P; Demény, MÁ; Dull, K; Kiss, B; Kovács, I; Póliska, S; Pór, Á; Szántó, M; Szegedi, A; Szöllősi, AG; Ujlaki, G | 1 |
| An, B; Hong, N; Kong, Q; Liu, F; Sang, H; Shan, Y; Wu, Y; Yu, P; Zhang, X | 1 |
| Bai, Y; Chen, W; Ge, H; Li, B; Li, Z; Liu, H; Mao, Y; Sun, L; Wang, D; Wang, Y; Yu, Y; Zhen, Q | 1 |
| Chu, MY; Lee, CL; Liu, CT; Song, YC; Wang, CM; Yen, HR | 1 |
| Pu, S; Sun, L; Zhao, K; Zhou, D | 1 |
| Li, P; Lin, Y; Liu, X; Wang, N; Xie, X; Zhang, L | 1 |
| Cao, Z; Du, L; Han, C; Li, M; Liu, Z; Wei, J; Xu, Q; Zhang, C; Zhu, X | 1 |
| Bhattacharyya, S; Gorai, P; Modak, BK; Mondal, A; Mondal, NK; Pramanik, A; Sarkar, D | 1 |
| Becker, M; Bezdek, S; Bieber, K; Gross, N; Gullberg, D; Gupta, Y; Hdnah, A; Ibrahim, SM; Künzel, S; Ludwig, RJ; Mousavi, S; Prüssmann, J; Sadik, CD; Sayegh, JP; Sezin, T; Vorobyev, A | 1 |
| Chan, CI; Chen, SJ; Hseu, JH; Hseu, YC; Vadivalagan, C; Wu, PY; Yang, HL; Yen, HR | 1 |
| Abreu, EP; Bittencourt, FV; Gontijo, JRV; Schwan, NV | 1 |
| Bhuvarahamurthy, S; Kalaiyazhagan, A; Meganathan, J; Ramamoorthy, R; Venugopal, B; Vijayapoopathi, S | 1 |
| Ben-Shabat, S; Feinshtein, V; Sintov, AC; Yariv, D; Zamansky, M | 1 |
| Chen, K; Li, XZ; Liu, X; Tian, JY; Wang, Y; Xu, ZH; Yuan, M; Zhang, JC | 1 |
| Ansari, B; Dashti, M; Haghnavaz, N; Moghadam, M; Pordel, S; Rezaee, M; Sankian, M; Shobeiri, SS | 1 |
| Goddard, WA; Han, JH; Jang, Y; Kim, JH; Kim, SK; Kim, YC; Ko, B; Kwak, SH; Lee, JE; Park, HD; You, H | 1 |
| Jing, X; Liu, Z; Meng, L; Su, H; Zhang, Z | 1 |
| Fukazawa, Y; Kiguchi, N; Kishioka, S; Saika, F | 1 |
| Bai, J; Fu, D; Guo, Y; Hu, H; Li, J; Li, M; Qu, Z; Si, W; Song, G; Song, X; Tian, Z; Wang, K; Wu, M; Wu, X; Xu, M; Yan, D; Yang, Z; Zhou, X | 1 |
| Guillaume, P; Lariosa-Willingham, K; Leonoudakis, D; Simon, F; Stratton, J; Walker, K; Warren, L | 1 |
| Collado-Diaz, V; Friess, MC; Hagedorn, O; Haghayegh Jahromi, N; Halin, C; Jadhav, M; Leroux, JC; Polomska, A; Proulx, ST; Vallone, A; Vranova, M; Willrodt, AH | 1 |
| Chen, H; Dai, Z; Deng, J; Han, L; Liang, CL; Liu, C; Liu, H; Lu, C; Wang, Y; Wei, J; Yan, Y | 1 |
| Bahramizadeh, M; Esmaily, H; Golmohammadzadeh, S; Hatamipour, M; Jafari, MR; Jafarian, AH; Kiafar, B; Moosavian, SA; Nikpoor, AR; Rezaeemehr, Z | 1 |
| Agarwal, R; Anderson, BR; Bagnowski, K; Daniel, WL; Giljohann, DA; Kang, RS; Liu, H; Nallagatla, S; Paller, AS; Radecki, S; Schook, A; Yu, JM | 1 |
| Azam, T; Beckman, K; de Graaf, DM; Dinarello, CA; Fischer, S; Fujita, M; Højen, JF; Kristensen, MLV; Lunding, LP; McKee, AS; Swartzwelter, BJ; Tolstrup, M; Wade, MT; Wegmann, M | 1 |
| Chen, W; He, Q; Long, J; Shi, Q; Zhang, B | 1 |
| Aminzadeh-Gohari, S; Feichtinger, RG; Kofler, B; Koller, A; Lang, R; Leitner, J; Sanio, P; Sternberg, F; Weber, DD; Weiss, R | 1 |
| Hayashi, H; Ikeda, Y; Ju, N; Morishita, R; Nakagami, H; Nakamura, A; Rakugi, H; Shimamura, M; Yoshida, S | 1 |
| Akdis, CA; Boyman, O; Hafner, J; Impellizzieri, D; Kolios, AGA; Kurzbach, D; Nguyen, TT; Nilsson, J; Özcan, A; Sahin, D; Tan, G; Yawalkar, N | 1 |
| Carmichael, DJ; Han, G; Havnaer, A; Lee, HH; Martinez, LR | 1 |
| Bao, YL; Jiang, BW; Li, YX; Liu, L; Song, ZB; Tan, LP; Wang, SY; Wang, Y; Yu, CL; Zhang, WJ | 1 |
| Antal, D; Bai, P; Hegedűs, C; Kiss, B; Márton, J; Méhes, G; Szántó, M; Szegedi, A; Szödényi, A; Virág, L | 1 |
| Fukaya, S; Fukuyasu, A; Hau, CS; Hayashi, K; Ishikawa, T; Kamata, M; Ohnishi, T; Shimizu, T; Tada, Y; Takeoka, S; Tanaka, T | 1 |
| Feng, H; Kong, Y; Liu, Z; Lu, Q; Su, Y; Wang, H; Wu, H; Wu, R; Zhang, S; Zhao, M | 1 |
| Huang, C; Le, K; Sun, Y; Wu, S; Xie, M; Xu, M; Zhao, M | 1 |
| Guo, J; He, F; Long, F; Tu, J; Yin, Z | 1 |
| Chen, D; Jia, J; Li, H; Lin, Y; Liu, J; Mo, X; Wang, N; Yan, F; Zheng, Y | 1 |
| Hiebert, P; Kim, TG; Kim, YS; Lee, J; Song, K; Werner, S | 1 |
| Cao, Z; Fu, W; Ma, X; Sun, N; Wang, Y; Xu, J; Zhou, K; Zhu, C | 1 |
| Chen, H; Han, L; Li, L; Lu, C; Lu, Y; Wei, J; Zhang, HY; Zhong, XQ | 1 |
| Chen, J; Dang, E; Fu, M; Li, W; Lin, Y; Qiao, H; Wang, G; Zhang, C; Zhu, Z | 1 |
| Chen, T; Fu, L; Li, L; Liu, Y; Lu, Y; Nie, J; Wang, W; Wu, B; Zhang, D; Zhang, L; Zhou, P | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alanazi, WA; Alasmari, AF; Alasmari, F; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Ibrahim, KE; Nadeem, A | 1 |
| Han, D; Huynh, M; Hwang, ST; Jena, PK; Sheng, L; Shi, Z; Wan, YY; Wu, X; Yu, S; Zhou, Y | 1 |
| Cao, J; Che, D; Gao, J; Geng, S; Han, H; Hao, Y; He, L; Kong, S; Liu, R; Peng, B; Shi, J; Wang, J; Zhang, Y; Zheng, Y | 1 |
| Altavilla, D; Arcoraci, V; Bitto, A; Ieni, A; Irrera, N; Lentini, M; Mannino, F; Minutoli, L; Pallio, G; Squadrito, F; Squadrito, V; Vaccaro, M | 1 |
| Bentley, MVLB; Caron, AL; Del Ciampo, JO; Kravicz, M; Medina, WSG; Praça, FG; Silvestrini, AVP; Suzuki, I; Viegas, JSR | 1 |
| Chen, H; Duan, X; Huang, Y; Jin, Z; Liu, N; Liu, X; Ming, Z; Zhang, S | 1 |
| Chang, DC; Hsiao, CY; Hung, CF; Li, HJ; Pu, CM; Wu, NL | 1 |
| Abou-Faycal, C; Aouadi, I; Armspach, JP; Bahram, S; Carapito, R; Chatelus, E; De Cauwer, A; Frisch, B; Georgel, P; Macquin, C; Mariotte, A; Paul, N; Pichot, A; Po, C; Sibilia, J | 1 |
| Alalaiwe, A; Chen, EL; Fang, JY; Hsiao, CY; Lien, WC; Lin, CF; Lin, CY | 1 |
| Colantoni, A; Di Fusco, D; Di Grazia, A; Dinallo, V; Laudisi, F; Marafini, I; Monteleone, G; Monteleone, I; Stolfi, C | 1 |
| Fukai, S; Fukushi, M; Hanada, K; Iio, K; Irie, T; Komakura, K; Mizukami, Y; Obika, S; Ohtake, F; Oikawa, D; Phuong, HT; Saeki, Y; Sakamoto, S; Sato, Y; Sugawara, K; Tanaka, K; Terawaki, S; Tokunaga, F; Tsuruta, D | 1 |
| Acinas, O; Alvarez, P; Augustín, JJ; Genre, F; Iglesias, M; Mendiguren, MA; Merino, J; Merino, R; San Segundo, D; Tamayo, E; Vázquez, JA | 1 |
| Chen, J; Chen, R; Chen, Y; Chen, Z; Cui, L; Diao, H; Gong, Y; Hu, Y; Shi, Y; Wang, Y; Yu, Q; Yu, Y; Zhang, X | 1 |
| Chao, YH; Chen, HH; Huang, WC; Lee, PY; Lin, CC; Tung, YT | 1 |
| Briseño-Lugo, PE; Cancino-Diaz, JC; Cancino-Diaz, ME; Díaz-Toalá, I; Gómez-Chávez, F; Gutiérrez-Gonzalez, G; Mendoza-Figueroa, JS; Pérez-Tapia, SM; Rodríguez-Martínez, S; Torales-Cardeña, A; Vázquez-Sánchez, EA; Zapi-Colín, LA | 1 |
| Benedetti, M; Bueno, CA; Gentilini, MV; Marini, V; Nabaes Jodar, MS; Nebreda, AD; Salinas, FM; Shayo, C; Vázquez, L; Viegas, M | 1 |
| Angelatos, AS; King, NJC; Macia, L; Mazur, E; Niewold, P; Pinget, GV; Tan, J | 1 |
| Matsushima, Y; Mizutani, K; Okada, K; Yamanaka, K | 1 |
| Cheng, Y; Guan, W; Kuang, H; Liu, Y; Sun, Y; Tan, J; Yang, B | 1 |
| Choi, CW; Kang, JS; Kim, BR; Kim, Y; Yang, S; Youn, SW | 1 |
| Balamuralidhara, V; Gupta, NV; Iriventi, P; Osmani, RAM | 1 |
| Li, J; Liu, A; Tu, Y; Wang, Q; Zhang, B; Zhao, W | 1 |
| Choo, YK; Jang, WG; Jeon, SH; Kim, CH; Lee, JH; Park, JH; Park, MY | 1 |
| Blanzat, M; Caminade, AM; Clement, E; Fruchon, S; Jebbawi, R; Lacoste, E; Oukhrib, A; Poupot, R; Turrin, CO | 1 |
| Brain, SD; Caton, PW; Evans, EA; Frame, J; Hannen, RF; Kodji, X; Philpott, MP; Rizvi, A; Sayers, SR; Shaikh, M; Xia, Y | 1 |
| Ahmad, J; Ahmad, MZ; Algahtani, MS; Nourein, IH | 1 |
| Alalaiwe, A; Fang, JY; Lin, ZC; Tang, KW; Tseng, CH; Wang, PW | 1 |
| Bawankule, DU; Chanotiya, CS; Khan, F; Rai, VK; Saxena, A; Shukla, A; Sinha, P; Tandon, S; Yadav, KS; Yadav, NP | 1 |
| Bae, EJ; Hao, L; Jang, HY; Park, BH; Park, J | 1 |
| Anbardar, MH; Chavoshy, F; Tamaddon, AM; Zadeh, BSM | 1 |
| Gao, XH; Geng, L; Guo, H; Lan, XO; Qi, RQ; Wang, HX; Xu, YY; Yang, Y; Yu, YJ | 1 |
| Gyulai, R; Horváth, S; Kemény, Á; Pintér, E | 1 |
| Ding, X; Hong, S; Kuai, L; Li, B; Li, H; Li, X; Liu, L; Lu, Y; Luo, Y; Na, C; Ru, Y; Song, J; Sun, X; Xing, M; Zhang, R; Zhou, Y | 1 |
| Huang, X; Li, Q; Mei, Z; Tu, C; Wang, W; Xiang, X; Xiong, H; Zhao, Z | 1 |
| Cai, S; Chen, H; Chen, L; Dong, L; Gong, F; Li, B; Li, J; Mao, J; Qian, Y; Shi, J; Tan, Z; Xiao, Y; Xu, Y; Zeng, F; Zheng, F | 1 |
| An, S; Bai, H; Chen, J; Dang, E; Li, Q; Lin, Y; Meng, H; Sha, N; Shao, S; Wang, G; Zhu, Z | 1 |
| Chong, J; Hsu, DK; Huynh, M; Hwang, ST; Mendoza, L; Shi, Z; Wu, X; Yamada, D | 1 |
| Chen, H; Chen, Y; Han, L; Liu, H; Lu, C; Tang, B; Yan, Y; Yu, J | 1 |
| Chen, Y; Dai, Z; Han, L; Huang, RY; Liang, CL; Liu, H; Lu, C; Qiu, F; Yan, Y; Zhang, Q | 1 |
| Chen, W; Hu, X; Jiang, J; Liu, J; Liu, W; Qie, C; Xie, X | 1 |
| Cowin, AJ; Fenix, K; Grubor-Bauk, B; Kopecki, Z; Wijesundara, DK | 1 |
| Amagai, M; Iriki, H; Ito, H; Kurebayashi, Y; Mukai, M; Takahashi, H | 1 |
| Chen, B; Jing, H; Kuang, Z; Li, L; Liu, J; Liu, Y; Qiu, X; Sun, T; Wang, L; Wu, D; Wu, M; Wu, W; Wu, Y; Wu, Z; Yi, S; Zhou, S | 1 |
| Ampawong, S; Aramwit, P; Buaban, T; Kanjanapruthipong, T; Kengkoom, K; Muangkaew, W; Sukphopetch, P | 1 |
| Bäumer, W; Brehm, R; Bruer, G; Gutzmer, R; Kietzmann, M; Langeheine, M; Rode, K; Rossbach, K; Schaper-Gerhardt, K; Wahle, K; Werfel, T | 1 |
| Bian, G; Chen, Z; Deng, S; Feng, H; Li, Y; Wang, L; Wang, Y; Xie, Q; Yu, Y | 1 |
| Adams, DR; Kim, HY; Park, JW; Park, WJ; Pyne, NJ; Pyne, S; Shin, SH; Yoon, HS | 1 |
| He, D; Li, JQ; She, SY; Tong, RS; Zhang, SH; Zhong, ZD | 1 |
| Akiyama, M; Fukushima, H; Hasegawa, Y; Iwata, Y; Saito, K; Sugiura, K; Tanaka, Y; Watanabe, S | 1 |
| Dang, EL; Fu, M; Qiao, HJ; Wang, G; Xiao, CY; Zhang, C; Zhu, ZL | 1 |
| Dinarello, CA; Fauerbye, A; Iversen, L; Johansen, C; López-Vales, R; Nielsen, AL; Rønholt, K; Vestergaard, C | 1 |
| Di, T; Guo, J; Guo, X; Li, P; Liu, Y; Meng, Y; Qi, C; Wang, Y; Zhang, L; Zhao, J | 1 |
| Khaledi, M; Nabavi, MB; Nazemi, M; Rezaie, A; Safdarian, M; Sharif Makhmal Zadeh, B | 1 |
| Atwood, S; Chen, Z; Dai, X; Dragan, M; Greenberg, E; Gutierrez, G; Haensel, D; Han, W; Kessenbrock, K; Nguyen, Q; Pearlman, E; Shi, Y; Sun, P; Vu, R; Wu, J | 1 |
| Elder, JT; Mi, QS; Mishina, Y; Parajuli, N; Yi, Q; Yu, Q; Zhou, L | 1 |
| Aoudjit, F; Berrazouane, S; Côté, MF; Defrêne, J; Esparza, N; Gobeil, S; Pagé, N; Tessier, PA | 1 |
| Lou, F; Sun, Y; Wang, H | 1 |
| Choo, ABH; Lai, RC; Lane, EB; Lim, SK; Sim, WK; Zhang, B | 1 |
| Dandekar, S; Garcia-Melchor, E; Haas, KN; Huynh, M; Hwang, ST; Law, T; Millar, NL; Nguyen, M; Rolston, M; Santos Rocha, C; Shi, Z; Wan, YY; Wu, X; Yamada, D | 1 |
| Chao, T; Gu, Y; He, L; Huang, R; Jia, T; Kong, E; Li, W; Liang, Y; Liu, Q; Liu, Z; Lu, L; Maeda, T; Pierre, P; Tian, S; Wang, Y; Yang, W; Zhang, L; Zhou, B | 1 |
| Gao, S; Li, Q; Liu, W; Mao, Y; Xin, Y | 1 |
| Bai, C; Chen, H; He, X; Huang, Z; Lei, Y; Li, Y; Liu, Z; Sheng, L; Tang, L; Tian, X; Wei, F; Xu, X; Yang, Y; Yu, B; Zhang, B; Zhou, X | 1 |
| Aira, LE; Debes, GF | 1 |
| Azouz, A; Goriely, S; Istaces, N; Le, A; Nguyen, M; Thomas, S | 1 |
| Bao, X; Chen, W; Ding, Y; Gao, Y; Lu, J; Peng, C; Shi, Y; Xing, K; Yi, X; Zhen, T; Zhu, S | 1 |
| Fujimoto, M; Naka, T; Nakajima, H; Nakajima, K; Ohko, K; Sano, S; Serada, S; Takaishi, M | 1 |
| Arima, Y; Hara, Y; Ito, M; Iwama, A; Kaibori, Y; Kamiyama, F; Kawada, A; Kitahata, K; Matsuo, K; Nagakubo, D; Nakayama, T; Oiso, N; Quan, YS; Yoshie, O | 1 |
| Chen, L; Qin, B; Shen, Z; Sun, C; Wang, S; Xie, Z; Yang, J | 1 |
| Bamberg, C; Bivik Eding, C; Enerbäck, C; Helleday, T; Karsten, S; Köhler, I; Pham, T; Scobie, M; Sjögren, F; Verma, D; Warpman Berglund, U | 1 |
| Jin, M; Li, H; Li, S; Wang, H; Xu, Y | 1 |
| Cheng, J; Hu, J; Kong, H; Lu, F; Luo, J; Qu, H; Zhang, M; Zhang, Y; Zhao, Y | 1 |
| Asano, Y; Kamata, M; Mitsui, A; Okura, I; Sato, S; Shimizu, T; Tada, Y | 1 |
| Cui, Y; Fei, WM; Guo, XD; Hao, YY; Liang, L; Zhang, C; Zhao, ZQ | 1 |
| Dong, P; Feng, J; Hu, Q; Li, D; Li, J; Liu, D; Liu, S; Shen, R; Sun, J; Tao, W; Wan, H; Yan, Y; Zhang, F; Zhang, L; Zhang, R | 1 |
| Bae, EJ; Hao, L; Kwon, BM; Mao, Y; Park, BH; Park, J | 1 |
| Cargnelutti, DE; Fernandez-Muñoz, JM; Germanó, MJ; Innocenti, AC; Jahn, GA; Mackern-Oberti, JP; Moreno-Sosa, T; Neira, FJ; Pietrobon, EO; Sánchez, MB; Valdez, SR; Zoppino, FCM | 1 |
| Cai, R; Gu, J; Li, N; Lu, C; Wei, H; Wu, D; Xie, F; Zhang, M | 1 |
| Hisa, K; Inoue, R; Ogawa, C; Suzuki, T; Yamamoto, Y; Yonejima, Y | 1 |
| Chen, H; Han, L; Ma, Y; Qiong, H; Xu, J; Yan, K; Zhang, N; Zhang, Z | 1 |
| Chang, L; Fujita, Y; Hashimoto, K; Hashimoto, Y; Ishima, T; Matsue, H; Shinno-Hashimoto, H; Wei, Y | 1 |
| Chen, J; Cheng, Q; Dou, H; Guo, M; Hou, Y; Lu, L; Qiao, X; Wang, H | 1 |
| Alić, A; Elez-Burnjaković, N; Hadžić, M; Haverić, A; Haverić, S; Lojo-Kadrić, N; Mujezinović, I; Pojskić, L; Ramić, J; Smajlović, A | 1 |
| Dhakal, H; Jang, YH; Kang, J; Kim, JY; Kim, N; Kim, SH; Lee, SJ; Lee, WJ; Park, KD | 1 |
| Alavala, S; Jerald, MK; Nalban, N; Sangaraju, R; Sistla, R | 1 |
| Liu, Y; Luo, S; Wang, H; Xi, C; Xiong, C | 1 |
| Gulino, GR; Lories, R; Martens, T; Van Mechelen, M; Vanden Berghe, P | 1 |
| Chen, Z; Di, T; Li, P; Wang, Y; Zhai, C; Zhao, J | 1 |
| Jensen, LE; Kilpatrick, LE; Sun, S | 1 |
| Bian, L; Blevins, M; Deng, H; Fan, B; Fujita, M; Han, G; High, W; Huang, M; Li, H; Norris, D; Wang, XJ; Yang, C; Zhang, C; Zhao, R | 1 |
| Fujimoto, M; Fujisawa, Y; Ichimura, Y; Ishitsuka, Y; Kubota, N; Mizuno, S; Nakamura, Y; Okiyama, N; Saito, A; Takahashi, S; Tanaka, R; Watanabe, R | 1 |
| Chan, TC; Chang, WY; Huang, WC; Krueger, JG; Lee, MS; Tsai, TF | 1 |
| Ding, XJ; Jiang, JS; Kuai, L; Li, B; Li, W; Liu, L; Luo, Y; Ru, Y; Song, JK; Yin, SY; Zhang, Y | 1 |
| Estadt, SN; Gharaee-Kermani, M; Gruszka, D; Gudjonsson, JE; Kahlenberg, JM; Liu, J; Lowe, L; Reed, TJ; Theros, J; Tsoi, LC; Ward, NL; Wolf-Fortune, SJ; Xing, X | 1 |
| Chen, Y; Geng, Y; Lai, S; Wang, J; Zhang, S; Zhou, T; Zhou, Y | 1 |
| Ajebo, E; Bollag, WB; Chen, X; Choudhary, V; Cohen, E; Custer, VE; Hossack, S; Kaddour-Djebbar, I; Uaratanawong, R; Yang, R | 1 |
| Di, T; Li, N; Li, P; Lin, Y; Meng, Y; Wang, M; Wang, Y; Xie, X; Xu, X; Zhai, Y; Zhao, J | 1 |
| Dong, Z; Han, X; Liu, Z; Peng, R; Wang, C; Xu, J; Xu, L; Yang, R; Zhu, W; Zhuang, Q | 1 |
| Bai, R; Bi, Z; Dong, Y; Dou, R; Li, D; Liu, Z; Mao, C; Su, W; Xiangfei, D; Yang, P; Yang, Y; Yuan, X | 1 |
| Kamata, Y; Kosaka, R; Matsuda, H; Ogawa, H; Sakaguchi, A; Takahashi, N; Takamori, K; Tominaga, M; Umehara, Y | 1 |
| Ahmad, SF; Al-Harbi, NO; Attia, SM; El-Sherbeeny, AM; Fardan, AS; Ibrahim, KE; Nadeem, A | 1 |
| Li, P; Li, X; Lin, Y; Liu, W; Wang, Y; Xie, X; Zhang, L | 1 |
| Bürger, C; Diehl, S; Han, YY; Kaufmann, R; Lang, V; Ringel, C; Shirsath, N; Weigert, A; Wolf, P | 1 |
| Huo, R; Li, H; Li, N; Shen, B; Shen, Z; Wu, P; Xu, H | 1 |
| Bevilacqua, D; Cassatella, MA; Costa, S; DeFranco, AL; Girolomoni, G; Hou, B; Lonardi, S; Lowell, CA; Marini, O; Panato, A; Rodegher, P; Scapini, P; Tagliaro, F; Vermi, W | 1 |
| Hawiger, D; Hsueh, EC; Li, L; Liu, X; Luo, H; Opejin, A; Peng, G; Wang, T; Wang, Y; Ye, J | 1 |
| Alflen, A; Denny, M; Hartmann, AK; Langguth, P; Lopez, PA; Probst, HC; Radsak, MP; Schild, H; Stassen, M; Tenzer, S; von Stebut, E | 1 |
| Jeon, YJ; Kim, TY; Lee, JH; Sah, SK; Shin, J; Yang, HS | 1 |
| Cho, S; Jin, SP; Kim, MW; Koh, SJ; Lee, DH; Park, HS; Yoon, HS; Yu, DA; Yun, HT | 1 |
| Bernard, FX; Bodet, C; Buffière-Morgado, A; Camus, M; Couderc, E; Favot, L; Garcia, M; Guillet, G; Huguier, V; Jégou, JF; Lacombe, C; Lecron, JC; Levillain, P; Mcheik, J; Morel, F; Paquier, C; Pohin, M; Yssel, H | 1 |
| Böhm, B; Brüne, B; Burkhardt, H; Sadik, CD; Scholz, T; Weigert, A | 1 |
| Alsaleh, G; Bahram, S; Blüml, S; Chan, S; Flacher, V; Georgel, P; Holcmann, M; Kastner, P; Kirstetter, P; Mariotte, A; Mueller, C; Nehmar, R; Niederreiter, B; Puchner, A; Saferding, V; Schabbauer, G; Sibilia, J; Vandamme, T; Voisin, B | 1 |
| Akiyama, T; Jensen, LE; Sakai, K; Sanders, KM; Yanushefski, KM; Yosipovitch, G; Youssef, MR | 1 |
| Brunner, SM; Ebner, S; Holub, BS; Kofler, B; Koller, A; Lang, R; Reitsamer, HA; Schwarzenbacher, D; Sternberg, F; Stockinger, J; Trost, A; Vidali, S | 1 |
| Korn, T; Muschaweckh, A; Petermann, F | 1 |
| Dainichi, T; Egawa, G; Honda, T; Kabashima, K; Kitoh, A; Kusuba, N; Miyachi, Y; Nakajima, S; Otsuka, A | 1 |
| Abdelaziz, EZ; Bayomy, NA; Okasha, EF | 1 |
| Cao, J; Dang, E; Fu, M; Jin, B; Li, W; Liu, Y; Wang, G; Xiao, C; Yao, X; Zhang, C; Zhu, Z | 1 |
| Fluhr, JW; Gruber, AD; Hedtrich, S; Hönzke, S; Kleuser, B; Mundhenk, L; Ostrowski, A; Pischon, H; Radbruch, M; Schumacher, F | 1 |
| Haba, R; He, YY; Katsuki, N; Kubota, Y; Kushida, Y; Moriue, T; Nakai, K; Naruse, F; Nishiyama, F; Yoneda, K | 1 |
| Gao, Q; Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK | 1 |
| Panonnummal, R; Sabitha, M | 1 |
| Adachi, A; Dainichi, T; Egawa, G; Ginhoux, F; Honda, T; Ikuta, K; Kabashima, K; Kitoh, A; Kunisawa, J; Nagatake, T; Nakamizo, S; Nomura, T; Otsuka, A | 1 |
| Bao, J; Jiang, ZH; Jin, HT; Li, C; Li, WF; Liu, HQ; Wang, AP; Wang, YM; Wei, JF | 1 |
| Chen, H; Duan, X; Gan, L; He, M; Hu, F; Liu, X; Ming, Z; Poorun, D; Wang, X; Xu, J; Zhang, S; Zhu, K | 1 |
| Kim, CH; Kim, HJ; Lee, MH; Lee, YS; Won, HR | 1 |
| Favot, L; Jégou, JF; Lecron, JC; Mcheik, J; Morel, F; Pohin, M; Silvain, C; Vasseur, P; Venisse, N | 1 |
| Bu, DF; Cao, CX; Dang, NN; Han, YF; Jiang, ZX; Liu, FT; Man, XY; Meng, Z; Shi, ZR; Tan, GZ; Wang, L; Wei, KH; Zhang, YP | 1 |
| Chen, X; Cheng, L; Dai, L; Deng, H; Deng, J; Li, Y; Lin, Y; Mao, Y; Shi, G; Su, X; Wang, Y; Wei, Y; Yang, Y; Yu, D; Zhang, J; Zhang, S; Zhang, X; Zhang, Y | 1 |
| Fukushige, T; Hashiguchi, T; Higashi, Y; Ibusuki, A; Kanekura, T; Yamakuchi, M | 1 |
| Ahmad, SF; Al-Harbi, NO; Attia, SM; Bakheet, SA; El-Sherbeeny, AM; Nadeem, A | 1 |
| Akira, S; Sano, S; Satoh, T; Takaishi, M | 1 |
| Dang, E; Fang, H; Han, C; Jin, L; Li, B; Qiao, H; Wang, G; Zhuang, Y | 1 |
| Cho, HJ; Hong, IK; Kim, H; Lee, SY; Nam, S; Yang, H | 1 |
| Araújo, MM; Arruda, C; Carvalho, T; Marcato, PD; Pivetta, TP; Simões, S | 1 |
| Feng, B; He, S; Li, C; Liu, B; Liu, H; Lu, C; Su, Z; Tang, L; Wang, X; Xu, F; Zhao, J; Zheng, G; Zheng, X; Zhu, W; Zhu, Y | 1 |
| Han, M; Hu, R; Huang, G; Li, H; Liu, H; Liu, X; Liu, Y; Otsu, K; Xiao, S; Zhao, W; Zheng, T | 1 |
| Chen, H; Duan, X; Gan, L; Jaypaul, H; Liu, N; Liu, X; Makamure, JT; Ming, Z; Wang, X; Zhang, S; Zhu, K | 1 |
| Cardoso, RM; Hansen, PR; Madsen, M; Nielsen, LB; Pedersen, TX; van Eck, M | 1 |
| Bíró, T; Brain, SD; Gyömörei, C; Gyulai, R; Horváth, S; Kelemen, B; Kemény, Á; Kodji, X; Komlódi, R; Perkecz, A; Pintér, E; Sándor, Z; Sétáló, G; Szőke, É; Tóth, BI | 1 |
| Palmer, G; Palomo, J; Rodriguez, E; Talabot-Ayer, D; Troccaz, S | 1 |
| Condon, L; Curtright, A; Dhaka, A; Esancy, K; Feng, J; Kimball, C | 1 |
| Brüne, B; Kenner, L; Ringel, C; Schlederer, M; Shirsath, N; Tangermann, S; Wagner, K; Wolf, P | 1 |
| Kim, SH; Kim, TG; Lee, JW; Lee, M; Lee, MG; Park, J | 1 |
| Honma, M; Igawa, S; Iinuma, S; Ishida-Yamamoto, A; Kishibe, M; Saito, N; Shibuya, T | 1 |
| Artym, J; Fiedorowicz, A; Jeleń, M; Kaleta-Kuratewicz, K; Kałas, W; Kochanowska, I; Kocięba, M; Kuropka, P; Kuryszko, J; Madej, JP; Morak-Młodawska, B; Pawlak, A; Pluta, K; Strządała, L; Zaczyńska, E; Zimecki, M | 1 |
| Adachi, A; Arita, M; Dainichi, T; Egawa, G; Hanakawa, S; Honda, T; Kabashima, K; Kitoh, A; Kusuba, N; Miyachi, Y; Murata, T; Nakajima, S; Nakashima, C; Narumiya, S; Ono, S; Otsuka, A; Sawada, Y; Ueharaguchi, Y | 1 |
| Hung, CF; Lee, GA; Li, HJ; Wu, NL | 1 |
| Falke, J; Hulsbergen-van de Kaa, CA; Maj, R; Oosterwijk, E; Witjes, JA | 1 |
| Chen, L; Liu, W; Ning, J; Shen, Y; Sun, Y; Wang, M; Wang, T; Wang, Y; Zhang, F | 1 |
| Carey, CD; Diaz-Perez, JA; Falo, LD; Killeen, ME; Mathers, AR; Yang, Y | 1 |
| Chen, C; Duan, Q; Liu, J; Liu, Z; Shao, Y; Wang, X; Wu, N; Yang, H; Yang, P; Zhang, M; Zheng, Y | 1 |
| Fukami, S; Kai, H; Morita, M; Moriuchi, M; Nakano, Y; Piruzyan, M; Shuto, T; Suico, MA; Takada, M; Tsurekawa, Y | 1 |
| Chen, L; Gao, L; Huang, J; Pang, X; Sun, Y; Wang, H; Wang, J; Wang, T; Zhang, K | 1 |
| Chen, C; Duan, Q; Jia, J; Jing, H; Li, C; Li, F; Liu, J; Shao, Y; Wang, N; Wang, Q; Wang, X; Xiao, L; Yang, P; Zheng, Y | 1 |
| Bhatta, AK; Ji, J; Keyal, U; Wang, P; Wang, X; Zhang, G; Zhao, Z; Zhu, L | 1 |
| Blanco, L; Calvo, A; Espuelas, S; Fernández-Rubio, C; Irache, JM; Larrea, E; Moreno, E; Nguewa, P; Sanmartín, C; Schwartz, J | 1 |
| Han, L; Hou, S; Shan, S; Wang, H; Xu, R; Zhu, C | 1 |
| Dainichi, T; Egawa, G; Hayden, MS; Honda, T; Ishii, KJ; Kabashima, K; Kitoh, A; Kobayashi, T; Matsumoto, R; Nakajima, S; Nakano, Y; Nomura, T; Otsuka, A; Sakurai, K; Sugimoto, Y; Tanaka, M; Tsuchiya, S | 1 |
| Cao, H; Chen, L; Li, X; Shen, X; Shi, R; Wang, D; Xia, Q; Xu, H; Xue, F; Yang, H; Yuan, W; Zhao, X; Zheng, J | 1 |
| Hsu, PY; Su, CC; Yang, TH; Yen, HH | 1 |
| Chen, G; Liao, Y; Liu, Y; Lu, Q; Shen, W; Su, Y; Wu, R; Zhang, J; Zhao, M; Zheng, M | 1 |
| Di Meglio, P; Maybury, CM; Smith, CH | 1 |
| Ahn, SH; Nguyen, LTH; Nguyen, UT; Yang, IJ | 1 |
| Anderson, LS; Han, D; Hwang, ST; Imai, Y; Simon, SI; Wu, X; Yu, S; Zhou, Y | 1 |
| Arkless, KL; Aubdool, AA; Brain, SD; Caton, P; Cleary, SJ; Evans, E; Kee, Z; Kodji, X; Pitchford, SC | 1 |
| Hsu, PY; Su, CC; Yang, HJ; Yang, TH | 1 |
| Davis, R; Griffith, AD; Hadiono, M; Pietro, A; Popkin, DL; Yang, JS; Zaidi, AK | 1 |
| Li, RH; Qiao, M; Sun, Q; Wang, XY; Yan, JJ; Zhao, XT | 1 |
| Cun, D; Lin, Z; Liu, Z; Sun, L; Tong, HH; Wang, R; Yan, R; Zheng, Y | 1 |
| Haba, R; Kubota, Y; Kushida, Y; Nakai, K | 1 |
| Auepemkiate, S; Chorachoo, J; Furnholm, T; Johnston, A; Lambert, S; Reingold, L; Roberts, L; Voravuthikunchai, SP | 1 |
| Bezdek, S; Bucala, R; Busch, H; Dahlke, M; Leng, L; Mousavi, S; Rades, D; Sadik, CD; Zillikens, D | 1 |
| Brand, A; Clausen, BE; Daiber, A; Karbach, S; Klebow, S; Kolbinger, F; Kossmann, S; Münzel, T; Roohani, S; Schüler, R; Ullmann, E; Veras, FP; Waisman, A; Wenzel, P; Wild, J; Wohn, C | 1 |
| Albanesi, C; Cavani, A; Dinarello, CA; Doti, N; Eisenmesser, EZ; Gubinelli, E; Madonna, S; Mazzanti, C; Mercurio, L; Morelli, M; Pagnanelli, G; Ruvo, M; Scarponi, C | 1 |
| Bezdek, S; Guillen, N; Meshrkey, F; Mócsai, A; Mousavi, S; Nimmerjahn, F; Sadik, CD; Seeling, M; Sezin, T; Thieme, M; Wannick, M; Zillikens, D | 1 |
| Akiyama, T; Hashimoto, T; Sakai, K; Sanders, KM; Yosipovitch, G | 1 |
| Deng, Y; Dong, Y; Huang, X; Liu, M; Liu, Q; Wu, T; Yu, P; Zhang, J | 1 |
| Carstens, E; Carstens, M; Domocos, DT; Follansbee, T; Han, D; Hwang, ST; Shi, Z; Wu, X; Yu, S; Zhou, Y | 1 |
| Chen, M; Li, Y; Tang, F; Tong, M; Wen, H; Xiao, R; Zhang, G; Zhao, M | 1 |
| Akiyama, T; Sakai, K | 1 |
| Han, D; Hwang, ST; Jena, PK; Sheng, L; Wan, YJY; Wu, X; Yu, S; Zhou, Y | 1 |
| Pruthi, V; Raghuwanshi, N; Raj, U; Srivastava, AK; Varadwaj, P; Yadav, TC | 1 |
| Farber, JM; Hwang, ST; Singh, TP; Zhang, HH | 1 |
| Fujimori, Y; Hamada, A; Imai, Y; Yamahara, K; Yamanishi, K | 1 |
| Dang, E; Fang, H; Guo, W; Jiang, M; Ke, Y; Qiao, H; Qiao, P; Shen, S; Wang, G; Zhang, J; Zhuang, Y | 1 |
| Di, T; Li, N; Li, P; Li, X; Liu, Z; Meng, Y; Wang, M; Xie, X; Zhai, C; Zhang, L | 1 |
| Cataisson, C; Day, CP; Flowers, B; Fraser, E; Li, L; Sanchez, V; Yuspa, SH | 1 |
| Kurschus, FC; Mohebiany, AN; Moos, S; Waisman, A | 1 |
| Cao, J; Chen, J; Chen, X; Fu, Y; Guo, L; Hu, J; Li, P; Li, W; Li, Y; Liu, L; Peng, J; Qiu, C; Qu, R; Vasilev, K; Wang, W; Zhao, Y; Zhou, G | 1 |
| Boehncke, WH; Borowczyk-Michalowska, J; Brembilla, NC; Conrad, C; Fallon, PG; Kavanagh, RD; Kaya, G; Mylonas, A; Senra, L; Wrobel, LJ; Yawalkar, N | 1 |
| Chen, HD; Gao, XH; Gao, YL; Han, Y; Huang, Y; Niu, XL; Qi, RQ; Sun, YZ | 1 |
| Chen, H; Dai, Z; Han, L; Huang, H; Li, L; Lu, C; Lu, Y; Wang, A; Wei, J; Zhong, X | 1 |
| Khan, W; Kommineni, N; Raza, K; Saka, R; Sathe, P | 1 |
| Hemmi, H; Ikumi, K; Imai, M; Kaisho, T; Morita, A; Nishida, E; Odanaka, M; Osaga, S; Shime, H; Taguchi, O; Yamazaki, S | 1 |
| Cho, KA; Hahn, S; Kim, YH; Lee, Y; Park, JW; Park, WJ; Ryu, KH; Shin, SH; Woo, SY | 1 |
| Gyulai, R; Horváth, S; Kemény, Á; Komlódi, R; Perkecz, A; Pintér, E | 1 |
| Feng, L; Guo, M; Huang, W; Kong, L; Shao, F; Song, P; Wu, X; Xu, F; Xu, L; Xu, Q | 1 |
| Cui, J; Gong, Y; Liang, C; Liu, X; Shao, C; Sun, S; Tian, F; Wang, Q; Wei, H; Wu, G; Xia, Y; Xu, B; Xu, M; Yang, G; Zhang, F; Zhang, L; Zhang, X; Zhao, H; Zhou, S; Zou, Y | 1 |
| Dong, Y; Duan, Y; Fu, D; Guo, S; Hu, H; Kalvakolanu, DV; Song, X; Tian, Z; Wang, Q | 1 |
| Challa, VS; Godugu, C; Pooladanda, V; Sunkari, S; Thatikonda, S | 1 |
| Kempen, L; Meyne, LM; Mousavi, S; Sadik, CD; Sezin, T; Zillikens, D | 1 |
| Billuart, P; Brüne, B; Burkhardt, H; da Silva, P; de Bruin, N; Elwakeel, E; Ernst, A; Han, Y; Huard, A; Lang, G; Mora, J; Parnham, MJ; Putyrski, M; Sala, C; Schmid, T; Scholz, A; Scholz, T; Schuster, C; Weigert, A; Wiechmann, S | 1 |
| Deng, H; Fan, X; Li, F; Meng, Q; Sun, R; Yan, K; Yang, X; Yuan, D | 1 |
| Cocozza, F; Gravisaco, MJ; Menay, F; Mongini, C; Sciullo, PD; Waldner, CI | 1 |
| Chen, L; Chen, Y; Guo, L; Liu, C; Ren, W; Sun, L; Xu, H; Yin, H; Yu, L; Yue, W; Zhang, K; Zhang, Y; Zhou, B | 1 |
| Barber, G; Creagh, EM; Kenealy, S; Lavelle, EC; Liddicoat, A; Manils, J; Munoz-Wolf, N; Raverdeau, M | 1 |
| Cheng, YG; Guan, W; Guo, S; Kuang, HX; Liu, Y; Tan, JY; Yang, BY | 1 |
| Chen, W; Deng, G; Gu, Z; Ji, X; Sun, Y; Wang, P; Wang, X; Zhan, T; Zheng, W | 1 |
| Backer, RA; Brand, A; Clausen, BE; Diener, N; Jiang, A; Karram, K; Mellman, I; Stoitzner, P; Tripp, C; Zahner, SP | 1 |
| Lin, Z; Liu, Z; Meng, S; Sun, L; Wang, L; Wang, Z; Xi, L; Zheng, Y | 1 |
| Chen, Y; Fang, W; He, S; Huang, L; Leng, Y; Li, B; Li, Y; Liu, D; Liu, G; Liu, R; Liu, X; Wang, R; Yang, Z; Ye, C; Yin, H | 1 |
| Fukaya, S; Fukuyasu, A; Hayashi, K; Ishikawa, T; Kamata, M; Ohnishi, T; Shimizu, T; Tada, Y; Tanaka, T | 1 |
| Honda, K; Lee, HC; Ohba, M; Okuno, T; Takahashi, N; Takamori, K; Tominaga, M; Yasukawa, K; Yokomizo, T | 1 |
| Iversen, L; Johansen, C; Ommen, P; Weimar, I | 1 |
| Bäumer, W; Dickhaut, J; Japtok, L; Kietzmann, M; Kleuser, B; Mischke, R; Schaper, K | 1 |
| Hu, J; Li, H; Wen, C; Yang, R; Zhao, H; Zhao, M; Zhou, Q | 1 |
| Becher, B; Cheong, C; Clausen, BE; Haak, S; Holzmann, B; Kant, M; Ober-Blöbaum, JL; Onderwater, S; Pantelyushin, S; Prens, EP; Reizis, B; Weighardt, H; Wohn, C; Zahner, SP | 1 |
| Cho, SD; Han, JH; Kang, MJ; Kim, B; Kim, BY; Kim, DJ; Kim, JB; Park, JH; Park, SY | 1 |
| Hu, JH; Li, H | 1 |
| Flutter, B; Nestle, FO | 1 |
| Dou, W; Hu, J; Sun, J; Zhao, Y | 1 |
| Hau, CS; Kanda, N; Sato, S; Shibata, S; Tada, Y; Watanabe, S | 1 |
| Honda, T; Kabashima, K; Malissen, B; Nakamizo, S; Nakamura, M; Ohmori, S; Sawada, Y; Sugita, K; Tokura, Y; Yoshiki, R; Yoshioka, H | 1 |
| Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
| Fujimoto, C; Kamijima, R; Kataoka, S; Nakajima, K; Sano, S; Takaishi, M; Terada, Y; Yokogawa, M | 1 |
| Abe, J; Ishii, S; Kita, Y; Matsushima, K; Nakamura, M; Sato, S; Shimizu, T; Sumida, H; Yanagida, K | 1 |
| Bai, XC; Chen, TY; Feng, JY; Li, YM; Ma, J; Qin, S; Wen, J; Zheng, RC; Zhong, BL; Zhou, GB | 1 |
| Aspord, C; Charles, J; Leccia, MT; Leloup, C; Molens, JP; Plumas, J; Tramcourt, L | 1 |
| Alvarez, D; Naval, E; Ordovas-Montanes, J; Paust, S; Perro, M; Riol-Blanco, L; Thiriot, A; von Andrian, UH; Wood, JN | 1 |
| Basu, A; Dutta, K; Kundu, K; Mahadevan, A; Mukherjee, S; Nazmi, A; Shankar, SK | 1 |
| Sadik, CD; Sezin, T; Zillikens, D | 1 |
| Ha, HL; Kim, JC; Morasso, MI; Pisitkun, P; Siebenlist, U; Tang, W; Tassi, I; Udey, MC; Wang, H | 1 |
| Boakye, CH; Godugu, C; Mendonca Faria, HA; Patel, AR; Singh, M; Somagoni, J; Zucolotto, V | 1 |
| Cai, JP; Chan, AS; Chan, KH; Chen, H; Jahan, AS; Lau, CC; Li, C; Li, CG; Li, L; To, KK; Tsang, AK; Wu, WL; Yuen, KY; Zhang, AJ | 1 |
| Borkner, L; Frenzel, DF; Scharffetter-Kochanek, K; Scheurmann, J; Singh, K; Weiss, JM | 1 |
| Gao, Q; Ge, J; Song, S; Su, Z; Sun, G; Sun, W; Sun, X; Wang, H; Wang, Y; Xie, S; Yi, L; Zhang, B | 1 |
| Fukami, K; Kanemaru, K; Matsuyuki, A; Nakamura, Y | 1 |
| Kim, CH; Kim, JY; Lee, AY | 1 |
| Flagler, ND; Janardhan, KS; King, D; Myers, P; Petranka, JG; Putney, JW; Steinckwich, N | 1 |
| Jessen, N; Kjær, TN; Pedersen, SB; Stenderup, K; Thorsen, K | 1 |
| Chen, F; Chen, Y; Cheng, L; Hao, F; Niu, J; Qian, T; Shi, X; Song, Z; Wang, H; Yan, H; Zhai, Z; Zhang, D; Zhang, N; Zhong, B | 1 |
| Ayithan, N; Hwang, ST; Imai, Y; Wang, L; Wu, X; Yuan, Y | 1 |
| Chen, X; Huo, R; Li, H; Li, N; Shen, B; Shen, Z; Sun, Y; Wang, B; Wu, P; Zhai, T; Zhang, J; Zhou, Z | 1 |
| Bando, Y; Honma, M; Igawa, S; Iinuma, S; Iizuka, H; Ishida-Yamamoto, A; Kishibe, M; Saito, N; Takahashi, H; Yoshida, S | 1 |
| Aihara, M; Komitsu, N; Watanabe, T; Watanabe, Y; Yamaguchi, Y | 1 |
| Dong, G; Fan, H; Hou, Y; Huang, Y; Ji, J; Liu, F; Ren, D; You, M | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Al-Hosaini, KA; Al-Sharary, SD; Ansari, MA; Attia, SM; El-Sherbeeny, AM; Nadeem, A; Siddiqui, N; Zoheir, KM | 1 |
| Di, T; Li, P; Lin, Y; Liu, X; Wang, Y; Zeng, Z; Zhang, L; Zhao, J | 1 |
| Chen, CC; Fang, JY; Kao, HC; Lin, YK; Yang, SH | 1 |
| Kang, KS; Kim, TY; Park, KH; Sah, SK; Yun, CO | 1 |
| Bajenoff, M; Chelbi, R; Dalod, M; Henri, S; Jorquera, A; Malissen, B; Malosse, C; Tamoutounour, S; Terhorst, D; Wohn, C | 1 |
| Li, MH; Lin, CC; Pan, IH; Wen, SF; Wu, HC; Yao, HJ | 1 |
| Babu, RJ; Boakye, CH; Desai, PR; Kikwai, LC; Patlolla, R; Shah, PP; Singh, M | 1 |
| Charpin-El Hamri, G; Fussenegger, M; Geering, B; Schukur, L | 1 |
| Hu, J; Sun, J; Wang, X | 1 |
| Amiaud, J; Bart, G; Blanchard, F; Bourreille, A; Boutet, MA; Brulin, B; Charrier, C; Gabay, C; Le Goff, B; Lecron, JC; Morel, F; Palmer, G; Penhoat, M; Rolli-Derkinderen, M; Vigne, S | 1 |
| Liu, JH; Luo, DQ; Wu, HH; Xie, WL; Zhao, YK | 1 |
| Fukui, T; Matsuzaki, Y; Nakano, H; Rokunohe, A; Rokunohe, D; Sakuraba, Y; Sawamura, D | 1 |
| Ait-Oufella, H; Bagot, M; Battistella, M; Bensussan, A; Bouaziz, JD; Boufenzer, A; Cochaud, S; Gibot, S; Hau, E; Joffre, J; Laurans, L; Le Buanec, H; Masson, A; Zeboudj, L | 1 |
| Ballegeer, M; Grine, L; Libert, C; Lienenklaus, S; Sanders, NN; Steeland, S; Van Ryckeghem, S; Vandenbroucke, RE; Weiss, S | 1 |
| Adhami, VM; Chamcheu, JC; Chaves-Rodriquez, MI; Longley, BJ; Mukhtar, H; Siddiqui, IA; Wood, GS | 1 |
| Bao, YL; Huang, YX; Li, WL; Li, YX; Song, ZB; Sun, LG; Wang, Q; Yang, XG; Yu, CL; Zhang, WJ | 1 |
| Chao, YH; Chen, DY; Chen, HH; Chung, TW; Li, YR; Lin, CC; Yang, DH | 1 |
| Cao, W; Chen, G; Gao, Q; Song, S; Su, Z; Wang, H; Xie, S; Xu, H; Yin, S; Zhang, B | 1 |
| Chang, KT; Choo, YK; Kim, CH; Kim, JS; Kim, SU; Lee, JM; Yoo, JK | 1 |
| Cho, D; Houh, Y; Kim, KE; Park, HJ | 1 |
| Morimura, S; Oka, T; Sato, S; Sugaya, M | 1 |
| Cochez, PM; Coulie, PG; Dauguet, N; de Heusch, M; Dumoutier, L; Hendrickx, E; Lemaire, MM; Michiels, C; Renauld, JC; Ryffel, B; Togbe, D; Van Belle, AB; Warnier, G | 1 |
| Amiaud, J; Atanassov, H; Bernard, FX; Blanchard, F; Favot, L; Guesdon, W; Jégou, JF; Lecron, JC; Mcheik, J; Mekouo, AA; Morel, F; Paris, I; Pohin, M; Rabeony, H; Richards, CD | 1 |
| Dainichi, T; Hirakawa, S; Honda, T; Kabashima, K; Kitoh, A; Miyachi, Y; Nakajima, S; Nakashima, C; Nonomura, Y; Otsuka, A; Wong, LS; Yamamoto, Y | 1 |
| Cavanagh, J; Graham, GJ; McColl, A; Nerurkar, L; Thomson, CA | 1 |
| Liu, JH; Luo, DQ; Wang, F; Wu, HH; Zhao, YK | 1 |
| Bai, S; Hou, S; Liu, X; Zhang, Z | 1 |
| Alrefai, H; Avots, A; Bukur, V; Goebeler, M; Kerstan, A; Klein-Hessling, S; Muhammad, K; Patra, AK; Pham, DA; Rudolf, R; Sahin, U; Serfling, E; Tenzer, S | 1 |
| Bezdek, S; Hdnah, A; Ibrahim, S; Ludwig, RJ; Mousavi, S; Sadik, CD; Sezin, T; Zillikens, D | 1 |
| Athari, SK; Bessis, N; Biton, J; Boissier, MC; Caux, F; Girard, JP; Herbelin, A; Hervé, R; Lemeiter, D; Poirier, E; Raffaillac, A; Semerano, L | 1 |
| Benito, C; Casas, E; Ciruela, F; de Anta, JM; Díez-Villanueva, A; Ferran, M; Gómez, D; López-Cano, M; Manils, J; Marruecos, L; Perrino, FW; Soler, C; Vavouri, T; Viña-Vilaseca, A | 1 |
| Chong, HT; Cowin, AJ; Ibbetson, J; Kopecki, Z; Sidhu, S; Yang, GN | 1 |
| Amberg, N; Holcmann, M; Sibilia, M; Stulnig, G | 1 |
| Adhami, VM; Chamcheu, JC; Chaves-Rodriquez, MI; Dodwad, SM; Esnault, S; Longley, BJ; Mukhtar, H; Satyshur, KA; Sechi, M; Siddiqui, IA; Syed, DN; Wood, GS | 1 |
| Hercogová, J; Hornová, M; Hudcovic, T; Jůzlová, K; Klimešová, K; Kostovčík, M; Kverka, M; Málková, J; Novosádová, I; Rossmann, P; Stehlíková, Z; Štepánková, R; Tlaskalová-Hogenová, H; Zákostelská, Z | 1 |
| Akiyama, T; Jensen, L; Sakai, K; Sanders, KM; Yanushefski, KM; Yosipovitch, G; Youssef, MR | 1 |
| Chen, YJ; Cheng, HY; Ho, LW; Huang, SW; Kao, JK; Narita, M; Shieh, JJ; Takahashi, M; Wang, ST; Wu, CY | 1 |
| Albanesi, C; Avigliano, L; Cavani, A; Madonna, S; Mauriello, A; Melino, G; Palombo, R; Savini, I; Terrinoni, A | 1 |
| Liu, J; Luo, H; OuYang, Q; Pan, Y; Xuan, C | 1 |
| Li, D; Lohcharoenkal, W; Meisgen, F; Nikamo, P; Pivarcsi, A; Sonkoly, E; Srivastava, A; Ståhle, M; Xu Landén, N | 1 |
| Burden, AD; Graham, GJ; Holmes, S; Le Brocq, ML; McKimmie, CS; Schalkwijk, J; Shams, K; Singh, M; van den Bogaard, EH; Wilson, GJ | 1 |
| Chuang, JH; Huang, CC; Huang, FC; Huang, YH; Kuo, KC; Shih, HH; Tiao, MM; Yang, YL | 1 |
| Choo, YK; Kim, CH; Kwak, DH; Lee, JH; Lee, JM; Lim, CY; Park, MY; Yoo, JK | 1 |
| Courthion, H; Denis, MC; Gabriel, D; Gurny, R; Kalia, Y; Karagianni, N; Kranidioti, K; Lapteva, M; Möller, M; Mugnier, T | 1 |
| Finkelstein, D; Gangwar, R; Gingras, S; Häcker, H; Ippagunta, SK; Pelletier, S; Redecke, V; Vogel, P | 1 |
| Amberg, N; Glitzner, E; Holcmann, M; Sibilia, M; Stulnig, G | 1 |
| Cao, T; Gao, T; Ge, R; Guo, S; Li, B; Li, C; Liu, L; Wang, G; Wang, H; Zhang, W | 1 |
| Cho, KA; Kim, JY; Lee, KH; Park, M; Woo, SY | 1 |
| Alignani, D; Guruceaga, E; Hervas-Stubbs, S; Infante, S; Lasarte, JJ; Llopiz, D; Ruiz, M; Sarobe, P; Silva, L; Villanueva, L | 1 |
| Chen, W; Fei, C; Gong, Y; Shi, Y; Tong, Y; Wang, X; Wang, Y; Xu, H; Yu, Q; Zhang, X | 1 |
| Cao, N; Chen, T; Fu, LX; Guo, ZP; Qin, S; Yin, B | 1 |
| Espinosa, A; Iversen, L; Johansen, C; Langkilde, A; Ottosson, V; Raaby, L; Vinter, H; Wahren-Herlenius, M | 1 |
| Gudjonsson, JE; Hawkes, JE; Ward, NL | 1 |
| Fu, M; Gao, J; Li, W; Liu, Y; Sun, S; Wang, G; Xiao, C; Yao, X; Zhu, Z | 1 |
| Chen, J; Li, S; Liu, YJ; Qiao, Y; Wu, J; Yang, Y; Zhang, M; Zhu, S | 1 |
| Itankar, PR; Joshi, A; Parmar, KM; Prasad, SK | 1 |
| Alvarez, P; Jensen, LE | 1 |
| Drutskaya, MS; Korneev, KV; Kuprash, DV; Nedospasov, SA; Sviriaeva, EN | 1 |
| Florencia, EF; Hekking-Weijma, IM; Onderdijk, AJ; Prens, EP | 1 |
| Cen, J; Chen, S; Han, K; Li, H; Wei, Q; Wu, H; Yang, Y | 1 |
| Cochez, PM; Dauguet, N; Dumoutier, L; Hendrickx, E; Michiels, C; Renauld, JC; Warnier, G | 1 |
| Amin, MR; Benedict, PA; Branski, RC; Dion, GR; Hiwatashi, N; Sin, DN; Teng, SE | 1 |
| Cho, JH; Choe, J; Choi, SS; Hahn, TW; Han, JA; Jung, YJ; Jung, YM; Kim, KC; Ko, HJ; Lee, HJ; Lee, KH; Lee, YS; Yoon, BI | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Almukhlafi, TS; El-Sherbeeny, AM; Nadeem, A | 1 |
| Devi, N; Jain, A; Katare, OP; Sharma, G; Thakur, K | 1 |
| Arita, K; Hirai, M; Kurebayashi, Y; Mori, H; Yamaguchi, T | 1 |
| Ahmad, SF; Al-Harbi, MM; Al-Harbi, NO; Alotaibi, MR; AlSaad, AM; Ansari, MA; Nadeem, A | 1 |
| Diaconu, D; Fritz, Y; Gudjonsson, JE; Liang, Y; Michaels, KA; Sarkar, MK; Sutter, AJ; Swindell, WR; Tsoi, A; Ward, NL; Xing, X | 1 |
| Boon, L; Cornelissen, F; Florencia, E; Kant, M; Laman, JD; Lubberts, E; Mourits, S; Mus, AM; Prens, EP; van der Fits, L; Voerman, JS | 1 |
| Barberis, A; Carson, DA; Chan, M; Corr, M; Cottam, HB; Crain, B; Hayashi, T; Leoni, L; Maj, R | 1 |
| Olbert, PJ | 1 |
| Arum, CJ | 1 |
| Anderson, BJ; Bailey, KW; Larson, D; Smee, DF; Tarbet, EB; Wong, MH | 1 |
| Carbajal, S; DiGiovanni, J; Elder, JT; Gudjonsson, JE; Han, G; Johnston, A; Lu, J; Nair, RP; Pittelkow, MR; Prens, EP; Sano, S; Swindell, WR; Voorhees, JJ; Wang, XJ; Ward, NL; Wohn, C; Xing, X | 1 |
| McLaughlin, PJ; Stucki, JK; Zagon, IS | 1 |
| Cheung, PH; Foreman, O; Hain, HS; Kaur, P; Kavirayani, A; Saha, S; Tung, D | 1 |
| Desai, PR; Patel, AR; Shah, PP; Singh, MS | 1 |
| de Heusch, M; Dumoutier, L; Dunussi-Joannopoulos, K; Fouser, LA; Hendrickx, E; Lemaire, MM; Renauld, JC; Van Belle, AB; Warnier, G | 1 |
| Bult, H; De Meyer, GR; De Meyer, I; Martinet, W; Schrijvers, DM; Timmermans, JP | 1 |
| Becher, B; Haak, S; Heppner, FL; Ingold, B; Kulig, P; Navarini, AA; Pantelyushin, S | 1 |
| Baek, JO; Byamba, D; Kim, TG; Lee, MG; Wu, WH | 1 |
| El Malki, K; Huppert, J; Karbach, SH; Karram, K; Kuhlmann, CR; Kurschus, FC; Luhmann, HJ; Münzel, T; Nikolaev, A; Reissig, S; Schüler, R; von Stebut, E; Waisman, A; Wörtge, S; Zayoud, M | 1 |
| Asano, Y; Kadono, T; Kanda, N; Sato, S; Shibata, S; Sugaya, M; Tada, Y; Watanabe, S; Yanaba, K | 1 |
| Asselbergh, B; De Rycke, R; Declercq, W; Deforce, D; Denecker, G; Gilbert, B; Hachem, JP; Hoste, E; Prens, EP; van der Fits, L; Van Nieuwerburgh, F; Vandenabeele, P | 1 |
| Dapavo, P; Hirsch, E; Ji, H; Okkenhaug, K; Perino, A; Roller, A; Soro, E | 1 |
| Stanley, MA | 1 |
| Ault, KA; Cohoon, KP; Ramsey, KH; Shaba, N | 1 |
| Reifenberger, J; Schön, MP | 1 |
| Blatt, LM; Day, CW; Julander, JG; Morrey, JD; Sidwell, RW; Smee, DF | 1 |
| Benninghoff, B; Jablonska, S; Majewski, S; Marczak, M; Mlynarczyk, B | 1 |
| Ito, JI; Lyons, JM; Morré, SA | 2 |
| Hwang, D; Kawamoto, H; Liu, H; Scherr, DS; Schwartz, M; Smith, EB; You, X | 1 |
| Bian, T; Jin, SX; Wang, X; Wu, QZ; Yao, X; Yin, KS | 1 |
| Altintas, D; Cetinkaya, MB; Kandemir, B; Kokcu, A; Tosun, M | 1 |
| Nafz, J; Nindl, I; Ohnesorge, M; Rösl, F; Stockfleth, E | 1 |
| Bernstein, DI; Harrison, CJ; Miller, RL; Shahwan, A; Tepe, ER | 1 |
| Gerster, JF; Imbertson, LM; Miller, RL; Reiter, MJ | 1 |
4 review(s) available for imiquimod and Disease Models, Animal
| Article | Year |
|---|---|
Methodological shortcomings in the reports of the imiquimod psoriatic model.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Mice; Psoriasis; Skin | 2022 |
Mouse Models of Psoriasis: A Comprehensive Review.
Topics: Animals; Cytokines; Disease Models, Animal; Humans; Imiquimod; Mice; Psoriasis; Skin | 2022 |
[Mechanism of psoriasis generation in animal models].
Topics: Aminoquinolines; Amphiregulin; Animals; Disease Models, Animal; EGF Family of Proteins; Humans; Imiquimod; Keratin-14; Keratin-5; Keratinocytes; Membrane Glycoproteins; Mice, Transgenic; Psoriasis; Receptor, TIE-2; STAT3 Transcription Factor; Toll-Like Receptor 7; Transforming Growth Factor beta1 | 2013 |
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Disease Models, Animal; Humans; Imiquimod; Skin Diseases; Skin Neoplasms; Virus Diseases | 2002 |
502 other study(ies) available for imiquimod and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF-κB-mediated inflammation.
Topics: Animals; Cytokines; Disease Models, Animal; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Skin | 2021 |
C-type lectin receptor Dectin3 deficiency balances the accumulation and function of FoxO1-mediated LOX-1
Topics: Adoptive Transfer; Adult; Animals; Apoptosis; Cell Differentiation; Cell Nucleus; Disease Models, Animal; Female; Forkhead Box Protein O1; Gene Expression Regulation; Gene Silencing; Humans; Imiquimod; Lectins, C-Type; Lupus Erythematosus, Systemic; Male; Mice; Mice, Inbred C57BL; Middle Aged; Monocytes; Myeloid-Derived Suppressor Cells; Proto-Oncogene Proteins c-akt; RAW 264.7 Cells; Receptors, Immunologic; Scavenger Receptors, Class E; Syk Kinase; Terpenes | 2021 |
Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis.
Topics: Animals; Disease Models, Animal; Female; Imiquimod; Interferon Inducers; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; T-Lymphocytes, Regulatory | 2021 |
Positive Allosteric Modulation of A
Topics: Adenosine; Animals; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Immunity; Interleukin-17; Interleukin-23; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |
Apremilast downregulates interleukin-17 production and induces splenic regulatory B cells and regulatory T cells in imiquimod-induced psoriasiform dermatitis.
Topics: Animals; B-Lymphocytes, Regulatory; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Interleukin-17; Mice; Psoriasis; Spleen; T-Lymphocytes, Regulatory; Thalidomide | 2021 |
Cutaneous Liver X Receptor Activation Prevents the Formation of Imiquimod-Induced Psoriatic Dermatitis.
Topics: Administration, Cutaneous; Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Liver X Receptors; Psoriasis; Skin | 2022 |
Losartan ointment attenuates imiquimod-induced psoriasis-like inflammation.
Topics: Administration, Cutaneous; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Imiquimod; Interleukin-17; Losartan; Male; Mice; Ointments; Psoriasis; Receptor, Angiotensin, Type 1; Skin; Th17 Cells | 2021 |
First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Disease Susceptibility; Imiquimod; Immunosuppressive Agents; Inflammation Mediators; Keratinocytes; Membrane Proteins; Mice; Mice, Knockout; Phosphate-Binding Proteins; Psoriasis; Signal Transduction; T-Lymphocyte Subsets | 2021 |
Alkyl-Terminated Gold Nanoparticles as a Self-Therapeutic Treatment for Psoriasis.
Topics: Animals; Disease Models, Animal; Gold; Imiquimod; Keratinocytes; Metal Nanoparticles; Mice; Nanoparticles; Psoriasis | 2021 |
Cudraxanthone D Ameliorates Psoriasis-like Skin Inflammation in an Imiquimod-Induced Mouse Model via Inhibiting the Inflammatory Signaling Pathways.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Female; Humans; Imiquimod; Interferon-gamma; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Moraceae; NF-kappa B; Plant Extracts; Plant Roots; Psoriasis; Treatment Outcome; Tumor Necrosis Factor-alpha; Xanthones | 2021 |
Gomisin M2 alleviates psoriasis‑like skin inflammation by inhibiting inflammatory signaling pathways.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Female; Humans; Imiquimod; Inflammation; Interferon-gamma; Keratinocytes; Lignans; Mice, Inbred C57BL; NF-kappa B; Psoriasis; Signal Transduction; STAT1 Transcription Factor; Th1 Cells; Th17 Cells; Tumor Necrosis Factor-alpha | 2021 |
MiR-193b-3p-ERBB4 axis regulates psoriasis pathogenesis via modulating cellular proliferation and inflammatory-mediator production of keratinocytes.
Topics: Animals; Antagomirs; Base Sequence; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; HaCaT Cells; Humans; Imiquimod; Inflammation; Inflammation Mediators; Keratinocytes; Male; Mice, Inbred C57BL; MicroRNAs; Models, Biological; Psoriasis; Receptor, ErbB-4; RNA, Messenger; Skin | 2021 |
Adipocyte-Derived CTRP3 Exhibits Anti-Inflammatory Effects via LAMP1-STAT3 Axis in Psoriasis.
Topics: Adipocytes; Adipokines; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Humans; Imiquimod; Interleukin-17; Keratinocytes; Lysosomal Membrane Proteins; Mice; Psoriasis; STAT3 Transcription Factor | 2022 |
High salt diet impairs dermal tissue remodeling in a mouse model of IMQ induced dermatitis.
Topics: Animals; Biomarkers; Body Weight; Cell Movement; Cells, Cultured; Cytokines; Dermatitis; Dermis; Disease Models, Animal; Extracellular Matrix; Fibroblasts; Humans; Imiquimod; Inflammation; Inflammation Mediators; Leukocytes, Mononuclear; Male; Mice, Inbred C57BL; Probiotics; Sodium Chloride, Dietary | 2021 |
Curcumin and ustekinumab cotherapy alleviates induced psoriasis in rats through their antioxidant, anti-inflammatory, and antiproliferative effects.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Curcumin; Cytokines; Disease Models, Animal; Imiquimod; Interleukin-12 Subunit p40; Interleukin-17; Psoriasis; Rats; Skin; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Ustekinumab | 2022 |
NF-κB1 Contributes to Imiquimod-Induced Psoriasis-Like Skin Inflammation by Inducing Vγ4
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Interleukin-17; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |
Lymphatic Dysfunction Exacerbates Cutaneous Tumorigenesis and Psoriasis-Like Skin Inflammation through Accumulation of Inflammatory Cytokines.
Topics: Animals; Carcinogenesis; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Lymphatic System; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |
TMT-based proteomics analysis reveals the protective effect of Jueyin granules on imiquimod-induced psoriasis mouse model by causing autophagy.
Topics: Animals; Autophagy; Disease Models, Animal; Humans; Imiquimod; Mice; Neoplasm Recurrence, Local; Proteomics; Psoriasis | 2022 |
Salubrinal protects against inflammatory response in macrophage and attenuates psoriasiform skin inflammation by antagonizing NF-κB signaling pathway.
Topics: Animals; Cinnamates; Disease Models, Animal; Imiquimod; Inflammation; Macrophages; Male; Mice; Mice, Inbred C57BL; NF-kappa B; Protective Agents; Psoriasis; RAW 264.7 Cells; Signal Transduction; Skin; Thiourea; Tumor Necrosis Factor-alpha | 2022 |
A systematic comparison of the effect of topically applied anthraquinone aglycones to relieve psoriasiform lesion: The evaluation of percutaneous absorption and anti-inflammatory potency.
Topics: Administration, Topical; Animals; Anthraquinones; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Emodin; HaCaT Cells; Humans; Imiquimod; Inflammation; Keratinocytes; Macrophages; Mice; Psoriasis; Rheum; Skin Absorption; Swine | 2022 |
Terrestrosin D ameliorates skin lesions in an imiquimod-induced psoriasis-like murine model by inhibiting the interaction between Substance P and Dendritic cells.
Topics: Animals; Cell Proliferation; Cytokines; Dendritic Cells; Disease Models, Animal; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Saponins; Skin; Substance P | 2022 |
Decreased microRNA-126 expression in psoriatic CD4
Topics: Animals; Cell Differentiation; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; MicroRNAs; Psoriasis; Skin; Th17 Cells | 2022 |
Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Mice; Psoriasis; Skin; Toll-Like Receptor 7 | 2022 |
Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor γt inverse agonists.
Topics: Amino Acid Sequence; Animals; Autoimmune Diseases; Chromones; Disease Models, Animal; Drug Development; Drug Inverse Agonism; Female; Humans; Imiquimod; Inflammation; Interleukin-17; Molecular Docking Simulation; Protein Binding; Protein Conformation; Pyrans; Receptors, Retinoic Acid; Skin; Structure-Activity Relationship; Sulfonamides; Th17 Cells | 2022 |
Protective effect of Yangxue Jiedu Soup against psoriasis-like lesions by regulating TLR4/NF-κB signaling pathway mediated by secretion of exosome HSP70.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drugs, Chinese Herbal; HSP70 Heat-Shock Proteins; Imiquimod; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Phytotherapy; Psoriasis; Signal Transduction; Toll-Like Receptor 4 | 2022 |
Topical astilbin ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice via suppression dendritic cell-Th17 inflammation axis.
Topics: Animals; Cytokines; Dendritic Cells; Disease Models, Animal; Flavonols; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |
Celastrol gel ameliorates imiquimod-induced psoriasis-like dermatitis in mice by targeting Langerhans cells.
Topics: Animals; Disease Models, Animal; Female; Gels; Imiquimod; Interleukin-23; Langerhans Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Pentacyclic Triterpenes; Psoriasis; Tripterygium | 2022 |
Topical Treatment of Colquhounia Root Relieves Skin Inflammation and Itch in Imiquimod-Induced Psoriasiform Dermatitis in Mice.
Topics: Animals; Disease Models, Animal; Eczema; Imiquimod; Inflammation; Mice; Psoriasis; Skin | 2022 |
LCN2 Mediates Skin Inflammation in Psoriasis through the SREBP2‒NLRC4 Axis.
Topics: Animals; Apoptosis Regulatory Proteins; Calcium-Binding Proteins; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Keratinocytes; Lipocalin-2; Mice; Psoriasis; Skin; Sterol Regulatory Element Binding Protein 2 | 2022 |
Design and synthesis of the 4H-chromenone derivatives against psoriasis.
Topics: Animals; Disease Models, Animal; Imiquimod; Interleukin-17; Mice; Mice, Inbred BALB C; Psoriasis; Tumor Necrosis Factor-alpha | 2022 |
Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model.
Topics: Animals; Disease Models, Animal; Imiquimod; Mice; Psoriasis; Receptors, Aryl Hydrocarbon; Skin; Th17 Cells | 2022 |
Transcutaneous delivery of mung bean-derived nanoparticles for amelioration of psoriasis-like skin inflammation.
Topics: Animals; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Nanoparticles; Psoriasis; Skin; Vigna | 2022 |
Oral Dimethyl Fumarate Targets HCA2-Expressing Skin Cells in the Imiquimod Mouse Model.
Topics: Animals; Dimethyl Fumarate; Disease Models, Animal; Imiquimod; Immunosuppressive Agents; Mice; Skin | 2022 |
KdPT alleviates imiquimod-induced psoriasis-like skin lesion in mice via inhibiting proliferation and inflammation response.
Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Cytokines; Disease Models, Animal; Endothelial Cells; Imiquimod; Inflammation; Interleukin-6; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 2022 |
Selenium-Rich Yeast Peptide Fraction Ameliorates Imiquimod-Induced Psoriasis-like Dermatitis in Mice by Inhibiting Inflammation via MAPK and NF-κB Signaling Pathways.
Topics: Animals; Cell Line; Dermatitis; Disease Models, Animal; Female; Humans; Hydrogen Peroxide; Imiquimod; Inflammation; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Peptides; Psoriasis; RAW 264.7 Cells; Selenium; Signal Transduction; Skin; Yeasts | 2022 |
The effectiveness of synthetic methoxylated isoflavones in delivering to the skin and alleviating psoriasiform lesions via topical absorption.
Topics: Animals; Disease Models, Animal; Imiquimod; Isoflavones; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Swine | 2022 |
Adiponectin-derived pentapeptide ameliorates psoriasiform skin inflammation by suppressing IL-17 production in γδT cells.
Topics: Adiponectin; Animals; Disease Models, Animal; Eczema; Imiquimod; Inflammation; Interleukin-17; Mice; Psoriasis; Receptors, Adiponectin; Skin | 2022 |
Evaluation of methotrexate-loaded surfactants, ceramides and cholesterol-based lamellar phases as a topical treatment for psoriasis.
Topics: Animals; Ceramides; Cholesterol; Disease Models, Animal; Imiquimod; Methotrexate; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Surface-Active Agents | 2022 |
3, 3'- diindolylmethane hinders IL-17A/IL-17RA interaction and mitigates imiquimod-induced psoriasiform in mice.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Indoles; Interleukin-17; Janus Kinases; Keratinocytes; Mice; Psoriasis; Signal Transduction; Skin; STAT Transcription Factors; Vascular Endothelial Growth Factor A | 2022 |
Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61.
Topics: Animals; China; Cysteine-Rich Protein 61; Disease Models, Animal; Drugs, Chinese Herbal; Imiquimod; Inflammation; Intercellular Adhesion Molecule-1; Interferon-gamma; Mice; Mice, Inbred BALB C; Psoriasis; RNA, Messenger | 2022 |
CHRNA5 Is Overexpressed in Patients with Psoriasis and Promotes Psoriasis-Like Inflammation in Mouse Models.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Humans; Imiquimod; Inflammation; JNK Mitogen-Activated Protein Kinases; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Knockout; Mitogen-Activated Protein Kinase Kinases; Nerve Tissue Proteins; NF-kappa B; Psoriasis; Receptors, Nicotinic | 2022 |
Transglutaminase 3 Attenuates Skin Inflammation in Psoriasis by Inhibiting NF-κB Activation through Phosphorylated STAT3-TET3 Signaling.
Topics: Animals; Cysteamine; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; RNA, Small Interfering; Skin; STAT3 Transcription Factor; Transglutaminases | 2022 |
Free Fatty Acid Receptor 4 (FFA4) Activation Ameliorates Imiquimod-Induced Psoriasis in Mice.
Topics: Animals; Cytokines; Disease Models, Animal; Fatty Acids, Nonesterified; Fatty Acids, Omega-3; Imiquimod; Interleukin-17; Interleukin-23; Mice; Psoriasis; Skin | 2022 |
The Essential Oil Derived from
Topics: Animals; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Interleukin-1; Interleukin-17; Interleukin-23; Interleukin-6; Keratinocytes; Mice; Mice, Inbred BALB C; Oils, Volatile; Perilla frutescens; Psoriasis; Skin | 2022 |
Synthesis and In-Vivo Evaluation of Benzoxazole Derivatives as Promising Anti-Psoriatic Drugs for Clinical Use.
Topics: Animals; Benzoxazoles; Disease Models, Animal; Imiquimod; Mice; Mice, Inbred CBA; Pharmaceutical Preparations; Psoriasis; Skin | 2022 |
Psoriasis-like skin lesions occurring at remote sites after topical imiquimod.
Topics: Animals; Cytokines; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases | 2022 |
Lck signaling inhibition causes improvement in clinical features of psoriatic inflammation through reduction in inflammatory cytokines in CD4+ T cells in imiquimod mouse model.
Topics: Adjuvants, Immunologic; Animals; CD4-Positive T-Lymphocytes; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Interleukin-17; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mice; Psoriasis; Pyrazoles; Pyrimidines; Skin; Tumor Necrosis Factor-alpha | 2022 |
Epicutaneous Application of Imiquimod to Model Psoriasis-Like Skin Disease Induces Water-Saving Aestivation Motifs and Vascular Inflammation.
Topics: Animals; Disease Models, Animal; Estivation; Humans; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Water | 2022 |
Dietary olive oil intake aggravates psoriatic skin inflammation in mice via Nrf2 activation and polyunsaturated fatty acid imbalance.
Topics: Animals; Dermatitis; Diet; Disease Models, Animal; Fatty Acids, Unsaturated; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; Olive Oil; Psoriasis; Skin; Skin Diseases | 2022 |
Estradiol suppresses psoriatic inflammation in mice by regulating neutrophil and macrophage functions.
Topics: Animals; Disease Models, Animal; Estradiol; Imiquimod; Inflammation; Interleukin-17; Interleukin-23; Macrophages; Mice; Mice, Knockout; Neutrophils; Psoriasis; Receptors, Estrogen; Skin | 2022 |
Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses.
Topics: Animals; Disease Models, Animal; Gels; Imiquimod; Nanoparticles; Psoriasis; Skin; Thalidomide | 2022 |
Lithosepermic Acid Restored the Skin Barrier Functions in the Imiquimod-Induced Psoriasis-like Animal Model.
Topics: Animals; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |
Dimeric translationally controlled tumor protein-binding peptide 2 attenuates imiquimod-induced psoriatic inflammation through induction of regulatory T cells.
Topics: Animals; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Peptides; Psoriasis; Skin; T-Lymphocytes, Regulatory; Th17 Cells; Tumor Protein, Translationally-Controlled 1 | 2022 |
Sprouty1 exerts a preventive effect on the initiation of psoriasis by inhibiting innate immune antimicrobial peptide cathelicidin and immunocytes.
Topics: Animals; Antimicrobial Cationic Peptides; Antimicrobial Peptides; Cathelicidins; Disease Models, Animal; Eosine Yellowish-(YS); Hematoxylin; Humans; Imiquimod; Immunity, Innate; Inflammation; Interleukin-17; Keratinocytes; Membrane Proteins; Mice; Phosphoproteins; Psoriasis; Skin | 2022 |
Tiamulin inhibits TNF-α and alleviates psoriasis-like dermatitis.
Topics: Animals; Dermatitis; Disease Models, Animal; Diterpenes; Imiquimod; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Tumor Necrosis Factor-alpha | 2022 |
An Emerging Role of
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Imiquimod; Interleukin-17; Interleukin-23; Male; Mice; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Proanthocyanidins; Psoriasis; Reactive Oxygen Species; RNA, Messenger; Skin; Superoxide Dismutase; Vascular Endothelial Growth Factor A | 2022 |
Anti-IL-17A ssDNA aptamer ameliorated psoriasis skin lesions in the imiquimod-induced psoriasis mouse model.
Topics: Animals; Antibodies, Monoclonal; Disease Models, Animal; DNA, Single-Stranded; Imiquimod; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Psoriasis; RNA, Messenger; Skin | 2022 |
Topical VX-509 attenuates psoriatic inflammation through the STAT3/FABP5 pathway in keratinocytes.
Topics: Animals; Disease Models, Animal; Fatty Acid-Binding Proteins; Heterocyclic Compounds, 2-Ring; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Psoriasis; Skin; STAT3 Transcription Factor; Valine | 2022 |
Potential mechanism of oral baicalin treating psoriasis via suppressing Wnt signaling pathway and inhibiting Th17/IL-17 axis by activating PPARγ.
Topics: Animals; Disease Models, Animal; Estrogens; Flavonoids; Imiquimod; Interleukin-17; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; PPAR gamma; Protein Kinases; Psoriasis; Skin; Skin Diseases; Th17 Cells; Tumor Necrosis Factor-alpha; Wnt Signaling Pathway | 2022 |
Dynamic trafficking patterns of IL-17-producing γδ T cells are linked to the recurrence of skin inflammation in psoriasis-like dermatitis.
Topics: Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin-17; Mice; Psoriasis; Skin; T-Lymphocytes | 2022 |
Exacerbation of psoriatic arthritis due to topical imiquimod therapy.
Topics: Administration, Topical; Aminoquinolines; Animals; Arthritis, Psoriatic; Disease Models, Animal; Humans; Imiquimod; Psoriasis; Skin | 2023 |
Functional Interplay between IL-9 and Peptide YY Contributes to Chronic Skin Inflammation.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Interleukin-9; Keratinocytes; Mice; Peptide YY; Psoriasis; Skin | 2022 |
Calcium/calmodulin-dependent protein kinase IV promotes imiquimod-induced psoriatic inflammation via macrophages and keratinocytes in mice.
Topics: Animals; Calcium; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Disease Models, Animal; Humans; Imiquimod; Inflammation; Keratinocytes; Macrophages; Mice; Psoriasis | 2022 |
Topical administration of the secretome derived from human amniotic epithelial cells ameliorates psoriasis-like skin lesions in mice.
Topics: Administration, Topical; Animals; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin 1 Receptor Antagonist Protein; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Secretome; Skin | 2022 |
Sinomenine Suppressed Keratinocyte Proliferation and Imiquimod-Induced Psoriasis-Like Dermatitis by Regulating lncRNA XIST.
Topics: Animals; Anti-Inflammatory Agents; Cell Proliferation; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; RNA, Long Noncoding; Skin Diseases | 2022 |
Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - Smilax glabra Roxb herb pair for the treatment of psoriasis.
Topics: Amino Acids; Animals; Carnitine; Cimicifuga; Cytokines; Disease Models, Animal; Imiquimod; Interleukin-6; Keratinocytes; Mice; Mice, Inbred BALB C; Network Pharmacology; Plant Extracts; Psoriasis; RNA-Seq; Skin; Smilax | 2022 |
Dysbiosis in imiquimod-induced psoriasis alters gut immunity and exacerbates colitis development.
Topics: Animals; Colitis; Colon; Dextran Sulfate; Disease Models, Animal; Dysbiosis; Imiquimod; Inflammatory Bowel Diseases; Mice; Mice, Inbred C57BL; Psoriasis | 2022 |
Elevated cholesteryl ester transfer and phospholipid transfer proteins aggravated psoriasis in imiquimod-induced mouse models.
Topics: Animals; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Imiquimod; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phospholipid Transfer Proteins; Psoriasis | 2022 |
Effect on ethanolic extract of sechiumedule fruitson imquimod-induced psoriasis like dermatitis in wistar rats.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Male; Mice; Psoriasis; Rats; Rats, Wistar; Skin | 2022 |
Decreasing GDF15 Promotes Inflammatory Signals and Neutrophil Infiltration in Psoriasis Models.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Neutrophil Infiltration; Psoriasis; Skin | 2023 |
NMR-based metabolomic analysis for the effects of moxibustion on imiquimod-induced psoriatic mice.
Topics: Alanine; Animals; Asparagine; Aspartic Acid; Cytokines; Disease Models, Animal; Glucose; Histidine; Imiquimod; Interleukin-17; Interleukin-23; Interleukin-8; Magnetic Resonance Spectroscopy; Mice; Moxibustion; Psoriasis; Skin; Taurine; Triglycerides; Valine | 2023 |
Imiquimod-induced ex vivo model of psoriatic human skin via interleukin-17A signalling of T cells and Langerhans cells.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Langerhans Cells; Psoriasis; Skin; T-Lymphocytes | 2022 |
Inhibition of JAK1/STAT3 pathway by 2-methoxyestradiol ameliorates psoriatic features in vitro and in an imiquimod-induced psoriasis-like mouse model.
Topics: 2-Methoxyestradiol; Animals; Cell Proliferation; Dermatitis; Disease Models, Animal; Endothelial Cells; Humans; Imiquimod; Interleukin-17; Janus Kinase 1; Keratinocytes; Mercaptoethanol; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Ointments; Psoriasis; Skin; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A | 2022 |
[The number of regulatory T cells in spleen and serum-related cytokines increase in mouse model of psoriasis induced by imiquimod].
Topics: Animals; Cytokines; Disease Models, Animal; Female; Imiquimod; Interleukin-10; Interleukin-17; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Spleen; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1 | 2022 |
Novel RNA polymerase I inhibitor CX-5461 suppresses imiquimod-induced experimental psoriasis.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Disease Models, Animal; Endothelial Cells; Imiquimod; Inflammation; Keratinocytes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Psoriasis; RNA Polymerase I; Skin | 2023 |
Oestrogen inhibits psoriasis-like dermatitis induced by imiquimod in mice in relation to increased IL-10 producing cells despite elevated expression of IL-22, IL-23, IL-17 mRNA.
Topics: Animals; Dermatitis; Disease Models, Animal; Estrogens; Female; Imiquimod; Inflammation; Interleukin-10; Interleukin-17; Interleukin-22; Interleukin-23; Interleukins; Mice; Mice, Inbred BALB C; Psoriasis; RNA, Messenger | 2023 |
Lenalidomide attenuates IMQ-induced inflammation in a mouse model of psoriasis.
Topics: Animals; Disease Models, Animal; Imiquimod; Inflammation; Lenalidomide; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Psoriasis; Skin; Tumor Microenvironment | 2022 |
Reduction of Methyltransferase-like 3-Mediated RNA N6-Methyladenosine Exacerbates the Development of Psoriasis Vulgaris in Imiquimod-Induced Psoriasis-like Mouse Model.
Topics: Adenosine; Animals; Disease Models, Animal; Humans; Imiquimod; Inflammation; Methyltransferases; Mice; Psoriasis; RNA; RNA, Messenger | 2022 |
Eupatilin inhibits keratinocyte proliferation and ameliorates imiquimod-induced psoriasis-like skin lesions in mice via the p38 MAPK/NF-κB signaling pathway.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Imiquimod; Interleukin-17; Interleukin-23; Interleukin-6; Keratinocytes; Lipopolysaccharides; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Psoriasis; Skin; Skin Diseases; Tumor Necrosis Factor-alpha | 2023 |
Knockdown of Bcl-3 alleviates psoriasis and dyslipidemia comorbidity by regulating Akt pathway.
Topics: Animals; Apolipoproteins E; Cholesterol; Comorbidity; Disease Models, Animal; Dyslipidemias; Glycogen Synthase Kinase 3 beta; Imiquimod; Leukemia, B-Cell; Mice; Mice, Inbred BALB C; NF-kappa B; Proto-Oncogene Proteins c-akt; Psoriasis; RNA, Small Interfering; Skin | 2022 |
Allicin ameliorates imiquimod-induced psoriasis-like skin inflammation via disturbing the interaction of keratinocytes with IL-17A.
Topics: Animals; Dermatitis; Disease Models, Animal; Guinea Pigs; Imiquimod; Inflammation; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Rabbits; Skin | 2023 |
A Study on MDA5 Signaling in Splenic B Cells from an Imiquimod-Induced Lupus Mouse Model with Proteomics.
Topics: Animals; DEAD-box RNA Helicases; Disease Models, Animal; Imiquimod; Interferon-Induced Helicase, IFIH1; Lupus Erythematosus, Systemic; Mice; Proteomics; Signal Transduction; Toll-Like Receptor 7; Virus Diseases | 2022 |
CCN1 upregulates IL-36 via AKT/NF-κB and ERK/CEBP β-mediated signaling pathways in psoriasis-like models.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Proto-Oncogene Proteins c-akt; Psoriasis; Signal Transduction; Skin | 2023 |
Tryptanthrin ameliorates imiquimod-induced psoriasis in mice by suppressing inflammation and oxidative stress via NF-κB/MAPK/Nrf2 pathways.
Topics: Animals; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Psoriasis; Signal Transduction; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2023 |
Neutrophils inhibit γδ T cell functions in the imiquimod-induced mouse model of psoriasis.
Topics: Animals; Disease Models, Animal; Disease Progression; Eczema; Imiquimod; Mice; NADP; NADPH Oxidases; Neutrophils; Psoriasis | 2022 |
Kaempferol modulates IFN-γ induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions.
Topics: Animals; Disease Models, Animal; Imiquimod; Interferon-gamma; Janus Kinases; Kaempferols; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Signal Transduction; Skin; STAT Transcription Factors; Suppressor of Cytokine Signaling Proteins | 2023 |
A Dietary Oxysterol, 7-Ketocholesterol, Exacerbates Imiquimod-Induced Psoriasis-like Dermatitis in Steatohepatitic Mice.
Topics: Animals; Dermatitis; Diet, High-Fat; Disease Models, Animal; Imiquimod; Ketocholesterols; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oxysterols; Psoriasis | 2022 |
Lipidomic profiling reveals metabolic signatures in psoriatic skin lesions.
Topics: Animals; Ceramides; Disease Models, Animal; Imiquimod; Inflammation; Keratinocytes; Lipidomics; Lipids; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
FcγRIIB inhibits inflammation in a murine model of psoriasis.
Topics: Animals; Dermatitis; Disease Models, Animal; Forkhead Transcription Factors; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2022 |
Development and evaluation emulgel for effective management of the imiquimod-induced psoriasis.
Topics: Animals; Body Weight; Disease Models, Animal; Imiquimod; Inflammation; Male; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Comparative studies on mannan and imiquimod induced experimental plaque psoriasis inflammation in inbred mice.
Topics: Animals; Dexamethasone; Disease Models, Animal; Imiquimod; Inflammation; Mannans; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Potential skin health promoting benefits of costunolide: a therapeutic strategy to improve skin inflammation in imiquimod-induced psoriasis.
Topics: Animals; Cytokines; Dermatitis; Disease Models, Animal; Health Promotion; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Sesquiterpenes; Skin | 2023 |
Imiquimod induces skin inflammation in humanized BRGSF mice with limited human immune cell activity.
Topics: Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammation; Mice; Psoriasis; Skin | 2023 |
Oral exposure to citrinin significantly exacerbates the pathophysiology of a mouse model of imiquimod-induced psoriasis via direct activation of dendritic cell.
Topics: Aminoquinolines; Animals; Citrinin; Dendritic Cells; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Aberrant promoter methylation of Wnt inhibitory factor-1 gene is a potential target for treating psoriasis.
Topics: Animals; Decitabine; Disease Models, Animal; DNA Methylation; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Promoter Regions, Genetic; Psoriasis; Skin | 2023 |
Topical application of imatinib mesylate ameliorated psoriasis-like skin lesions in imiquimod-induced murine model via angiogenesis inhibition.
Topics: Animals; Disease Models, Animal; Humans; Imatinib Mesylate; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Vascular Endothelial Growth Factor A | 2023 |
Fufang Shengdi mixture alleviates psoriasis-like skin inflammation via promoting Annexin-A proteins expression.
Topics: Animals; Annexins; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases; Tumor Necrosis Factor-alpha | 2023 |
Isostearic acid is an active component of imiquimod formulations used to induce psoriaform disease models.
Topics: Animals; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Skin; Toll-Like Receptor 7 | 2023 |
The Impact of Proinflammatory Cytokines and Imiquimod on GLUT1 in HaCaT Keratinocytes - a Potential Anti-Psoriatic Therapeutic Target?
Topics: Animals; Cytokines; Disease Models, Animal; Glucose Transporter Type 1; Humans; Imiquimod; Inflammation; Interleukin-17; Interleukin-23; Interleukin-6; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 2023 |
Palbociclib blocks neutrophilic phosphatidylinositol 3-kinase activity to alleviate psoriasiform dermatitis.
Topics: Animals; Anti-Inflammatory Agents; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammation; Mice; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Psoriasis | 2023 |
Impact of Obesity on the IL-6 Immune Marker and Th17 Immune Cells in C57BL/6 Mice Models with Imiquimod-Induced Psoriasis.
Topics: Animals; Biomarkers; Cytokines; Disease Models, Animal; Imiquimod; Interleukin-6; Mice; Mice, Inbred C57BL; Obesity; Psoriasis; Skin; Th17 Cells | 2023 |
Specific Activation of CB2R Ameliorates Psoriasis-Like Skin Lesions by Inhibiting Inflammation and Oxidative Stress.
Topics: Animals; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Kelch-Like ECH-Associated Protein 1; Keratinocytes; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; Oxidative Stress; Psoriasis; Skin; Skin Diseases | 2023 |
Diosmin nanocrystal gel alleviates imiquimod-induced psoriasis in rats via modulating TLR7,8/NF-κB/micro RNA-31, AKT/mTOR/P70S6K milieu, and Tregs/Th17 balance.
Topics: Animals; Anti-Inflammatory Agents; Diosmin; Disease Models, Animal; Imiquimod; Mice; Mice, Inbred BALB C; MicroRNAs; Nanoparticles; NF-kappa B; Proto-Oncogene Proteins c-akt; Psoriasis; Rats; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Skin; Toll-Like Receptor 7; TOR Serine-Threonine Kinases | 2023 |
Lysophosphatidylcholine facilitates the pathogenesis of psoriasis through activating keratinocytes and T cells differentiation via glycolysis.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Imiquimod; Keratinocytes; Lysophosphatidylcholines; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Diseases | 2023 |
Translation-dependent skin hyperplasia is promoted by type 1/17 inflammation in psoriasis.
Topics: Animals; Disease Models, Animal; Eukaryotic Initiation Factor-4E; Humans; Hyperplasia; Imiquimod; Inflammation; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 2023 |
Soluble adenylyl cyclase contributes to imiquimod-mediated inflammation and is a potential therapeutic target in psoriasis.
Topics: Adenylyl Cyclases; Animals; Disease Models, Animal; Eczema; Imiquimod; Inflammation; Mice; Psoriasis; Skin; Th17 Cells | 2023 |
Etanercept ameliorates psoriasis progression through regulating high mobility group box 1 pathway.
Topics: Animals; Disease Models, Animal; Etanercept; HMGB1 Protein; Imiquimod; Inflammation; Keratinocytes; Lipopolysaccharides; Mice; Psoriasis; Receptor for Advanced Glycation End Products | 2023 |
Piperine ameliorates psoriatic skin inflammation by inhibiting the phosphorylation of STAT3.
Topics: Alkaloids; Animals; Cytokines; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Phosphorylation; Psoriasis; Skin; STAT3 Transcription Factor | 2023 |
Topics: Animals; Cytokines; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukins; Keratinocytes; Mice; Psoriasis; Skin; TEA Domain Transcription Factors; Th1 Cells; Th17 Cells; Transcription Factor AP-2 | 2023 |
Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response.
Topics: Animals; Disease Models, Animal; Eczema; Histone Deacetylase 1; Humans; Imiquimod; Interleukin-17; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
RNA sequencing and metabolic analysis of imiquimod-induced psoriasis-like mice with chronic restrain stress.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Sequence Analysis, RNA; Skin | 2023 |
TRPV4 Regulates the Development of Psoriasis by Controlling Adenosine Triphosphate Expression in Keratinocytes and the Neuroimmune System.
Topics: Adenosine Triphosphate; Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Knockout; Neuropeptides; Psoriasis; Skin; TRPV Cation Channels | 2023 |
Centella asiatica alleviates psoriasis through JAK/STAT3-mediated inflammation: An in vitro and in vivo study.
Topics: Animals; Antioxidants; Centella; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Skin | 2023 |
SLC35E1 promotes keratinocyte proliferation in psoriasis by regulating zinc homeostasis.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Homeostasis; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Nucleotide Transport Proteins; Psoriasis | 2023 |
Benzoylaconitine Alleviates Progression of Psoriasis via Suppressing STAT3 Phosphorylation in Keratinocytes.
Topics: Animals; Cell Proliferation; Cytokines; Disease Models, Animal; Imiquimod; Keratinocytes; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Phosphorylation; Psoriasis; Skin; Tumor Necrosis Factor-alpha | 2023 |
Liangxue Jiedu formula improves imiquimod-induced psoriasiform dermatitis with circadian desynchrony by regulating Th17 cell differentiation based on network pharmacological analysis.
Topics: Animals; Cell Differentiation; Dermatitis; Disease Models, Animal; Imiquimod; Interleukin-17; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Th17 Cells | 2023 |
Anti-interleukin 33 treatment alleviates psoriatic dermatitis in mice induced imiquimod.
Topics: Animals; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Interleukin-33; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
PARP2 promotes inflammation in psoriasis by modulating estradiol biosynthesis in keratinocytes.
Topics: Animals; Aromatase; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Psoriasis; RNA, Messenger; Skin | 2023 |
Effect and mechanism of hydrogen-rich bath on mice with imiquimod-induced psoriasis.
Topics: Animals; Disease Models, Animal; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Water | 2023 |
RasGRP1 influences imiquimod-induced psoriatic inflammation via T-cell activation in mice.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Vascular Endothelial Growth Factor A | 2023 |
An alkaloid-rich phytopharmaceutical prepared from Qing Dai against IL-17A-induced psoriasis.
Topics: Alkaloids; Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Imiquimod; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Quality of Life; Skin | 2024 |
Gentiopicroside-Loaded Chitosan Nanoparticles Inhibit TNF-α-Induced Proliferation and Inflammatory Response in HaCaT Keratinocytes and Ameliorate Imiquimod-Induced Dermatitis Lesions in Mice.
Topics: Animals; Cell Proliferation; Chitosan; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Interleukin-17; Interleukin-6; Keratinocytes; Mice; Mice, Inbred BALB C; Nanoparticles; Psoriasis; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2023 |
IL-17A exacerbates psoriasis in a STAT3 overexpressing mouse model.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Interleukin-17; Mice; Psoriasis; Skin | 2023 |
Qingre Lishi Decoction ameliorates imiquimod-induced psoriasis-like skin lesions in SKH-1 mice by regulating the Treg-DC-Th17 axis and inhibiting MAPK-mediated DC maturation.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Psoriasis; Skin; Skin Diseases; T-Lymphocytes, Regulatory; Th17 Cells | 2024 |
Characterization and active component identification of Premna herbacea roxb. root extract reveals anti-inflammatory effect and amelioration of imiquimod induced psoriasis via modulation of macrophage inflammatory response.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Humans; Imiquimod; Inflammation; Macrophages; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Plant Extracts; Psoriasis; Skin | 2023 |
Forward genetics and functional analysis highlight Itga11 as a modulator of murine psoriasiform dermatitis.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Integrin alpha Chains; Mice; Psoriasis; Skin | 2023 |
Tranexamic acid improves psoriasis-like skin inflammation: Evidence from in vivo and in vitro studies.
Topics: Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Inflammasomes; Inflammation; Interleukin-17; Keratin-17; Keratinocytes; Mice; Mice, Inbred BALB C; NF-E2-Related Factor 2; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; Skin; Tranexamic Acid | 2023 |
Imiquimod-induced extensive plaque psoriasis.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Nutraceutical combination ameliorates imiquimod-induced psoriasis in mice.
Topics: Animals; Cannabidiol; Dietary Supplements; Disease Models, Animal; Erythema; Humans; Imiquimod; Inositol; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Cannabidiol-Loaded Lipid-Stabilized Nanoparticles Alleviate Psoriasis Severity in Mice: A New Approach for Improved Topical Drug Delivery.
Topics: Animals; Cannabidiol; Disease Models, Animal; Emulsions; Imiquimod; Interleukin-17; Lipids; Mice; Mice, Inbred BALB C; Nanoparticles; Psoriasis; Rats; Skin | 2023 |
Mechanisms of the PD-1/PD-L1 pathway in itch: From acute itch model establishment to the role in chronic itch in mouse.
Topics: Animals; B7-H1 Antigen; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Disease Models, Animal; Imiquimod; Immune Checkpoint Inhibitors; Mice; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor; Pruritus; Psoriasis; Spinal Cord Dorsal Horn | 2023 |
Topical anti-TNF-a ssDNA aptamer decreased the imiquimod induced psoriatic inflammation in BALB/c mice.
Topics: Animals; Disease Models, Animal; DNA, Single-Stranded; Imiquimod; Inflammation; Interleukin-17; Mice; Mice, Inbred BALB C; Psoriasis; RNA, Messenger; Skin; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2023 |
Discovery of 3-Phenyl Indazole-Based Novel Chemokine-like Receptor 1 Antagonists for the Treatment of Psoriasis.
Topics: Animals; Chemokines; Cricetinae; Cricetulus; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Development of a Deep Eutectic Solvent-Assisted Kaempferol Hydrogel: A Promising Therapeutic Approach for Psoriasis-like Skin Inflammation.
Topics: Animals; Antioxidants; Deep Eutectic Solvents; Disease Models, Animal; Hydrogels; Imiquimod; Inflammation; Kaempferols; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2023 |
Characterization of spinal microglial activation in a mouse model of imiquimod-induced psoriasis.
Topics: Animals; Disease Models, Animal; Imiquimod; Mice; Microglia; Pruritus; Psoriasis; Spinal Cord | 2023 |
Staphylococcus warneri strain XSB102 exacerbates psoriasis and promotes keratinocyte proliferation in imiquimod-induced psoriasis-like dermatitis mice.
Topics: Animals; Cell Proliferation; Dermatitis; Disease Models, Animal; Homeodomain Proteins; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Repressor Proteins; Skin; Staphylococcus | 2023 |
Imiquimod-induced pruritus in female wild-type and knockin Wistar rats: underscoring behavioral scratching in a rat model for antipruritic treatments.
Topics: Animals; Antipruritics; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred C57BL; Pruritus; Psoriasis; Rats; Rats, Wistar; Skin | 2023 |
Opposing roles of endothelial and leukocyte-expressed IL-7Rα in the regulation of psoriasis-like skin inflammation.
Topics: Animals; Antibodies, Neutralizing; CD4-Positive T-Lymphocytes; Disease Models, Animal; Endothelial Cells; Female; Gene Expression Regulation; Humans; Imiquimod; Inflammation; Interleukin-7; Lymph Nodes; Lymphatic Vessels; Male; Mice; Mice, Inbred C57BL; Organ Specificity; Oxazolone; Psoriasis; Receptors, Interleukin-7; Signal Transduction; Skin; Tetradecanoylphorbol Acetate | 2019 |
Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Proliferation; Cytokines; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin-17; Interleukin-6; Kaempferols; Mice, Inbred BALB C; Psoriasis; Signal Transduction; Skin | 2019 |
Development, characterization and evaluation of topical methotrexate-entrapped deformable liposome on imiquimod-induced psoriasis in a mouse model.
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; Female; Folic Acid Antagonists; Imiquimod; Immunosuppressive Agents; Liposomes; Methotrexate; Mice, Inbred BALB C; Psoriasis | 2019 |
Targeting the IL-17 Receptor Using Liposomal Spherical Nucleic Acids as Topical Therapy for Psoriasis.
Topics: Administration, Cutaneous; Animals; Biomarkers; Cells, Cultured; Disease Models, Animal; DNA, Antisense; Gene Knockdown Techniques; Humans; Imiquimod; Keratinocytes; Liposomes; Mice; Nanospheres; Primary Cell Culture; Psoriasis; Receptors, Interleukin-17; RNA, Messenger; Severity of Illness Index; Skin | 2020 |
IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.
Topics: A549 Cells; Animals; Antibodies, Blocking; Antibodies, Monoclonal; Cell Line, Tumor; Disease Models, Animal; HEK293 Cells; Humans; Imiquimod; Inflammation; Interleukin-1; Interleukin-1 Receptor Accessory Protein; Interleukin-1beta; Interleukin-33; Male; Mice; Mice, Inbred C57BL; Ovalbumin; Peritonitis; Pneumonia; Psoriasis; Signal Transduction; Uric Acid | 2019 |
Ginsenoside Rg1 abolish imiquimod-induced psoriasis-like dermatitis in BALB/c mice via downregulating NF-κB signaling pathway.
Topics: Animals; Dermatitis; Disease Models, Animal; Down-Regulation; Ginsenosides; Humans; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Signal Transduction; Transcription Factor RelA; Tumor Necrosis Factor-alpha | 2019 |
The Influence of Ketogenic Diets on Psoriasiform-Like Skin Inflammation.
Topics: 3-Hydroxybutyric Acid; Animals; Biopsy; Blood Glucose; Diet, Ketogenic; Disease Models, Animal; Fatty Acids, Omega-3; Humans; Imiquimod; Male; Mice; Psoriasis; Severity of Illness Index; Skin; Triglycerides; Weight Gain | 2020 |
Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis.
Topics: Animals; Cytokines; Disease Models, Animal; Imiquimod; Male; Mice; Mice, Inbred BALB C; Peptides; Psoriasis; RANK Ligand | 2019 |
Nanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in Psoriasis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Female; Gold; Humans; Imiquimod; Immunity; Methotrexate; Mice; Mice, Inbred C57BL; Nanoparticles; Psoriasis; Skin; Th17 Cells; Xenograft Model Antitumor Assays | 2020 |
Biological depletion of neutrophils attenuates pro-inflammatory markers and the development of the psoriatic phenotype in a murine model of psoriasis.
Topics: Animals; Biomarkers; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Inflammation; Leukocyte Reduction Procedures; Mice; Mice, Inbred BALB C; Neutrophils; Phenotype; Psoriasis | 2020 |
Convallatoxin induces HaCaT cell necroptosis and ameliorates skin lesions in psoriasis-like mouse models.
Topics: Animals; Disease Models, Animal; Female; HaCaT Cells; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Necroptosis; Protein Kinases; Psoriasis; Reactive Oxygen Species; Skin; Strophanthins | 2020 |
Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis.
Topics: Animals; Cell Line; Cell Proliferation; Cytokines; Disease Models, Animal; Gene Expression; Humans; Imiquimod; Inflammation; Interleukin-6; Keratinocytes; Male; Mice; Mice, Knockout; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Psoriasis; RNA, Messenger; Severity of Illness Index; Th17 Cells; TRPV Cation Channels | 2020 |
Calcipotriol and betamethasone dipropionate exhibit different immunomodulatory effects on imiquimod-induced murine psoriasiform dermatitis.
Topics: Administration, Cutaneous; Animals; Betamethasone; Calcitriol; Cytokines; Dermatologic Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Gene Expression Regulation; Glucocorticoids; Humans; Imiquimod; Mice; Ointments; Psoriasis; Skin; Th1 Cells; Th17 Cells | 2020 |
Topical administration of nanocarrier miRNA-210 antisense ameliorates imiquimod-induced psoriasis-like dermatitis in mice.
Topics: Administration, Cutaneous; Animals; Antagomirs; Disease Models, Animal; Drug Carriers; Female; Gels; Humans; Imiquimod; Lipoproteins, HDL; Mice; MicroRNAs; Nanoparticles; Psoriasis; Skin; Th1 Cells; Th17 Cells | 2020 |
The potential of Diosgenin in treating psoriasis: Studies from HaCaT keratinocytes and imiquimod-induced murine model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line; Cell Proliferation; Cytokines; Diosgenin; Disease Models, Animal; Female; Human Umbilical Vein Endothelial Cells; Humans; Imiquimod; Keratinocytes; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Receptors, Interleukin | 2020 |
Acitretin inhibits IL-17A-induced IL-36 expression in keratinocytes by down-regulating IκBζ.
Topics: Acitretin; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Down-Regulation; Female; Humans; I-kappa B Kinase; Imiquimod; Interleukin-1; Interleukin-17; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis | 2020 |
Mechanism of danshensu-induced inhibition of abnormal epidermal proliferation in psoriasis.
Topics: Adaptor Proteins, Signal Transducing; Administration, Oral; Animals; Apoptosis; Cell Cycle Proteins; Cell Line; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Epidermis; Female; G1 Phase Cell Cycle Checkpoints; Humans; Imiquimod; Injections, Intraperitoneal; Keratinocytes; Lactates; Mice; Psoriasis; Salvia miltiorrhiza; Transcription Factors; YAP-Signaling Proteins | 2020 |
Tussilagonone Ameliorates Psoriatic Features in Keratinocytes and Imiquimod-Induced Psoriasis-Like Lesions in Mice via NRF2 Activation.
Topics: Administration, Cutaneous; Adult; Animals; Anti-Inflammatory Agents; Cell Line; Cell Proliferation; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Imiquimod; Keratinocytes; Mice; NF-E2-Related Factor 2; Pentanoic Acids; Psoriasis; Sesquiterpenes; Tussilago | 2020 |
Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
Topics: Animals; Cell Differentiation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Female; Fluorescence Resonance Energy Transfer; Imiquimod; Mice; Mice, Inbred BALB C; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Nuclear Receptor Subfamily 1, Group F, Member 3; Psoriasis; Quinolines; Structure-Activity Relationship; Sulfonamides; Th17 Cells | 2020 |
PSORI-CM02 formula alleviates imiquimod-induced psoriasis via affecting macrophage infiltration and polarization.
Topics: Adjuvants, Immunologic; Animals; Cell Differentiation; Cytokines; Disease Models, Animal; Drugs, Chinese Herbal; Imiquimod; Macrophages; Mice; Psoriasis; RAW 264.7 Cells; RNA, Messenger; Skin | 2020 |
Aryl Hydrocarbon Receptor in Cutaneous Vascular Endothelial Cells Restricts Psoriasis Development by Negatively Regulating Neutrophil Recruitment.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Biopsy; Disease Models, Animal; Down-Regulation; Endothelial Cells; Endothelium, Vascular; Female; Humans; Imiquimod; Intercellular Adhesion Molecule-1; Interleukin-23; Male; Mice; Mice, Knockout; Neutrophil Infiltration; Psoriasis; Receptors, Aryl Hydrocarbon; Skin | 2020 |
Effects of tumor necrosis factor-like ligand 1A (TL1A) on imiquimod-induced psoriasiform skin inflammation in mice.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Male; Mice; Psoriasis; Signal Transduction; Skin; Tumor Necrosis Factor Ligand Superfamily Member 15; Tumor Necrosis Factor-alpha | 2020 |
Bruton's tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Immunity, Innate; Interleukin-17; Interleukin-23; Intraepithelial Lymphocytes; Male; Mice; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrazoles; Pyrimidines; Signal Transduction; Skin | 2020 |
Diet-induced obesity exacerbates imiquimod-mediated psoriasiform dermatitis in anti-PD-1 antibody-treated mice: Implications for patients being treated with checkpoint inhibitors for cancer.
Topics: Animals; Diet, Western; Disease Models, Animal; Female; Humans; Imiquimod; Immune Checkpoint Inhibitors; Mice; Neoplasms; Obesity; Programmed Cell Death 1 Receptor; Psoriasis; Risk Factors; Skin; Symptom Flare Up | 2020 |
Imiquimod-related dermatitis is mainly mediated by mast cell degranulation via Mas-related G-protein coupled receptor B2.
Topics: Animals; Calcium Signaling; Cell Degranulation; Dermatitis; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; HEK293 Cells; Humans; Imiquimod; Male; Mast Cells; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, G-Protein-Coupled | 2020 |
PDRN, a Bioactive Natural Compound, Ameliorates Imiquimod-Induced Psoriasis through NF-κB Pathway Inhibition and Wnt/β-Catenin Signaling Modulation.
Topics: Animals; beta Catenin; Cytokines; Disease Models, Animal; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; NF-kappa B; Polydeoxyribonucleotides; Psoriasis; Receptor, Adenosine A2A; Skin; Wnt Signaling Pathway | 2020 |
Nanostructured lipid carrier co-delivering tacrolimus and TNF-α siRNA as an innovate approach to psoriasis.
Topics: Administration, Cutaneous; Animals; Delayed-Action Preparations; Disease Models, Animal; Down-Regulation; Drug Synergism; Female; Imiquimod; Liposomes; Male; Mice; Mice, Inbred BALB C; Nanoparticles; NIH 3T3 Cells; Particle Size; Psoriasis; RNA, Small Interfering; Tacrolimus; Tumor Necrosis Factor-alpha | 2020 |
Inhibition of keratinocyte necroptosis mediated by RIPK1/RIPK3/MLKL provides a protective effect against psoriatic inflammation.
Topics: Acrylamides; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Female; HaCaT Cells; Humans; Imidazoles; Imiquimod; Indoles; Inflammation Mediators; Keratinocytes; Mice, Inbred BALB C; Necroptosis; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Psoriasis; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Skin; Sulfonamides | 2020 |
Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides.
Topics: Animals; Antimicrobial Cationic Peptides; Chemokine CCL20; Disease Models, Animal; Down-Regulation; Epidermis; Flavonoids; Humans; Hyperplasia; Imiquimod; Inflammation; Interleukin-17; Interleukin-22; Interleukins; Keratinocytes; Male; MAP Kinase Signaling System; Mice, Inbred BALB C; NF-kappa B; Phosphorylation; Psoriasis; RNA, Messenger; Skin; Tumor Necrosis Factor-alpha | 2020 |
A mouse model of MSU-induced acute inflammation
Topics: Acute Disease; Adjuvants, Immunologic; Administration, Topical; Animals; Antioxidants; Cytokines; Disease Models, Animal; Gout; Imiquimod; Inflammation; Injections, Subcutaneous; Interleukin-1beta; Magnetic Resonance Imaging; Mice; Mice, Knockout; Uric Acid | 2020 |
Development of flavanone and its derivatives as topical agents against psoriasis: The prediction of therapeutic efficiency through skin permeation evaluation and cell-based assay.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Cell Line; Disease Models, Animal; Female; Flavanones; Humans; Imiquimod; Keratinocytes; Mice; Models, Biological; Models, Molecular; Permeability; Psoriasis; Skin; Skin Absorption; Specific Pathogen-Free Organisms; Structure-Activity Relationship; Swine; Water Loss, Insensible | 2020 |
Albendazole negatively regulates keratinocyte proliferation.
Topics: Albendazole; Animals; cdc25 Phosphatases; Cell Line; Cell Proliferation; Cytokines; Dermatologic Agents; Disease Models, Animal; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Humans; Imiquimod; Inflammation Mediators; Keratinocytes; Keratins; Male; Mice, Inbred C57BL; Phosphorylation; Psoriasis; S Phase Cell Cycle Checkpoints; Signal Transduction; Skin | 2020 |
Molecular bases for HOIPINs-mediated inhibition of LUBAC and innate immune responses.
Topics: A549 Cells; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Disease Models, Animal; Enzyme Inhibitors; Female; HEK293 Cells; HeLa Cells; Humans; Imiquimod; Immunity, Innate; Inflammation Mediators; Intracellular Signaling Peptides and Proteins; Jurkat Cells; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, Inbred BALB C; Molecular Structure; Psoriasis; Signal Transduction; Structure-Activity Relationship; Transcription Factors; Ubiquitin-Protein Ligases; Ubiquitins | 2020 |
Therapeutic Effects of Anti-Bone Morphogenetic Protein and Activin Membrane-Bound Inhibitor Treatment in Psoriasis and Arthritis.
Topics: Adjuvants, Immunologic; Animals; Antibodies, Monoclonal; Arthritis, Experimental; Arthritis, Psoriatic; CD4-Positive T-Lymphocytes; Cell Differentiation; Collagen Type II; Disease Models, Animal; Imiquimod; Interleukin-17; Interleukin-2; Mannans; Membrane Proteins; Mice; Mice, Knockout; Psoriasis; Saccharomyces cerevisiae; Skin; T-Lymphocytes, Regulatory; Th17 Cells; Transforming Growth Factor beta | 2020 |
Interleukin-33 alleviates psoriatic inflammation by suppressing the T helper type 17 immune response.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Humans; Imiquimod; Immune Tolerance; Immunity, Cellular; Inflammation; Interleukin-17; Interleukin-33; Mice; Mice, Inbred C57BL; Psoriasis; Skin; Th17 Cells | 2020 |
Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.
Topics: Acarbose; Animals; Anti-Inflammatory Agents; Cyclosporine; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Humans; Imiquimod; Male; Mice; Psoriasis; T-Lymphocytes, Regulatory; Tumor Necrosis Factor-alpha | 2020 |
Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells.
Topics: Animals; Cell Line; Disease Models, Animal; Endothelial Cells; Female; Humans; Imiquimod; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Oligopeptides; Psoriasis; Transendothelial and Transepithelial Migration | 2020 |
Imiquimod suppresses respiratory syncytial virus (RSV) replication via PKA pathway and reduces RSV induced-inflammation and viral load in mice lungs.
Topics: A549 Cells; Animals; Antiviral Agents; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Cytokines; Disease Models, Animal; Epithelial Cells; Female; Humans; Imiquimod; Inflammation; Lung; Mice; Mice, Inbred BALB C; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Signal Transduction; Viral Load; Virus Replication | 2020 |
Immune Modulation of Monocytes Dampens the IL-17
Topics: Animals; Antigens, Ly; Disease Models, Animal; Humans; Imiquimod; Immunologic Factors; Interleukin-17; Interleukin-1beta; Interleukin-23; Intraepithelial Lymphocytes; Macrophages; Male; Mice; Monocytes; Psoriasis; Severity of Illness Index; Skin | 2020 |
The Role of Gut Microbiome in Psoriasis: Oral Administration of
Topics: Administration, Oral; Animals; Animals, Genetically Modified; Cytokines; Disease Models, Animal; Feces; Female; Gastrointestinal Microbiome; Humans; Imiquimod; Interleukin-17; Interleukin-22; Interleukins; Mice; Psoriasis; RNA, Ribosomal, 16S; Staphylococcus aureus; Streptococcus; Tumor Necrosis Factor-alpha; Up-Regulation | 2020 |
Spleen and thymus metabolomics strategy to explore the immunoregulatory mechanism of total withanolides from the leaves of Datura metel L. on imiquimod-induced psoriatic skin dermatitis in mice.
Topics: Animals; Datura metel; Disease Models, Animal; Imiquimod; Immunosuppressive Agents; Male; Metabolome; Metabolomics; Mice; Mice, Inbred C57BL; Plant Extracts; Plant Leaves; Psoriasis; Spleen; Thymus Gland; Withanolides | 2020 |
Regulatory T cells suppress skin inflammation in the imiquimod-induced psoriasis-like mouse model.
Topics: Animals; Dermatitis, Contact; Disease Models, Animal; Humans; Imiquimod; Interleukin-2 Receptor alpha Subunit; Intraepithelial Lymphocytes; Lymphocyte Depletion; Mice; Psoriasis; Severity of Illness Index; Skin; T-Lymphocytes, Regulatory; Time Factors | 2020 |
Design & development of nanosponge loaded topical gel of curcumin and caffeine mixture for augmented treatment of psoriasis.
Topics: Administration, Topical; Animals; beta-Cyclodextrins; Caffeine; Curcumin; Delayed-Action Preparations; Disease Models, Animal; Drug Combinations; Drug Compounding; Female; Formates; Imiquimod; Male; Mice; Nanostructures; Particle Size; Psoriasis | 2020 |
Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-κB/MAPK pathway.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Chromones; Cytokines; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Intercellular Adhesion Molecule-1; Keratinocytes; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; NF-kappa B; Oxidative Stress; Phosphorylation; Psoriasis; Signal Transduction; Skin | 2020 |
Therapeutic anti-psoriatic effects of myeloid-derived suppressor cells in combination with systemic tacrolimus (FK-506) in an imiquimod-induced mouse model of psoriasis.
Topics: Animals; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Immunomodulation; Immunosuppressive Agents; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Psoriasis; Skin; Spleen; T-Lymphocytes, Regulatory; Tacrolimus; Th1 Cells; Th17 Cells | 2020 |
An Anti-Inflammatory Poly(PhosphorHydrazone) Dendrimer Capped with AzaBisPhosphonate Groups to Treat Psoriasis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aza Compounds; Dendrimers; Diphosphonates; Disease Models, Animal; Hydrazones; Imiquimod; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Polymers; Psoriasis | 2020 |
Psoriatic skin inflammation induces a pre-diabetic phenotype via the endocrine actions of skin secretome.
Topics: Animals; Cell Proliferation; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Humans; Imiquimod; Inflammation; Insulin; Insulin Secretion; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Prediabetic State; Psoriasis; Skin | 2020 |
Co-Delivery of Imiquimod and Curcumin by Nanoemugel for Improved Topical Delivery and Reduced Psoriasis-Like Skin Lesions.
Topics: Administration, Topical; Animals; Curcumin; Disease Models, Animal; Drug Combinations; Drug Compounding; Emulsions; Imiquimod; Male; Mice; Mice, Inbred BALB C; Nanogels; Oleic Acid; Particle Size; Permeability; Polyethylene Glycols; Polyethyleneimine; Polysorbates; Psoriasis; Rats | 2020 |
Facile skin targeting of a thalidomide analog containing benzyl chloride moiety alleviates experimental psoriasis via the suppression of MAPK/NF-κB/AP-1 phosphorylation in keratinocytes.
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Keratinocytes; Male; MAP Kinase Signaling System; Mice; NF-kappa B; Phosphorylation; Psoriasis; Skin; Thalidomide; Transcription Factor AP-1; Tumor Necrosis Factor-alpha | 2020 |
Anti-psoriatic effect of Lavandula angustifolia essential oil and its major components linalool and linalyl acetate.
Topics: Acyclic Monoterpenes; Administration, Cutaneous; Animals; Cytokines; Dermatologic Agents; Disease Models, Animal; Female; Imiquimod; Inflammation Mediators; Lavandula; Mice, Inbred BALB C; Monoterpenes; Oils, Volatile; Plant Oils; Psoriasis; Rabbits; Signal Transduction; Skin | 2020 |
Inhibiting Protein Kinase Activity of Pyruvate Kinase M2 by SIRT2 Deacetylase Attenuates Psoriasis.
Topics: Acetylation; Animals; Disease Models, Animal; Down-Regulation; Humans; Imiquimod; Male; Mice; Mice, Knockout; Phosphorylation; Psoriasis; Pyruvate Kinase; Sirtuin 2; Skin; STAT3 Transcription Factor; Th17 Cells | 2021 |
Delivery and Anti-Psoriatic Effect of Silibinin-Loaded Polymeric Micelles: An Experimental Study in the Psoriatic Skin Model.
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; Imiquimod; Mice; Micelles; Nanoparticles; Particle Size; Polymers; Psoriasis; Signal Transduction; Silybin; Skin; Skin Absorption; STAT3 Transcription Factor | 2020 |
Shikonin inhibits CEBPD downregulation in IL‑17‑treated HaCaT cells and in an imiquimod‑induced psoriasis model.
Topics: Animals; CCAAT-Enhancer-Binding Protein-delta; Cell Proliferation; Disease Models, Animal; Down-Regulation; HaCaT Cells; Humans; Imiquimod; Interleukin-17; Interleukin-6; Mice; Naphthoquinones; Psoriasis; Signal Transduction; STAT3 Transcription Factor | 2020 |
A Localized Aldara (5% Imiquimod)-Induced Psoriasiform Dermatitis Model in Mice Using Finn Chambers.
Topics: Animals; Dermatitis; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred C57BL; Psoriasis; Skin | 2020 |
Role of keratinocytes and immune cells in the anti-inflammatory effects of Tripterygium wilfordii Hook. f. in a murine model of psoriasis.
Topics: Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cell Proliferation; Cytokines; Dermatologic Agents; Disease Models, Animal; Drugs, Chinese Herbal; Imiquimod; Keratinocytes; Male; Mice, Inbred BALB C; Plant Roots; Psoriasis; T-Lymphocytes, Regulatory; Tripterygium | 2020 |
Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Chaperonin 60; Disease Models, Animal; Down-Regulation; HaCaT Cells; HSP90 Heat-Shock Proteins; Humans; Imiquimod; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Molecular Docking Simulation; Protein Binding; Pruritus; Psoriasis; Quinolizines | 2020 |
An Autocrine Circuit of IL-33 in Keratinocytes Is Involved in the Progression of Psoriasis.
Topics: Adult; Animals; Autocrine Communication; Biopsy; Case-Control Studies; Disease Models, Animal; Disease Progression; Healthy Volunteers; Humans; Imiquimod; Injections, Intradermal; Interleukin-1 Receptor-Like 1 Protein; Interleukin-33; Keratinocytes; Male; Mice; Middle Aged; Psoriasis; Recombinant Proteins; Severity of Illness Index; Signal Transduction; Skin; Transcriptional Activation; Up-Regulation | 2021 |
Neutrophils Enhance Cutaneous Vascular Dilation and Permeability to Aggravate Psoriasis by Releasing Matrix Metallopeptidase 9.
Topics: Animals; Biopsy; Capillary Permeability; Cell Line; Chemotaxis; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; Female; Imiquimod; Interleukin-23; MAP Kinase Signaling System; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Mice; Neutrophil Infiltration; Neutrophils; Primary Cell Culture; Psoriasis; Recombinant Proteins; Skin; Transendothelial and Transepithelial Migration; Vasodilation | 2021 |
A monocyte-keratinocyte-derived co-culture assay accurately identifies efficacies of BET inhibitors as therapeutic candidates for psoriasiform dermatitis.
Topics: Acetanilides; Administration, Oral; Animals; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Drug Evaluation, Preclinical; Epigenesis, Genetic; Female; HaCaT Cells; Heterocyclic Compounds, 3-Ring; Humans; Imiquimod; Inflammation Mediators; Mice; Monocytes; Psoriasis; Pyridones; Skin; Sulfonamides | 2020 |
The Protective Effects of 18
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Glycyrrhetinic Acid; Imiquimod; Immunohistochemistry; Inflammation Mediators; Mice; Protective Agents; Psoriasis; Signal Transduction; STAT3 Transcription Factor; T-Lymphocyte Subsets; TOR Serine-Threonine Kinases | 2020 |
Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8
Topics: Animals; Artemisinins; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Evaluation, Preclinical; Humans; Imiquimod; Immunologic Memory; Interleukin-15; Interleukin-17; Male; Methotrexate; Mice; Psoriasis; Recurrence; Secondary Prevention; Skin; Skin Transplantation; Transplantation Chimera | 2020 |
Single-cell RNA-Seq reveals the transcriptional landscape and heterogeneity of skin macrophages in Vsir
Topics: Animals; Dendritic Cells; Disease Models, Animal; Female; Fibroblasts; Humans; Imiquimod; Macrophages; Membrane Proteins; Mice; Mice, Knockout; Psoriasis; RNA-Seq; Single-Cell Analysis; Skin; Transcription, Genetic; Transcriptome | 2020 |
Immunological Memory in Imiquimod-Induced Murine Model of Psoriasiform Dermatitis.
Topics: Animals; Cell Lineage; Disease Models, Animal; Epidermis; Gene Expression Regulation; Granzymes; Humans; Imiquimod; Immunologic Memory; Integrin alpha1; Mice; Psoriasis; T-Lymphocytes | 2020 |
Imiquimod-induced dermatitis impairs thymic tolerance of autoreactive CD4
Topics: Animals; CD4-Positive T-Lymphocytes; Dermatitis, Allergic Contact; Desmoglein 3; Disease Models, Animal; Humans; Imiquimod; Immune Tolerance; Mice; Mice, Knockout; Pemphigus; Skin; Thymus Gland | 2020 |
IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cells, Cultured; Disease Models, Animal; Gene Knock-In Techniques; Half-Life; Histocompatibility Antigens Class I; Imiquimod; Interleukin-17; Interleukin-23; Interleukin-23 Subunit p19; Leukocytes, Mononuclear; Macaca fascicularis; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Phosphorylation; Psoriasis; Receptors, Fc; Signal Transduction; Skin; STAT3 Transcription Factor | 2020 |
Evaluating the effect of rice (Oryza sativa L.: SRNC05053-6-2) crude extract on psoriasis using in vitro and in vivo models.
Topics: Animals; Antioxidants; Apoptosis; Cytokines; Disease Models, Animal; Epidermis; Filaggrin Proteins; Humans; Imiquimod; Oryza; Plant Extracts; Psoriasis; Rats; Rats, Sprague-Dawley; S100 Calcium Binding Protein A7; Skin; Skin, Artificial; Treatment Outcome | 2020 |
Histamine 2 Receptor Agonism and Histamine 4 Receptor Antagonism Ameliorate Inflammation in a Model of Psoriasis.
Topics: Animals; Disease Models, Animal; Histamine; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2020 |
DGT, a novel heterocyclic diterpenoid, effectively suppresses psoriasis via inhibition of STAT3 phosphorylation.
Topics: Animals; Disease Models, Animal; Diterpenes; Female; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Phosphorylation; Psoriasis; Skin | 2021 |
A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Disease Models, Animal; Enzyme Inhibitors; Humans; Imiquimod; In Vitro Techniques; Interleukin-17; Male; Mice; Mice, Inbred C57BL; Phosphotransferases (Alcohol Group Acceptor); Psoriasis; RNA, Messenger; Skin; Th17 Cells | 2020 |
Curcuma's extraction attenuates propranolol-induced psoriasis like in mice by inhibition of keratin, proliferating cell nuclear antigen and toll-like receptor expression.
Topics: Animals; Curcuma; Dermatologic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Epithelial Cells; Female; Guinea Pigs; Imiquimod; Keratins; Male; Mice; Mitosis; Plant Extracts; Proliferating Cell Nuclear Antigen; Propranolol; Psoriasis; Rhizome; Skin; Time Factors; Toll-Like Receptors; Vagina | 2020 |
Neutrophil extracellular traps are induced in a psoriasis model of interleukin-36 receptor antagonist-deficient mice.
Topics: Administration, Topical; Animals; Cells, Cultured; Chemokines; Cytokines; Disease Models, Animal; Extracellular Traps; Imiquimod; Interleukin-1; Macrophages, Peritoneal; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Neutrophils; Ornithine; Psoriasis | 2020 |
Small interfering RNA targeting of keratin 17 reduces inflammation in imiquimod-induced psoriasis-like dermatitis.
Topics: Animals; Dermatitis; Disease Models, Animal; Female; Humans; Imiquimod; Inflammation; Keratin-17; Mice; Mice, Inbred BALB C; Psoriasis; RNA, Small Interfering; Skin | 2020 |
IL-37 Expression Is Downregulated in Lesional Psoriasis Skin.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Inflammation; Interleukin-1; Interleukin-17; Keratinocytes; Mice; Mice, Inbred C57BL; Psoriasis; Tumor Necrosis Factor-alpha | 2020 |
Depressive-like behaviors in mice with Imiquimod-induced psoriasis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antidepressive Agents, Second-Generation; Behavior, Animal; Brain; Cytokines; Depression; Disease Models, Animal; Epinephrine; Exploratory Behavior; Fluoxetine; Food Preferences; gamma-Aminobutyric Acid; Imiquimod; Male; Mice, Inbred BALB C; Neurotransmitter Agents; Norepinephrine; Open Field Test; Psoriasis; Serotonin; Skin | 2020 |
Chemical profiling and anti-psoriatic activity of marine sponge (Dysidea avara) in induced imiquimod-psoriasis-skin model.
Topics: Animals; Anti-Inflammatory Agents; Biological Products; Disease Models, Animal; Drug Evaluation, Preclinical; Dysidea; Female; Humans; Imiquimod; Interleukin-17; Interleukin-22; Interleukins; Mice; Psoriasis; Severity of Illness Index; Skin; Tumor Necrosis Factor-alpha | 2020 |
OVOL1 Regulates Psoriasis-Like Skin Inflammation and Epidermal Hyperplasia.
Topics: Animals; Cell Differentiation; Cell Proliferation; Disease Models, Animal; DNA-Binding Proteins; Epidermis; Female; Humans; Hyperplasia; Imiquimod; Interleukin-1alpha; Male; Mice, Knockout; Psoriasis; RNA-Seq; Signal Transduction; Single-Cell Analysis; Transcription Factors; Up-Regulation | 2021 |
ALK3 Is Not Required for the Embryonic Development, Homeostasis, and Repopulation of Epidermal Langerhans Cells in Steady and Inflammatory States.
Topics: Animals; Bone Morphogenetic Protein 7; Bone Morphogenetic Protein Receptors, Type I; Disease Models, Animal; Embryo, Mammalian; Embryonic Development; Homeostasis; Humans; Imiquimod; Langerhans Cells; Mice; Mice, Knockout; Psoriasis; Severity of Illness Index; Signal Transduction | 2021 |
Deletion of
Topics: Animals; Antibodies, Blocking; Calgranulin A; Calgranulin B; Cells, Cultured; Disease Models, Animal; Humans; Hyperplasia; Imiquimod; Interleukin-17; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Skin; Th17 Cells | 2021 |
Protocol for Flow Cytometric Detection of Immune Cell Infiltration in the Epidermis and Dermis of a Psoriasis Mouse Model.
Topics: Aminoquinolines; Animals; Cytokines; Dermis; Disease Models, Animal; Epidermal Cells; Epidermis; Flow Cytometry; Imiquimod; Inflammation; Leukemic Infiltration; Mice; Psoriasis; Skin | 2020 |
Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation.
Topics: Administration, Topical; Animals; Biomarkers; Biopsy; Disease Models, Animal; Exosomes; Imiquimod; Mesenchymal Stem Cells; Mice; Permeability; Phenotype; Psoriasis; Skin; Skin Absorption | 2021 |
Short-Term Western Diet Intake Promotes IL-23‒Mediated Skin and Joint Inflammation Accompanied by Changes to the Gut Microbiota in Mice.
Topics: Animals; Arthritis, Psoriatic; Diet, Western; Disease Models, Animal; Dysbiosis; Gastrointestinal Microbiome; Humans; Imiquimod; Interleukin-23; Mice; Psoriasis; Signal Transduction | 2021 |
Zdhhc2 Is Essential for Plasmacytoid Dendritic Cells Mediated Inflammatory Response in Psoriasis.
Topics: Acyltransferases; Animals; Cell Line; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Interferon-alpha; Lymphocyte Activation; Male; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Signal Transduction; Skin; T-Lymphocytes; Tumor Suppressor Proteins; Up-Regulation | 2020 |
Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist.
Topics: Animals; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Imiquimod; Interleukin-17; Mice; Mice, Inbred C57BL; Psoriasis; Signal Transduction | 2021 |
Pentacyclic triterpene compounds from loquat leaves reduce skin inflammation and epidermal hyperplasia in psoriasis via inhibiting the Th17 cells.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cell Proliferation; Cell Survival; Cytokines; Disease Models, Animal; Epidermis; Eriobotrya; Humans; Hyperplasia; Imiquimod; Inflammation; Keratinocytes; Male; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Pentacyclic Triterpenes; Plant Leaves; Psoriasis; Th17 Cells | 2021 |
Skin-Homing Regulatory B Cells Required for Suppression of Cutaneous Inflammation.
Topics: Animals; B-Lymphocytes, Regulatory; Cell Movement; Dermatitis; Disease Models, Animal; Female; Humans; Imiquimod; Interleukin-10; Male; Mice; Psoriasis; Skin | 2021 |
JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara
Topics: Animals; Cytokines; Disease Models, Animal; Epigenome; ErbB Receptors; Female; Imiquimod; Inflammation Mediators; Keratinocytes; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 8; Myeloid Cells; Psoriasis; Signal Transduction; Skin; Transcriptome | 2020 |
Inhibition of phospholipases suppresses progression of psoriasis through modulation of inflammation.
Topics: Animals; Antigens, CD1; Cell Line; Disease Models, Animal; Gene Expression Regulation; Group IV Phospholipases A2; Humans; Imiquimod; Inflammation; Interleukin-17; Keratinocytes; Male; Mice, Inbred BALB C; Psoriasis; RNA, Small Interfering | 2021 |
The Skin-Liver Axis Modulates the Psoriasiform Phenotype and Involves Leucine-Rich α-2 Glycoprotein.
Topics: Animals; Biomarkers; Cytokines; Disease Models, Animal; Glycoproteins; Humans; Imiquimod; Inflammation Mediators; Liver; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Skin; Up-Regulation | 2021 |
CCR4 Involvement in the Expansion of T Helper Type 17 Cells in a Mouse Model of Psoriasis.
Topics: Animals; Cell Communication; Cell Proliferation; Cells, Cultured; Coculture Techniques; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Transgenic; Primary Cell Culture; Psoriasis; Receptors, CCR4; Skin; Th17 Cells | 2021 |
The nerve injuries attenuate the persistence of psoriatic lesions.
Topics: Adult; Aged; Aged, 80 and over; Animals; Denervation; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Imiquimod; Male; Mice; Middle Aged; Neuroimmunomodulation; Peripheral Nerve Injuries; Psoriasis; Retrospective Studies; Skin | 2021 |
MTH1 Inhibitors for the Treatment of Psoriasis.
Topics: Administration, Cutaneous; Animals; Apoptosis; Biopsy; Cell Line, Tumor; Disease Models, Animal; DNA Repair Enzymes; Female; Humans; Imiquimod; Keratinocytes; Mice; Oxidative Stress; Phosphoric Monoester Hydrolases; Primary Cell Culture; Psoriasis; Skin | 2021 |
miR-383 reduces keratinocyte proliferation and induces the apoptosis in psoriasis via disruption of LCN2-dependent JAK/STAT pathway activation.
Topics: Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Humans; Imiquimod; Janus Kinase 3; Keratinocytes; Lipocalin-2; Male; MicroRNAs; Psoriasis; Rats; Rats, Wistar; Signal Transduction; STAT3 Transcription Factor | 2021 |
Green Phellodendri Chinensis Cortex-based carbon dots for ameliorating imiquimod-induced psoriasis-like inflammation in mice.
Topics: Animals; Carbon; Cytokines; Disease Models, Animal; Imiquimod; Inflammation; Macrophages; Male; Mice; Mice, Inbred BALB C; Psoriasis; RAW 264.7 Cells; Skin | 2021 |
Fingolimod ameliorates imiquimod-induced psoriasiform dermatitis by sequestrating interleukin-17-producing ?d T cells in secondary lymph nodes.
Topics: Animals; Disease Models, Animal; Down-Regulation; Drug Evaluation, Preclinical; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Interleukin-17; Intraepithelial Lymphocytes; Langerhans Cells; Lymph Nodes; Mice; Psoriasis; Skin; Up-Regulation | 2021 |
Improved imiquimod-induced psoriasis like dermatitis using microneedles in mice.
Topics: Administration, Cutaneous; Animals; Cytokines; Dermatitis; Disease Models, Animal; Drug Delivery Systems; Female; Imiquimod; Inflammation; Mice; Mice, Inbred BALB C; Needles; Pharmaceutical Preparations; Polyesters; Polymers; Psoriasis; Skin; Swine | 2021 |
Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.
Topics: Administration, Topical; Animals; Benzimidazoles; Binding Sites; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Stability; Humans; Imiquimod; Interleukin-17; Interleukin-23; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Nuclear Receptor Subfamily 1, Group F, Member 3; Psoriasis; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Skin | 2021 |
2'-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice.
Topics: Animals; Biomarkers; Cell Survival; Cinnamates; Cytokines; Disease Management; Disease Models, Animal; Disease Susceptibility; Imiquimod; Mice; Psoriasis; Pyruvate Kinase; Signal Transduction; STAT3 Transcription Factor; T-Lymphocyte Subsets; Th17 Cells | 2021 |
Desmoglein-4 Deficiency Exacerbates Psoriasiform Dermatitis in Rats While Psoriasis Patients Displayed a Decreased Gene Expression of DSG4.
Topics: Animals; Case-Control Studies; CD3 Complex; Chemotaxis, Leukocyte; Desmogleins; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Inflammation Mediators; Psoriasis; Rats, Sprague-Dawley; Rats, Transgenic; Skin; T-Lymphocytes | 2021 |
Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.
Topics: Animals; Cinnamates; Cytokines; Depsides; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Interleukin-23; Janus Kinase 2; Mice; Mice, Inbred BALB C; Psoriasis; Rosmarinic Acid; Signal Transduction; Skin; STAT3 Transcription Factor; Th17 Cells | 2021 |
Supplemental Leuconostoc mesenteroides strain NTM048 attenuates imiquimod-induced psoriasis in mice.
Topics: Animals; Disease Models, Animal; Imiquimod; Leuconostoc mesenteroides; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2021 |
Glycyrrhizin improves the pathogenesis of psoriasis partially through IL-17A and the SIRT1-STAT3 axis.
Topics: Adult; Animals; Anti-Inflammatory Agents; Carbazoles; Disease Models, Animal; Female; Glycyrrhiza; Glycyrrhizic Acid; HaCaT Cells; Humans; Imiquimod; Interleukin-17; Mice; Psoriasis; RNA, Small Interfering; Sirtuin 1; Skin; STAT3 Transcription Factor | 2021 |
Abnormal composition of microbiota in the gut and skin of imiquimod-treated mice.
Topics: Animals; Dermatitis; Disease Models, Animal; Female; Gastrointestinal Microbiome; Imiquimod; Lactic Acid; Mice; Mice, Inbred C57BL; Microbiota; Psoriasis; Skin; Staphylococcus; Succinic Acid | 2021 |
Hippocampal microglia CD40 mediates NPSLE cognitive dysfunction in mice.
Topics: Animals; CD40 Antigens; Cognitive Dysfunction; Disease Models, Animal; Female; Hippocampus; Imiquimod; Interferon Inducers; Lupus Vasculitis, Central Nervous System; Mice; Mice, Inbred MRL lpr; Microglia | 2021 |
Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments.
Topics: Administration, Cutaneous; Animals; Betamethasone; Cytokines; Disease Models, Animal; Down-Regulation; Imiquimod; Male; Ointments; Psoriasis; Rats; Rats, Wistar; Severity of Illness Index; Signal Transduction; Skin; Transcriptome; Treatment Outcome; Up-Regulation | 2021 |
Protectin D1 reduces imiquimod-induced psoriasiform skin inflammation.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Docosahexaenoic Acids; Female; HaCaT Cells; Humans; Imiquimod; Injections, Subcutaneous; Keratinocytes; Mice; Phosphorylation; Psoriasis; Signal Transduction; Skin; Spleen; STAT1 Transcription Factor; Th1 Cells; Th17 Cells | 2021 |
Galangin ameliorates Imiquimod-Induced psoriasis-like skin inflammation in BALB/c mice via down regulating NF-κB and activation of Nrf2 signaling pathways.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Body Weight; Cytokines; Dermatitis; Disease Models, Animal; Down-Regulation; Flavonoids; Heme Oxygenase-1; Imiquimod; Male; Membrane Proteins; Mice, Inbred BALB C; NF-E2-Related Factor 2; NF-kappa B; Oxidative Stress; Peroxidase; Psoriasis; Signal Transduction; Spleen | 2021 |
Combination of retinoids and narrow-band ultraviolet B inhibits matrix metalloproteinase 13 expression in HaCaT keratinocytes and a mouse model of psoriasis.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; HaCaT Cells; Humans; Imiquimod; Keratinocytes; Matrix Metalloproteinase 13; Mice; Nicotinic Acids; Psoriasis; Retinoids; Ultraviolet Rays; Ultraviolet Therapy | 2021 |
Impact of barrier tissue inflammation and physical activity on joint homeostasis in mice.
Topics: Animals; Disease Models, Animal; Homeostasis; Humans; Imiquimod; Inflammation; Male; Mice; Mice, Inbred C57BL; Psoriasis | 2022 |
Taxifolin inhibits keratinocyte proliferation and ameliorates imiquimod-induced psoriasis-like mouse model via regulating cytoplasmic phospholipase A2 and PPAR-γ pathway.
Topics: Animals; Cell Line; Cell Proliferation; Cytoplasm; Disease Models, Animal; Down-Regulation; Humans; Imiquimod; Keratinocytes; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Phospholipases A2; Phosphorylation; PPAR gamma; Proteomics; Psoriasis; Quercetin; Signal Transduction | 2021 |
Transient Induction of Fever in the Imiquimod C57BL/6 Mouse Model of Psoriasis-Like Disease Involves IL-1 and IL-6 but Not IL-36.
Topics: Animals; Disease Models, Animal; Fever; Humans; Imiquimod; Interleukin-1; Interleukin-6; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Skin | 2022 |
Inhibition of CtBP-Regulated Proinflammatory Gene Transcription Attenuates Psoriatic Skin Inflammation.
Topics: Alcohol Oxidoreductases; Animals; Anti-Inflammatory Agents; Cell Proliferation; Disease Models, Animal; DNA-Binding Proteins; HaCaT Cells; Humans; Imiquimod; Keratinocytes; Mice; Mice, Transgenic; Psoriasis; Transcriptional Activation | 2022 |
Differential Involvement of Programmed Cell Death Ligands in Skin Immune Responses.
Topics: Animals; Antigen Presentation; B7-H1 Antigen; Calcitriol; Cells, Cultured; Cytokines; Dendritic Cells; Dermatitis, Atopic; Dermatitis, Contact; Dinitrofluorobenzene; Disease Models, Animal; Humans; Imiquimod; Inflammation; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Programmed Cell Death 1 Ligand 2 Protein; Psoriasis; Skin; Th1 Cells; Th17 Cells; Th2 Cells | 2022 |
Capsaicin attenuates imiquimod-induced epidermal hyperplasia and cutaneous inflammation in a murine model of psoriasis.
Topics: Administration, Topical; Animals; Antineoplastic Agents; Antipruritics; Capsaicin; Dermatitis; Disease Models, Animal; Epidermis; Female; Hyperplasia; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2021 |
Modular pharmacology-based approach to identify hub genes and kernel pathways of taodan granules treated psoriasis.
Topics: Algorithms; Animals; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; HaCaT Cells; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Network Pharmacology; Psoriasis; RNA, Messenger; Signal Transduction; Up-Regulation | 2021 |
IFN-κ Is a Rheostat for Development of Psoriasiform Inflammation.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Inflammation; Interferon Type I; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Skin; Up-Regulation | 2022 |
Curcumin alleviates imiquimod-induced psoriasis in progranulin-knockout mice.
Topics: Animals; Cell Proliferation; Curcumin; Disease Models, Animal; Humans; Imiquimod; Interleukin-17; Keratinocytes; Male; Mice; Mice, Knockout; Progranulins; Psoriasis | 2021 |
Glycerol Improves Skin Lesion Development in the Imiquimod Mouse Model of Psoriasis: Experimental Confirmation of Anecdotal Reports from Patients with Psoriasis.
Topics: Animals; Aquaporin 3; Disease Models, Animal; Glycerol; Humans; Imiquimod; Mice; Mice, Knockout; Phospholipase D; Psoriasis; Skin | 2021 |
Paeonol ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice by inhibiting the maturation and activation of dendritic cells.
Topics: Acetophenones; Aminoquinolines; Animals; Cell Differentiation; Cell Proliferation; Cytokines; Dendritic Cells; Disease Models, Animal; Imiquimod; Inflammation Mediators; Keratinocytes; Male; Mice; Mice, Inbred BALB C; Myeloid Differentiation Factor 88; Psoriasis; Skin; Toll-Like Receptor 8 | 2017 |
Near-Infrared-Triggered Photodynamic Therapy with Multitasking Upconversion Nanoparticles in Combination with Checkpoint Blockade for Immunotherapy of Colorectal Cancer.
Topics: Animals; Cell Line, Tumor; Chlorophyllides; Colonic Neoplasms; Colorectal Neoplasms; CTLA-4 Antigen; Disease Models, Animal; Female; HeLa Cells; Humans; Imiquimod; Immunotherapy; Mice; Mice, Inbred BALB C; Nanoparticles; Photochemotherapy; Photosensitizing Agents; Porphyrins | 2017 |
PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-κB and production of inflammatory cytokines.
Topics: Active Transport, Cell Nucleus; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Survival; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Drugs, Chinese Herbal; Female; Humans; Imiquimod; Interferon-gamma; Mice, Inbred BALB C; NF-kappa B; Phytotherapy; Psoriasis; Skin | 2017 |
Involvement of µ-opioid Receptors and κ-opioid Receptors in Itch-related Scratching Behaviour of Imiquimod-induced Psoriasis-like Dermatitis in Mice.
Topics: Aminoquinolines; Animals; Behavior, Animal; Disease Models, Animal; Drug Eruptions; Imiquimod; Male; Mice, Inbred C57BL; Narcotic Antagonists; Psoriasis; Receptors, Opioid, kappa; Receptors, Opioid, mu; Signal Transduction; Skin; Spinal Cord | 2017 |
IL-17A causes depression-like symptoms via NFκB and p38MAPK signaling pathways in mice: Implications for psoriasis associated depression.
Topics: Aminoquinolines; Animals; Brain; Depression; Depressive Disorder, Major; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin-17; MAP Kinase Signaling System; Mice; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Psoriasis | 2017 |
Imiquimod induced ApoE-deficient mice might be a composite animal model for the study of psoriasis and dyslipideamia comorbidity.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aminoquinolines; Animals; Back; Cell Proliferation; Cholesterol; Comorbidity; Disease Models, Animal; Dyslipidemias; Imiquimod; Interleukin-17; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout, ApoE; Psoriasis; Signal Transduction; Skin; STAT3 Transcription Factor | 2017 |
Blocking mTOR Signalling with Rapamycin Ameliorates Imiquimod-induced Psoriasis in Mice.
Topics: Administration, Topical; Aminoquinolines; Animals; Caspase 14; Dendritic Cells; Disease Models, Animal; Imiquimod; Immunosuppressive Agents; Keratin-10; Keratin-14; Ki-67 Antigen; Langerhans Cells; Lymph Nodes; Macrophages; Membrane Proteins; Mice, Inbred BALB C; Neovascularization, Physiologic; Protein Precursors; Psoriasis; Sirolimus; Skin; TOR Serine-Threonine Kinases | 2017 |
Cyr61/CCN1 induces CCL20 production by keratinocyte via activating p38 and JNK/AP-1 pathway in psoriasis.
Topics: Aminoquinolines; Animals; Biopsy; Chemokine CCL20; Cysteine-Rich Protein 61; Disease Models, Animal; Epidermis; Female; Gene Knockdown Techniques; Humans; Imiquimod; Interleukin-23; JNK Mitogen-Activated Protein Kinases; Keratinocytes; Lymphocyte Activation; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; p38 Mitogen-Activated Protein Kinases; Primary Cell Culture; Promoter Regions, Genetic; Psoriasis; RNA Interference; RNA, Small Interfering; Transcription Factor AP-1; Tumor Necrosis Factor-alpha; Up-Regulation | 2017 |
Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Immunity, Innate; Interleukin-1beta; Interleukin-23; Mice; Mice, Knockout; Myeloid Cells; Myeloid Differentiation Factor 88; Psoriasis; Skin | 2017 |
TLR7 Signaling Regulates Th17 Cells and Autoimmunity: Novel Potential for Autoimmune Therapy.
Topics: Aminoquinolines; Animals; Autoimmunity; Cell Differentiation; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Humans; Imiquimod; Immunotherapy; Inflammation; Interleukin-17; Membrane Glycoproteins; Mice; Signal Transduction; STAT3 Transcription Factor; Suppressor of Cytokine Signaling Proteins; Th1 Cells; Th17 Cells; Toll-Like Receptor 7 | 2017 |
Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Cell Movement; Disease Models, Animal; Emulsions; Epitopes; Flow Cytometry; Humans; Imiquimod; Langerhans Cells; Lymphocytic Choriomeningitis; Lymphocytic choriomeningitis virus; Major Histocompatibility Complex; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Myeloid Differentiation Factor 88; Signal Transduction; Skin; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Toll-Like Receptor 7; Vaccination | 2017 |
Rhododendrin inhibits toll-like receptor-7-mediated psoriasis-like skin inflammation in mice.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Glycosides; Humans; Imiquimod; Keratinocytes; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; NF-kappa B; Phenols; Primary Cell Culture; Psoriasis; Rhododendron; RNA, Messenger; Skin; Toll-Like Receptor 7 | 2017 |
Imiquimod-applied Interleukin-10 deficient mice better reflects severe and persistent psoriasis with systemic inflammatory state.
Topics: Adjuvants, Immunologic; Animals; Body Weight; Cytokines; Dermatitis; Disease Models, Animal; Epidermis; Imiquimod; Inflammation; Interleukin-10; Interleukin-17; Keratinocytes; Leukocyte Common Antigens; Male; Mice; Mice, Inbred C57BL; Organ Size; Psoriasis; RNA, Messenger; Skin; Spleen; Time Factors | 2018 |
Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesis.
Topics: Adult; Aged; Aminoquinolines; Animals; Cells, Cultured; Chemokine CCL20; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Female; Humans; Imiquimod; Interleukin-17; Keratinocytes; Liver; Male; Mice; Mice, Inbred C57BL; Middle Aged; Psoriasis; Receptors, CCR6; Recombinant Proteins; Serum Amyloid A Protein; Skin; Th17 Cells; Up-Regulation | 2017 |
GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency.
Topics: Aminoquinolines; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imiquimod; Interferon Inducers; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis | 2017 |
Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cytokines; Dendritic Cells; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Profiling; Humans; Ikaros Transcription Factor; Imiquimod; Interferon Type I; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Transgenic; Reverse Transcriptase Polymerase Chain Reaction; Toll-Like Receptor 7; Tumor Necrosis Factor-alpha | 2017 |
Role of neurturin in spontaneous itch and increased nonpeptidergic intraepidermal fiber density in a mouse model of psoriasis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies; Calcitonin Gene-Related Peptide; Disease Models, Animal; Gene Expression Regulation; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Imiquimod; Male; Mice; Mice, Inbred C57BL; Nerve Fibers; Neurturin; Pruritus; Psoriasis; Receptors, Purinergic P2X3; RNA, Messenger; Skin | 2017 |
Lack of Galanin Receptor 3 Alleviates Psoriasis by Altering Vascularization, Immune Cell Infiltration, and Cytokine Expression.
Topics: Adult; Animals; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Neovascularization, Pathologic; Nestin; Neutrophil Infiltration; Neutrophils; Psoriasis; Receptor, Galanin, Type 2; Receptor, Galanin, Type 3; Severity of Illness Index; Skin | 2018 |
IL-1β and IL-23 Promote Extrathymic Commitment of CD27
Topics: Aminoquinolines; Animals; Cell Differentiation; Cells, Cultured; Disease Models, Animal; Humans; Imiquimod; Interleukin-17; Interleukin-1beta; Interleukin-2 Receptor beta Subunit; Interleukin-23; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Receptors, Interleukin; T-Lymphocytes; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 2017 |
Inhibition of IL-17-committed T cells in a murine psoriasis model by a vitamin D analogue.
Topics: Animals; Calcitriol; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Interleukin-12 Subunit p40; Interleukin-17; Interleukin-23 Subunit p19; Mice; Psoriasis; Th17 Cells | 2018 |
Effect of Topical Application of Black Seed Oil on Imiquimod-Induced Psoriasis-like Lesions in the Thin Skin of Adult Male Albino Rats.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Chemotherapy, Adjuvant; Dermis; Disease Models, Animal; Epidermis; Fibrillar Collagens; Humans; Imiquimod; Male; Nigella sativa; Plant Oils; Psoriasis; Rats; Seeds; Treatment Outcome | 2018 |
CD100-Plexin-B2 Promotes the Inflammation in Psoriasis by Activating NF-κB and the Inflammasome in Keratinocytes.
Topics: Animals; Antigens, CD; Biopsy; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Gene Expression Regulation; Healthy Volunteers; Humans; Imiquimod; Inflammasomes; Keratinocytes; Mice, Inbred BALB C; Nerve Tissue Proteins; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Primary Cell Culture; Protein Binding; Psoriasis; RNA, Small Interfering; Semaphorins; Signal Transduction; Skin | 2018 |
How Effective Is Tacrolimus in the Imiquimod-Induced Mouse Model of Psoriasis?
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imiquimod; Immunosuppressive Agents; Male; Mice; Mice, Hairless; Mice, Inbred BALB C; Psoriasis; Skin; Tacrolimus; Treatment Outcome | 2018 |
IL-17A induces heterogeneous macrophages, and it does not alter the effects of lipopolysaccharides on macrophage activation in the skin of mice.
Topics: Animals; Cell Differentiation; CX3C Chemokine Receptor 1; Dermatitis, Atopic; Disease Models, Animal; Gene Expression Regulation; Imiquimod; Interleukin-17; Lectins, C-Type; Lipopolysaccharides; Macrophage Activation; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Transgenic; Nitric Oxide Synthase Type II; Phosphoproteins; Psoriasis; Receptors, Cell Surface; Signal Transduction; Skin; STAT1 Transcription Factor; STAT3 Transcription Factor | 2017 |
Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Topics: Acitretin; Angiogenesis Inhibitors; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Down-Regulation; Female; Imiquimod; Mice, Inbred BALB C; Microvessels; Neovascularization, Pathologic; Psoriasis; Signal Transduction; Skin; Thalidomide; Vascular Endothelial Growth Factor A | 2018 |
Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model.
Topics: Aminoquinolines; Animals; Chitin; Disease Models, Animal; Drug Delivery Systems; Humans; Imiquimod; Methotrexate; Mice; Mice, Inbred BALB C; Nanoparticles; Psoriasis; THP-1 Cells | 2018 |
High fat diet exacerbates murine psoriatic dermatitis by increasing the number of IL-17-producing γδ T cells.
Topics: Animals; Chemokine CCL20; Dermatitis; Diet, High-Fat; Disease Models, Animal; Endothelial Cells; Imiquimod; Interleukin-17; Keratinocytes; Male; Mice, Inbred C57BL; Mice, Obese; Obesity; Psoriasis; Skin; T-Lymphocytes | 2017 |
Anti-Psoriasis Effects and Mechanisms of Α-(8-Quinolinoxy) Zinc Phthalocyanine-Mediated Photodynamic Therapy.
Topics: Aminoquinolines; Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Epidermis; Epithelial Cells; Female; Guinea Pigs; Humans; Imiquimod; Indoles; Interleukin-17; Isoindoles; Lasers; Male; Mice; Mice, Inbred ICR; Mice, Nude; Organometallic Compounds; Photochemotherapy; Photosensitizing Agents; Propranolol; Psoriasis; Zinc Compounds | 2017 |
Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Dermatitis; Disease Models, Animal; Docosahexaenoic Acids; Drug Evaluation, Preclinical; Humans; Imiquimod; Male; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; NF-kappa B; Psoriasis; Severity of Illness Index; Signal Transduction; Skin; Skin Cream | 2018 |
Non-thermal atmospheric plasma ameliorates imiquimod-induced psoriasis-like skin inflammation in mice through inhibition of immune responses and up-regulation of PD-L1 expression.
Topics: Animals; B7-H1 Antigen; Bone Marrow Cells; CD4-Positive T-Lymphocytes; Cell Differentiation; Dendritic Cells; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Inflammation; Lymph Nodes; Mice; Plasma Gases; Psoriasis; Th17 Cells | 2017 |
Liver fibrosis is associated with cutaneous inflammation in the imiquimod-induced murine model of psoriasiform dermatitis.
Topics: Animals; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Drug Eruptions; Imiquimod; Interferon Inducers; Liver Cirrhosis; Male; Mice, Inbred C57BL; Psoriasis | 2018 |
Decrease of galectin-3 in keratinocytes: A potential diagnostic marker and a critical contributor to the pathogenesis of psoriasis.
Topics: Animals; Biomarkers; Cells, Cultured; Disease Models, Animal; Disease Progression; Galectin 3; Humans; Imiquimod; Inflammation; Keratinocytes; MAP Kinase Kinase 4; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutrophils; Phenylurea Compounds; Psoriasis; Receptors, Interleukin-8B; Signal Transduction; Skin | 2018 |
IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells.
Topics: Acute Disease; Animals; Colitis; Cytokines; Dextran Sulfate; Disease Models, Animal; Female; Humans; Imiquimod; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukins; Lymphocytes; Macrophages; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Phenotype; Psoriasis; Recombinant Proteins; T-Lymphocytes; Vascular Endothelial Growth Factor A | 2018 |
High-fat diet exacerbates imiquimod-induced psoriasis-like dermatitis in mice.
Topics: Animals; Body Weight; Cholesterol; Cytokines; Dermatitis; Diet, High-Fat; Disease Models, Animal; Disease Progression; Hyperlipidemias; Imiquimod; Inflammasomes; Inflammation; Male; Mice; Mice, Inbred C57BL; Neutrophils; Psoriasis; Skin | 2018 |
Systemic inflammation in asocial BTBR T
Topics: Adaptive Immunity; Animals; Arthritis, Psoriatic; Autism Spectrum Disorder; Disease Models, Animal; Disease Susceptibility; Imiquimod; Immunity, Innate; Inflammation; Male; Membrane Glycoproteins; Mice, Inbred C57BL; Skin; Social Behavior; Species Specificity; Th17 Cells; Toll-Like Receptor 7 | 2018 |
Regnase-1, an Immunomodulator, Limits the IL-36/IL-36R Autostimulatory Loop in Keratinocytes to Suppress Skin Inflammation.
Topics: Animals; Cells, Cultured; Dermatitis, Allergic Contact; Dinitrofluorobenzene; Disease Models, Animal; Humans; Imiquimod; Immunologic Factors; Interleukin-1; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Primary Cell Culture; Receptors, Interleukin-1; Ribonucleases; Signal Transduction; Skin | 2018 |
NB-UVB irradiation downregulates keratin-17 expression in keratinocytes by inhibiting the ERK1/2 and STAT3 signaling pathways.
Topics: Aminoquinolines; Animals; Apoptosis; Biomarkers; Cell Line; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Healthy Volunteers; Humans; Imiquimod; Keratin-17; Keratinocytes; Keratins; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Primary Cell Culture; Psoriasis; Radiation Dosage; Signal Transduction; Skin; STAT3 Transcription Factor; Treatment Outcome; Ultraviolet Therapy | 2018 |
Antiproliferation of keratinocytes and alleviation of psoriasis by the ethanol extract of Artemisia capillaris.
Topics: Aminoquinolines; Animals; Apoptosis; Artemisia; Cell Line; Cell Proliferation; Disease Models, Animal; Ethanol; Female; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Plant Extracts; Psoriasis | 2018 |
Development of nanoparticles from natural lipids for topical delivery of thymol: Investigation of its anti-inflammatory properties.
Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; Antioxidants; Betamethasone; Cell Death; Cell Line; Cell Survival; Disease Models, Animal; Drug Compounding; Drug Liberation; Ear; Edema; Humans; Imiquimod; Inflammation; Keratinocytes; Lipids; Mice, Inbred BALB C; Nanoparticles; Particle Size; Permeability; Psoriasis; Rheology; Skin; Sus scrofa; Thymol | 2018 |
Cryptotanshinone reduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3.
Topics: Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drugs, Chinese Herbal; Epidermis; Humans; Hyperplasia; Imiquimod; Keratinocytes; Male; Mice, Inbred C57BL; Phenanthrenes; Psoriasis; STAT3 Transcription Factor | 2018 |
p38α signaling in Langerhans cells promotes the development of IL-17-producing T cells and psoriasiform skin inflammation.
Topics: Animals; Cells, Cultured; Dendritic Cells; Disease Models, Animal; Imidazoles; Imiquimod; Inflammation; Interleukin-17; Interleukin-23; Interleukin-6; Langerhans Cells; Mice, Inbred C57BL; Mice, Transgenic; Mitogen-Activated Protein Kinase 14; Psoriasis; Pyridines; Signal Transduction; Skin; T-Lymphocytes; Th17 Cells | 2018 |
Ten-eleven Translocation-2 Regulates DNA Hydroxymethylation Status and Psoriasiform Dermatitis Progression in Mice.
Topics: 5-Methylcytosine; Aminoquinolines; Animals; Case-Control Studies; Cell Differentiation; Cell Proliferation; Chemokine CXCL1; Dioxygenases; Disease Models, Animal; Disease Progression; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Female; Humans; Imiquimod; Interferon-gamma; Interleukin-17; Mice, Inbred BALB C; Proto-Oncogene Proteins; Psoriasis; Skin; Time Factors | 2018 |
Imiquimod-Induced Psoriasis-Like Skin Lesions Do Not Accelerate Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice.
Topics: Animals; Atherosclerosis; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Knockout; Psoriasis; Receptors, LDL; Skin Diseases | 2018 |
TRPA1 Acts in a Protective Manner in Imiquimod-Induced Psoriasiform Dermatitis in Mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Cell Line; Disease Models, Animal; Female; Humans; Imiquimod; Male; Mice; Mice, Knockout; Neurons; Oximes; Psoriasis; Skin; TRPA1 Cation Channel; TRPV Cation Channels | 2018 |
The severity of imiquimod-induced mouse skin inflammation is independent of endogenous IL-38 expression.
Topics: Aminoquinolines; Animals; Cells, Cultured; Dermatitis; Disease Models, Animal; Drug Eruptions; Female; Imiquimod; Inflammation; Interleukin-1; Interleukins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Severity of Illness Index; Skin | 2018 |
A zebrafish and mouse model for selective pruritus via direct activation of TRPA1.
Topics: Animals; Animals, Genetically Modified; Disease Models, Animal; Evoked Potentials, Somatosensory; HEK293 Cells; Humans; Imiquimod; Isothiocyanates; Larva; Membrane Potentials; Mice; Neurons; Pruritus; TRPA1 Cation Channel; Zebrafish; Zebrafish Proteins | 2018 |
8-Methoxypsoralen Plus Ultraviolet A Reduces the Psoriatic Response to Imiquimod in a Murine Model.
Topics: Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Female; Gene Expression Regulation; Imiquimod; Methoxsalen; Mice, Inbred BALB C; Photosensitizing Agents; Psoriasis; PUVA Therapy; Signal Transduction; Skin; Time Factors | 2018 |
Resident and monocyte-derived Langerhans cells are required for imiquimod-induced psoriasis-like dermatitis model.
Topics: Aminoquinolines; Animals; Antigens, CD; Cytokines; Dendritic Cells; Disease Models, Animal; Epidermal Cells; Epidermis; Female; Gene Expression Profiling; Humans; Imiquimod; Langerhans Cells; Lectins, C-Type; Male; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Monocytes; Psoriasis | 2018 |
RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis.
Topics: Aminoquinolines; Animals; Cells, Cultured; Cytokines; Disease Models, Animal; Down-Regulation; Epidermal Cells; Epidermis; Female; Gene Knockdown Techniques; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred C57BL; Primary Cell Culture; Psoriasis; Receptor-Interacting Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand | 2018 |
Topically applied azaphenothiazines inhibit experimental psoriasis in mice.
Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; Caspases; Cell Line; Cytokines; Disease Models, Animal; fas Receptor; Female; HCT116 Cells; Humans; Imiquimod; Jurkat Cells; Leukocyte Count; Lipopolysaccharides; Mice, Inbred BALB C; NF-kappa B; Phenothiazines; Psoriasis; Skin | 2018 |
Thromboxane A
Topics: Animals; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Interleukin-17; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Receptors, G-Protein-Coupled; Receptors, Thromboxane A2, Prostaglandin H2; T-Lymphocytes; Thromboxane A2; Thromboxane-A Synthase | 2018 |
The Therapeutic Potential and Molecular Mechanism of Isoflavone Extract against Psoriasis.
Topics: Animals; Antioxidants; Cytokines; Disease Models, Animal; Epidermis; Foreskin; Humans; Imiquimod; Inflammation; Interleukin-17; Interleukin-22; Interleukins; Isoflavones; Keratinocytes; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Signal Transduction; Skin; Tumor Necrosis Factor-alpha | 2018 |
A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
Topics: Adenine; Adjuvants, Immunologic; Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Disease Models, Animal; Glycerophospholipids; Imiquimod; Immunologic Factors; Rats; Rats, Inbred F344; Toll-Like Receptor 7; Urinary Bladder; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Altered expression of matrix remodelling associated 7 (MXRA7) in psoriatic epidermis: Evidence for a protective role in the psoriasis imiquimod mouse model.
Topics: Animals; Calgranulin A; Calgranulin B; Cell Proliferation; Cytokines; Disease Models, Animal; Epidermis; Humans; Imiquimod; Keratinocytes; Membrane Proteins; Mice; Mice, Knockout; Protective Factors; Proteins; Psoriasis; RNA, Messenger; Skin | 2018 |
Extracellular ATP and IL-23 Form a Local Inflammatory Circuit Leading to the Development of a Neutrophil-Dependent Psoriasiform Dermatitis.
Topics: Adenosine Triphosphate; Animals; Dermatitis; Disease Models, Animal; Extracellular Space; Female; Humans; Imiquimod; Inflammation Mediators; Interleukin-17; Interleukin-1beta; Interleukin-23; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutrophils; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; Receptors, Purinergic P2X7; Signal Transduction; Skin | 2018 |
C10orf99 contributes to the development of psoriasis by promoting the proliferation of keratinocytes.
Topics: Adolescent; Adult; Animals; Antimicrobial Cationic Peptides; Cell Line; Cell Proliferation; Child; Disease Models, Animal; DNA-Binding Proteins; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression; Humans; Imiquimod; Keratinocytes; Male; Mice, Inbred BALB C; Middle Aged; Psoriasis; RNA Interference; Signal Transduction; Skin; Young Adult | 2018 |
Mild electrical stimulation with heat shock reduces inflammatory symptoms in the imiquimod-induced psoriasis mouse model.
Topics: Animals; beta-Defensins; Calgranulin A; Calgranulin B; CD3 Complex; Cell Line; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Models, Animal; Electric Stimulation Therapy; Female; Gene Expression; Humans; Hyperplasia; Hyperthermia, Induced; Imiquimod; Interleukin-17; Keratinocytes; Mice; Pancreatitis-Associated Proteins; Psoriasis; RNA, Messenger; Skin; T-Lymphocytes | 2018 |
Decryption of Active Constituents and Action Mechanism of the Traditional Uighur Prescription (BXXTR) Alleviating IMQ-Induced Psoriasis-Like Skin Inflammation in BALB/c Mice.
Topics: Aminoquinolines; Animals; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Drugs, Chinese Herbal; Gene Expression Regulation; Humans; Imiquimod; Interleukin-17; Interleukin-18; Interleukin-23; Keratinocytes; Male; Medicine, Chinese Traditional; Mice; Mice, Inbred BALB C; Psoriasis; Severity of Illness Index; Signal Transduction; Skin; Toll-Like Receptor 8; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2018 |
Cornulin Is Induced in Psoriasis Lesions and Promotes Keratinocyte Proliferation via Phosphoinositide 3-Kinase/Akt Pathways.
Topics: Animals; Blotting, Western; Cell Proliferation; Cells, Cultured; Cytokines; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Keratinocytes; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Psoriasis; RNA; Signal Transduction; Skin | 2019 |
Therapeutic effect of Imiquimod enhanced ALA-PDT on cutaneous squamous cell carcinoma.
Topics: Aged; Aminolevulinic Acid; Animals; Apoptosis; Carcinoma, Squamous Cell; Disease Models, Animal; Drug Therapy, Combination; Female; Humans; Imiquimod; Inflammation Mediators; Male; Mice; Photochemotherapy; Photosensitizing Agents; Skin Neoplasms; T-Lymphocytes | 2018 |
Combination of paromomycin plus human anti-TNF-α antibodies to control the local inflammatory response in BALB/ mice with cutaneous leishmaniasis lesions.
Topics: Animals; Antibodies; Antiprotozoal Agents; Cells, Cultured; Dermatitis; Disease Models, Animal; Drug Therapy, Combination; Female; Host-Pathogen Interactions; Imiquimod; Inflammation Mediators; Leishmania major; Leishmaniasis, Cutaneous; Macrophages; Mice, Inbred BALB C; Neutrophil Infiltration; Paromomycin; Skin; Tumor Necrosis Factor-alpha | 2018 |
Chlamydial Plasmid-Encoded Protein pGP3 Inhibits Development of Psoriasis-Like Lesions in Mice.
Topics: Aminoquinolines; Animals; Antigens, Bacterial; Antimicrobial Cationic Peptides; Bacterial Proteins; Cathelicidins; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin | 2018 |
Epithelial TRAF6 drives IL-17-mediated psoriatic inflammation.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Female; Humans; Imiquimod; Interleukin-17; Intraepithelial Lymphocytes; Keratinocytes; Male; Mice; Mice, Knockout; Primary Cell Culture; Psoriasis; Receptors, Interleukin-17; Signal Transduction; Skin; TNF Receptor-Associated Factor 6 | 2018 |
Local production of prolactin in lesions may play a pathogenic role in psoriatic patients and imiquimod-induced psoriasis-like mouse model.
Topics: Adult; Aged; Animals; Cabergoline; Cytokines; Dermis; Disease Models, Animal; Dopamine Agonists; Epidermis; Female; Humans; Imiquimod; Male; Methylcellulose; Mice; Middle Aged; Prolactin; Psoriasis; Receptors, Prolactin; Risk Adjustment; RNA, Messenger; Solvents; TRPV Cation Channels | 2018 |
Tetrathiomolybdate, a copper chelator inhibited imiquimod-induced skin inflammation in mice.
Topics: Animals; Anti-Inflammatory Agents; Chelating Agents; Copper; Cytokines; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Imiquimod; Inflammation Mediators; Keratinocytes; Male; Mice, Inbred C57BL; Molybdenum; Phosphorylation; Psoriasis; Signal Transduction; Skin; Spleen; STAT3 Transcription Factor | 2018 |
Overexpression of Wilms' tumor 1 in skin lesions of psoriasis is associated with abnormal proliferation and apoptosis of keratinocytes.
Topics: Adolescent; Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Disease Models, Animal; Female; Gene Knockdown Techniques; Humans; Imiquimod; Inflammation; Keratinocytes; Male; Mice, Inbred BALB C; Middle Aged; Psoriasis; Skin; WT1 Proteins; Young Adult | 2018 |
Aldara-induced dermatitis is associated with development of liver fibrosis in mice.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Inflammation; Liver Cirrhosis; Mice | 2018 |
Dang-Gui-Liu-Huang Tang a traditional herbal formula, ameliorates imiquimod-induced psoriasis-like skin inflammation in mice by inhibiting IL-22 production.
Topics: Administration, Cutaneous; Aminoquinolines; Angelica sinensis; Animals; Cell Line; Cell Proliferation; Disease Models, Animal; Drugs, Chinese Herbal; Humans; Imiquimod; Inflammation; Interleukin-22; Interleukins; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Th17 Cells; Tumor Necrosis Factor-alpha | 2018 |
Is CCR6 Required for the Development of Psoriasiform Dermatitis in Mice?
Topics: Administration, Cutaneous; Animals; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Knockout; Psoriasis; Receptors, CCR6; Skin | 2019 |
Sensory nerves mediate spontaneous behaviors in addition to inflammation in a murine model of psoriasis.
Topics: Animals; Calcitonin Gene-Related Peptide; Denervation; Disease Models, Animal; Diterpenes; Imiquimod; Inflammation; Male; Mice; Mice, Inbred C57BL; Psoriasis; Reactive Nitrogen Species; Reactive Oxygen Species; Sensory Receptor Cells; Skin; Substance P; TRPA1 Cation Channel; TRPV Cation Channels | 2019 |
5-hydroxytryptophan attenuates imiquimod-induced psoriasiform dermatitis probably through inhibition of IL-17A production and keratinocyte activation.
Topics: 5-Hydroxytryptophan; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Line; Cyclooxygenase 2; Disease Models, Animal; Epidermis; Humans; Imiquimod; Interferon-gamma; Interleukin-17; Interleukin-6; Keratinocytes; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Protein Biosynthesis; Psoriasis; Spleen; Tumor Necrosis Factor-alpha | 2018 |
A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice.
Topics: Animals; Cytokines; Dermatitis; Disease Models, Animal; Imiquimod; Inflammation; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Transgenic; Psoriasis; Skin; Toll-Like Receptor 7 | 2018 |
Downregulation of miR-145-5p contributes to hyperproliferation of keratinocytes and skin inflammation in psoriasis.
Topics: Adult; Animals; Antagomirs; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; Female; Gene Expression Profiling; Humans; Imiquimod; Keratinocytes; Male; MAP Kinase Kinase Kinases; Mice; MicroRNAs; Mitogen-Activated Protein Kinase Kinase Kinase 11; Oligonucleotide Array Sequence Analysis; Primary Cell Culture; Psoriasis; Skin; Young Adult | 2019 |
Comparison of normal versus imiquimod-induced psoriatic skin in mice for penetration of drugs and nanoparticles.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred C57BL; Nanoparticles; Psoriasis; Skin | 2018 |
Macrophages express βKlotho in skin lesions of psoriatic patients and the skin of imiquimod-treated mice.
Topics: Adult; Aged; Animals; Antibodies, Neutralizing; Case-Control Studies; Dermatitis, Atopic; Disease Models, Animal; Down-Regulation; Female; Humans; Imiquimod; Immunohistochemistry; Interleukin-17; Klotho Proteins; Macrophages; Male; Membrane Proteins; Mice; Middle Aged; Psoriasis; Skin | 2018 |
The small molecule rhodomyrtone suppresses TNF-α and IL-17A-induced keratinocyte inflammatory responses: A potential new therapeutic for psoriasis.
Topics: Animals; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Inflammation; Interleukin-17; Keratinocytes; Mice; NF-kappa B; Organ Culture Techniques; Psoriasis; Signal Transduction; Skin; Tumor Necrosis Factor-alpha; Xanthones | 2018 |
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Interleukin-23; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Mice; Mice, Knockout; Psoriasis; Skin | 2018 |
Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis.
Topics: Animals; Antibodies, Blocking; Aorta; Disease Models, Animal; Disease Progression; Humans; Imiquimod; Immunotherapy; Inflammation; Interleukin-17; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Oxidative Stress; Psoriasis; Reactive Oxygen Species; Skin; Vascular Diseases | 2019 |
IL-38 has an anti-inflammatory action in psoriasis and its expression correlates with disease severity and therapeutic response to anti-IL-17A treatment.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal, Humanized; Case-Control Studies; Disease Models, Animal; Endothelial Cells; Female; Gene Expression Regulation; Humans; Imiquimod; Immunologic Factors; Interleukin-1; Interleukin-17; Interleukins; Keratinocytes; Male; Mice; Middle Aged; Primary Cell Culture; Psoriasis; Receptors, Interleukin-1; Severity of Illness Index; Signal Transduction; Skin | 2018 |
Oral administration of the selective GPR120/FFA4 agonist compound A is not effective in alleviating tissue inflammation in mouse models of prototypical autoimmune diseases.
Topics: Acetic Acid; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aza Compounds; Disease Models, Animal; Fatty Acids, Omega-3; Humans; Imiquimod; Mice; Mice, Inbred C57BL; Pemphigoid, Bullous; Psoriasis; Receptors, G-Protein-Coupled; Treatment Outcome | 2018 |
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Topics: Animals; Antipruritics; Behavior, Animal; Disease Models, Animal; Imiquimod; Interleukin-22; Interleukin-23; Interleukins; Janus Kinase Inhibitors; Male; Mice, Inbred C57BL; Nerve Fibers; Piperidines; Pruritus; Psoriasis; Pyrimidines; Pyrroles; Skin | 2019 |
ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Humans; Imiquimod; Interleukin-12; Interleukin-17; Interleukin-6; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Psoriasis; raf Kinases; Signal Transduction; Skin; Small Molecule Libraries; Th17 Cells | 2019 |
TRPV1 mediates inflammation and hyperplasia in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice.
Topics: Animals; Cytokines; Disease Models, Animal; Epidermis; Female; Humans; Hyperplasia; Imiquimod; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; TRPV Cation Channels; Water Loss, Insensible | 2018 |
Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-κB and TLR7 pathways in mice.
Topics: Animals; Dermatitis; Disease Models, Animal; Imiquimod; Indole Alkaloids; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; Quinazolines; Signal Transduction; Skin; Skin Diseases; Th17 Cells; Toll-Like Receptor 7 | 2019 |
Disinhibition of Touch-Evoked Itch in a Mouse Model of Psoriasis.
Topics: Animals; Disease Models, Animal; Epidermis; Humans; Imiquimod; Interneurons; Male; Merkel Cells; Mice; Neurofilament Proteins; Pruritus; Psoriasis; Touch | 2019 |
A Western Diet, but Not a High-Fat and Low-Sugar Diet, Predisposes Mice to Enhanced Susceptibility to Imiquimod-Induced Psoriasiform Dermatitis.
Topics: Animals; Diet, Carbohydrate-Restricted; Diet, High-Fat; Diet, Western; Dietary Sugars; Disease Models, Animal; Disease Susceptibility; Female; Humans; Imiquimod; Mice; Obesity; Psoriasis | 2019 |
Structure-based drug designing and identification of Woodfordia fruticosa inhibitors targeted against heat shock protein (HSP70-1) as suppressor for Imiquimod-induced psoriasis like skin inflammation in mice model.
Topics: Animals; Disease Models, Animal; Gold; Heat-Shock Proteins; Humans; Imiquimod; Metal Nanoparticles; Mice; Molecular Docking Simulation; Psoriasis; Skin Diseases; Woodfordia | 2019 |
IL-23- and Imiquimod-Induced Models of Experimental Psoriasis in Mice.
Topics: Adjuvants, Immunologic; Administration, Topical; Animals; Cytokines; Disease Models, Animal; Flow Cytometry; Imiquimod; Injections, Intradermal; Interleukin-23; Mice; Psoriasis; Skin | 2019 |
Human amnion-derived mesenchymal stem cells ameliorate imiquimod-induced psoriasiform dermatitis in mice.
Topics: Amnion; Animals; Cells, Cultured; Chemokines; Culture Media, Conditioned; Disease Models, Animal; Humans; Imiquimod; Mesenchymal Stem Cell Transplantation; Mice; Mice, Inbred C57BL; Primary Cell Culture; Psoriasis; Skin; Treatment Outcome; Umbilical Cord | 2019 |
Mechanical Stretch Exacerbates Psoriasis by Stimulating Keratinocyte Proliferation and Cytokine Production.
Topics: Animals; Cell Proliferation; Cells, Cultured; Cytokines; Disease Models, Animal; Epidermis; Humans; Imiquimod; Inflammation Mediators; Keratinocytes; Mice; Mice, Inbred BALB C; Psoriasis; Stress, Mechanical; Tight Junctions | 2019 |
Hesperidin inhibits keratinocyte proliferation and imiquimod-induced psoriasis-like dermatitis via the IRS-1/ERK1/2 pathway.
Topics: Animals; Blotting, Western; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Hesperidin; Humans; Imiquimod; Keratinocytes; Lipopolysaccharides; Male; MAP Kinase Signaling System; Methotrexate; Mice; Mice, Inbred BALB C; Psoriasis; Real-Time Polymerase Chain Reaction | 2019 |
Topical Application of a Dual ABC Transporter Substrate and NF-κB Inhibitor Blocks Multiple Sources of Cutaneous Inflammation in Mouse Skin.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Humans; Imiquimod; Inflammation; Keratinocytes; Mice; NF-kappa B; Nicotinic Acids; Nitriles; Piperidines; Pyrrolidines; Skin; Skin Neoplasms | 2019 |
Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes.
Topics: Adjuvants, Immunologic; Animals; Biopsy, Needle; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Flow Cytometry; Imiquimod; Immunohistochemistry; Interleukin-17; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Psoriasis; Random Allocation; Real-Time Polymerase Chain Reaction; Signal Transduction; Tumor Necrosis Factor-alpha | 2019 |
Ghrelin protects against contact dermatitis and psoriasiform skin inflammation by antagonizing TNF-α/NF-κB signaling pathways.
Topics: Animals; Dermatitis, Contact; Disease Models, Animal; Fibroblasts; Gene Expression Regulation; Ghrelin; Humans; Imiquimod; Immune System Diseases; Inflammation; Mice; NF-kappa B; Oxazolone; Psoriasis; RAW 264.7 Cells; Signal Transduction; Skin; Tumor Necrosis Factor-alpha | 2019 |
IL-17E (IL-25) Enhances Innate Immune Responses during Skin Inflammation.
Topics: Acute Generalized Exanthematous Pustulosis; Adjuvants, Immunologic; Animals; Dermatitis; Disease Models, Animal; Female; Humans; Imiquimod; Immunity, Innate; Interleukin-17; Interleukins; Macrophages; Mice; Mice, Knockout; Neutrophils; p38 Mitogen-Activated Protein Kinases; Pyoderma Gangrenosum; Skin; Up-Regulation | 2019 |
Interleukin-18 exacerbates skin inflammation and affects microabscesses and scale formation in a mouse model of imiquimod-induced psoriasis.
Topics: Animals; Chemokine CXCL1; Cytokines; Disease Models, Animal; Imiquimod; Interleukin-17; Interleukin-18; Mice; Mice, Knockout; Psoriasis; Skin | 2019 |
Genistein suppresses psoriasis-related inflammation through a STAT3-NF-κB-dependent mechanism in keratinocytes.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Cytokines; Disease Models, Animal; Genistein; Heme; Humans; Imiquimod; Inflammation Mediators; Keratinocytes; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Psoriasis; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A | 2019 |
Dithranol-loaded nanostructured lipid carrier-based gel ameliorate psoriasis in imiquimod-induced mice psoriatic plaque model.
Topics: Administration, Cutaneous; Animals; Anthralin; Dermatologic Agents; Disease Models, Animal; Drug Carriers; Drug Liberation; Gels; Humans; Imiquimod; Lipids; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Ointments; Particle Size; Psoriasis; Severity of Illness Index; Skin; Treatment Outcome | 2019 |
Hyperglycemia Is Associated with Psoriatic Inflammation in Both Humans and Mice.
Topics: Animals; Blood Glucose; Cross-Sectional Studies; Disease Models, Animal; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Imiquimod; Insulin; Interleukin-17; Male; Mice; Middle Aged; Phototherapy; Psoriasis; Retrospective Studies; Severity of Illness Index; Skin; Treatment Outcome | 2019 |
Inhibiting Sphingosine Kinase 2 Derived-sphingosine-1-phosphate Ameliorates Psoriasis-like Skin Disease via Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes in Mice.
Topics: Administration, Topical; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Ceramidases; Disease Models, Animal; Enzyme Inhibitors; Gene Expression; Imiquimod; Immunity; Inflammation; Interleukin-17; Lysophospholipids; Male; Mice; Phosphotransferases (Alcohol Group Acceptor); Psoriasis; Quinolones; RNA, Messenger; Sphingosine; Suppressor of Cytokine Signaling 1 Protein; Th17 Cells | 2019 |
Methodological refinement of Aldara-induced psoriasiform dermatitis model in mice.
Topics: Animals; CD11b Antigen; Cytokines; Dermatitis; Disease Models, Animal; Female; Imiquimod; Mice, Inbred C57BL; Petrolatum; Psoriasis | 2019 |
cis-Khellactone Inhibited the Proinflammatory Macrophages via Promoting Autophagy to Ameliorate Imiquimod-Induced Psoriasis.
Topics: Adjuvants, Immunologic; Animals; Autophagy; Autophagy-Related Protein 7; Beclin-1; Cells, Cultured; Coumarins; Disease Models, Animal; Female; Gene Knockdown Techniques; Hepatocytes; Humans; Imiquimod; Macrophages; Male; Methotrexate; Mice; Mice, Inbred C57BL; Primary Cell Culture; Psoriasis; Toxicity Tests | 2019 |
Berberine downregulates CDC6 and inhibits proliferation via targeting JAK-STAT3 signaling in keratinocytes.
Topics: Animals; Anti-Inflammatory Agents; Berberine; Cell Cycle Proteins; Cell Line; Cell Proliferation; Disease Models, Animal; Female; Humans; Imiquimod; Janus Kinases; Keratinocytes; Mice; Mice, Inbred BALB C; Nuclear Proteins; Psoriasis; Signal Transduction; STAT3 Transcription Factor; Transfection | 2019 |
IL-33 contributes to disease severity in Psoriasis-like models of mouse.
Topics: Animals; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Inflammation; Interleukin-17; Interleukin-33; Interleukins; Mice; Mice, Inbred BALB C; Psoriasis; Skin; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2019 |
Protective effects of ambroxol in psoriasis like skin inflammation: Exploration of possible mechanisms.
Topics: Ambroxol; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Humans; Hyperplasia; Imiquimod; Inflammation; Inflammation Mediators; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred BALB C; Oxidative Stress; Psoriasis; RAW 264.7 Cells; Signal Transduction; Skin | 2019 |
GPR15 is not critically involved in the regulation of murine psoriasiform dermatitis.
Topics: Animals; Disease Models, Animal; Humans; Imiquimod; Interleukin-23; Mice; Mice, Knockout; Psoriasis; Receptors, G-Protein-Coupled; Skin | 2019 |
IL-38 Ameliorates Skin Inflammation and Limits IL-17 Production from γδ T Cells.
Topics: Animals; Antibodies; Cell Differentiation; Cytokines; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin-1; Interleukin-1 Receptor Accessory Protein; Interleukin-17; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Regeneration; Skin; T-Lymphocytes | 2019 |
Abnormal expression of SIRTs in psoriasis: Decreased expression of SIRT 1-5 and increased expression of SIRT 6 and 7.
Topics: Animals; Cell Line; Disease Models, Animal; Gene Expression Regulation, Enzymologic; Humans; Imiquimod; Mice; Psoriasis; Sirtuins | 2019 |
Systemic administration of imiquimod as an adjuvant improves immunogenicity of a tumor-lysate vaccine inducing the rejection of a highly aggressive T-cell lymphoma.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Extracts; Cell Line, Tumor; Disease Models, Animal; Female; Graft vs Tumor Effect; Humans; Imiquimod; Lymphoma, T-Cell; Mice; Mice, Inbred BALB C; Toll-Like Receptor 7 | 2019 |
Checkpoint blockade and nanosonosensitizer-augmented noninvasive sonodynamic therapy combination reduces tumour growth and metastases in mice.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Immunological; Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Hematoporphyrins; Humans; Imiquimod; Immunotherapy; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Treatment Outcome; Ultrasonic Therapy | 2019 |
Caspase-11-Mediated Cell Death Contributes to the Pathogenesis of Imiquimod-Induced Psoriasis.
Topics: Animals; Caspases, Initiator; Cell Death; Cell Proliferation; Disease Models, Animal; Humans; Imiquimod; Inflammation; Interleukin-1beta; Mice; Mice, Knockout; Neovascularization, Pathologic; Psoriasis; Ribonuclease, Pancreatic; Skin | 2019 |
Topics: Animals; Cytokines; Datura metel; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Gene Expression Regulation; Imiquimod; Male; Membrane Glycoproteins; Mice; Myeloid Differentiation Factor 88; NF-kappa B; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; Signal Transduction; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2019 |
Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice.
Topics: Animals; Astragalus propinquus; Cell Movement; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Inflammasomes; Inflammation; Inflammation Mediators; Macrophages; Mice; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Psoriasis; Pyroptosis; Sapogenins; Skin | 2019 |
E-Cadherin is Dispensable to Maintain Langerhans Cells in the Epidermis.
Topics: Animals; Cadherins; CD11c Antigen; Cell Differentiation; Cell Movement; Cell Shape; Cells, Cultured; Dermatitis, Contact; Disease Models, Animal; Epidermis; Homeostasis; Humans; Imiquimod; Langerhans Cells; Mice; Mice, Knockout; Psoriasis | 2020 |
Loading of water-insoluble celastrol into niosome hydrogels for improved topical permeation and anti-psoriasis activity.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents; Biomarkers; Cholesterol; Disease Models, Animal; Drug Compounding; Drug Delivery Systems; Female; Hexoses; Imiquimod; Interferon Inducers; Interleukins; Liposomes; Mice; Mice, Inbred C57BL; Pentacyclic Triterpenes; Plant Extracts; Psoriasis; Skin; Spleen; Tripterygium; Triterpenes | 2019 |
Total glucosides of paeony attenuates animal psoriasis induced inflammatory response through inhibiting STAT1 and STAT3 phosphorylation.
Topics: Animals; Cytokines; Disease Models, Animal; Female; Glucosides; Guinea Pigs; Imiquimod; Male; Mice, Inbred BALB C; Nuclear Receptor Subfamily 1, Group F, Member 3; Paeonia; Phosphorylation; Plant Roots; Psoriasis; STAT1 Transcription Factor; STAT3 Transcription Factor | 2019 |
Anti-IL-17A and IL-23p19 antibodies but not anti-TNFα antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.
Topics: Adoptive Transfer; Animals; Antibodies, Monoclonal; Disease Models, Animal; Female; Humans; Imiquimod; Interleukin-17; Interleukin-23 Subunit p19; Mice; Psoriasis; Signal Transduction; Skin; T-Lymphocytes, Regulatory; Th17 Cells; Tumor Necrosis Factor-alpha | 2019 |
Dietary supplementation of omega-3 fatty acid eicosapentaenoic acid does not ameliorate pruritus in murine models of atopic dermatitis and psoriasis.
Topics: Animals; Antigens, Dermatophagoides; Dermatitis, Atopic; Dietary Supplements; Disease Models, Animal; Eicosanoids; Eicosapentaenoic Acid; Humans; Imiquimod; Lipid Metabolism; Male; Mice; Pruritus; Psoriasis; Skin; Treatment Outcome | 2019 |
Investigating the Role of I Kappa B Kinase ε in the Pathogenesis of Psoriasis.
Topics: Animals; beta-Defensins; Biopsy; Chemokine CCL20; Chemokine CXCL1; Disease Models, Animal; Humans; I-kappa B Kinase; Imiquimod; Interleukin-17; Mice; Psoriasis; RNA, Messenger; Tumor Necrosis Factor-alpha | 2019 |
Sphingosine-1-phosphate exhibits anti-proliferative and anti-inflammatory effects in mouse models of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Calcitriol; Cell Differentiation; Cell Proliferation; Dermatologic Agents; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Imiquimod; Keratinocytes; Local Lymph Node Assay; Lysophospholipids; Mice; Mice, Inbred BALB C; Mice, SCID; Propylene Glycols; Psoriasis; Receptors, Lysosphingolipid; Skin; Skin Transplantation; Sphingosine; Sphingosine-1-Phosphate Receptors; Time Factors | 2013 |
Mustard seed (Sinapis Alba Linn) attenuates imiquimod-induced psoriasiform inflammation of BALB/c mice.
Topics: Aminoquinolines; Animals; Catalase; Cytokines; Dendritic Cells; Disease Models, Animal; Female; Glutathione Peroxidase; Imiquimod; Macrophages; Malondialdehyde; Mice; Mice, Inbred BALB C; Mustard Plant; NF-kappa B p50 Subunit; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Phytotherapy; Plant Preparations; Psoriasis; Seeds; Spleen; Superoxide Dismutase; T-Lymphocytes | 2013 |
Langerin(neg) conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice.
Topics: Aminoquinolines; Animals; Antigens, Surface; Disease Models, Animal; Imiquimod; Interleukin-23; Langerhans Cells; Lectins, C-Type; Mannose-Binding Lectins; Membrane Glycoproteins; Mice; Mice, Knockout; Myeloid Differentiation Factor 88; Psoriasis; Toll-Like Receptor 7 | 2013 |
TLR7 expression is decreased during tumour progression in transgenic adenocarcinoma of mouse prostate mice and its activation inhibits growth of prostate cancer cells.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinogenesis; Cell Growth Processes; Cell Line, Tumor; Cytokines; Disease Models, Animal; Disease Susceptibility; Epithelial Cells; Gene Expression Regulation, Neoplastic; Guanosine; Humans; Imiquimod; Inflammation Mediators; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Prostate; Prostatic Neoplasms; Toll-Like Receptor 7; Transgenes; Tumor Stem Cell Assay | 2013 |
TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Humans; Imiquimod; Membrane Glycoproteins; Mice; Psoriasis; Receptors, Purinergic P1; Toll-Like Receptor 7; Toll-Like Receptor 8 | 2013 |
A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; Calcitriol; Camptothecin; Clobetasol; Dermatologic Agents; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Nicotinic Acids; Psoriasis; Topoisomerase I Inhibitors | 2014 |
Prolactin induces the production of Th17 and Th1 cytokines/chemokines in murine Imiquimod-induced psoriasiform skin.
Topics: Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Female; Imiquimod; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Prolactin; Psoriasis; Real-Time Polymerase Chain Reaction; Recombinant Proteins; RNA, Messenger; Th1 Cells; Th17 Cells | 2014 |
IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing γδ T cells.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Dermatitis, Contact; Disease Models, Animal; Imiquimod; Interleukin-12; Interleukin-17; Interleukin-22; Interleukin-23 Subunit p19; Interleukins; Langerhans Cells; Lymph Nodes; Mice; Mice, Inbred C57BL; Organ Culture Techniques; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Receptors, CCR6; RNA, Messenger; Skin; Transplantation Chimera | 2014 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Epicutaneous application of toll-like receptor 7 agonists leads to systemic autoimmunity in wild-type mice: a new model of systemic Lupus erythematosus.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Autoantibodies; Autoimmunity; Disease Models, Animal; Imidazoles; Imiquimod; Lupus Erythematosus, Systemic; Mice; Skin; Spleen; Toll-Like Receptor 7 | 2014 |
Interplay between CXCR2 and BLT1 facilitates neutrophil infiltration and resultant keratinocyte activation in a murine model of imiquimod-induced psoriasis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Chemotaxis, Leukocyte; Disease Models, Animal; Imiquimod; Immunohistochemistry; Keratinocytes; Mice; Mice, Knockout; Neutrophil Infiltration; Neutrophils; Psoriasis; Real-Time Polymerase Chain Reaction; Receptors, Interleukin-8B; Receptors, Leukotriene B4 | 2014 |
Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis.
Topics: Aminoquinolines; Animals; Cell Differentiation; Cytokines; Disease Models, Animal; Fatty Acids, Omega-3; Female; Imiquimod; Inflammation; Inflammation Mediators; Interleukin-17; Interleukin-23; Keratinocytes; Male; Mice; Mice, Transgenic; Organ Size; Protective Agents; Psoriasis; Spleen; Th17 Cells | 2014 |
Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Topics: Administration, Topical; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Down-Regulation; Fibroblast Growth Factors; Humans; Imiquimod; Interleukin-8; Melanoma; Mice; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Middle Aged; Neovascularization, Pathologic; Ribonuclease, Pancreatic; Skin Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Nociceptive sensory neurons drive interleukin-23-mediated psoriasiform skin inflammation.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Female; Imiquimod; Inflammation; Interleukin-17; Interleukin-22; Interleukin-23; Interleukins; Langerhans Cells; Lymph Nodes; Male; Mice; Mice, Inbred C57BL; NAV1.8 Voltage-Gated Sodium Channel; Nociceptors; Psoriasis; Sensory Receptor Cells; Skin; T-Lymphocytes; TRPV Cation Channels | 2014 |
TLR7 is a key regulator of innate immunity against Japanese encephalitis virus infection.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Brain; Cell Line; Cell Line, Tumor; Cells, Cultured; Disease Models, Animal; DNA, Viral; Encephalitis Virus, Japanese; Encephalitis, Japanese; Gene Knockdown Techniques; Humans; Imiquimod; Immunity, Innate; Interferon Type I; Membrane Glycoproteins; Mice, Inbred BALB C; Mice, Transgenic; Microglia; Neurons; Toll-Like Receptor 7 | 2014 |
Leukotrienes do not modulate the course of Aldara™-induced psoriasiform dermatitis in mice.
Topics: Aminoquinolines; Animals; Arachidonate 5-Lipoxygenase; Disease Models, Animal; Imiquimod; Leukotrienes; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Leukotriene B4; Signal Transduction; Skin | 2015 |
IL-17 drives psoriatic inflammation via distinct, target cell-specific mechanisms.
Topics: Aminoquinolines; Animals; Cell Differentiation; Cell Proliferation; Disease Models, Animal; Epidermis; Imiquimod; Interleukin-17; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Real-Time Polymerase Chain Reaction | 2014 |
Nanomiemgel--a novel drug delivery system for topical application--in vitro and in vivo evaluation.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Capsaicin; Cell Proliferation; Diclofenac; Disease Models, Animal; Drug Delivery Systems; Drug Stability; Emulsions; Gels; Humans; Imiquimod; Immunohistochemistry; In Vitro Techniques; Inflammation; Keratinocytes; Micelles; Microdialysis; Microscopy, Atomic Force; Nanoparticles; Organ Size; Permeability; Psoriasis; Rats; Rheology; Skin Absorption; Spleen | 2014 |
Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies, Neutralizing; Antibodies, Viral; Disease Models, Animal; Escherichia coli; Gene Expression; Hemagglutination Inhibition Tests; Hemagglutinin Glycoproteins, Influenza Virus; Imiquimod; Immunoglobulin G; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Injections, Intraperitoneal; Mice, Inbred BALB C; Neutralization Tests; Orthomyxoviridae Infections; Protein Subunits; Recombinant Proteins; Survival Analysis; Vaccination; Vaccines, Subunit; Vaccines, Synthetic | 2015 |
Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Lymphocyte Count; Lymphocytes; Mice; Mice, Knockout; Osteopontin; Psoriasis; Skin; Spleen; Th17 Cells | 2015 |
SIRT1 Activation Ameliorates Aldara-Induced Psoriasiform Phenotype and Histology in Mice.
Topics: Aminoquinolines; Animals; Biopsy, Needle; Cell Differentiation; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Imiquimod; Immunohistochemistry; Keratinocytes; Mice; Phenotype; Psoriasis; Sensitivity and Specificity; Sirtuin 1; Transcriptional Activation | 2015 |
Obesity exacerbates imiquimod-induced psoriasis-like epidermal hyperplasia and interleukin-17 and interleukin-22 production in mice.
Topics: Aminoquinolines; Animals; Cell Line; Disease Models, Animal; Epidermis; Female; Humans; Hyperplasia; Imiquimod; Interleukin-17; Interleukin-22; Interleukins; Keratinocytes; Male; Membrane Glycoproteins; Mice; Mice, Mutant Strains; Obesity; Pancreatitis-Associated Proteins; Phosphatidylinositol 3-Kinases; Proteins; Psoriasis; Toll-Like Receptor 7 | 2015 |
Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine a in a murine model of imiquimod-induced psoriasis.
Topics: Aminoquinolines; Animals; Cyclosporine; Dermatitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosamine; Imiquimod; Immunomodulation; Mice; Mice, Inbred C57BL; Organ Size; Psoriasis; Spleen; T-Lymphocytes, Regulatory | 2015 |
Role of the store-operated calcium entry protein, STIM1, in neutrophil chemotaxis and infiltration into a murine model of psoriasis-inflamed skin.
Topics: Aminoquinolines; Animals; Calcium Channels; Chemotaxis, Leukocyte; Disease Models, Animal; HL-60 Cells; Humans; Imiquimod; In Vitro Techniques; Membrane Proteins; Mice; Mice, Knockout; Neoplasm Proteins; Neutrophil Infiltration; Neutrophils; Psoriasis; RNA, Small Interfering; Signal Transduction; Skin; Stromal Interaction Molecule 1 | 2015 |
Resveratrol ameliorates imiquimod-induced psoriasis-like skin inflammation in mice.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Interleukins; Male; Mice; Psoriasis; Resveratrol; Signal Transduction; Stilbenes | 2015 |
Downregulation of TNIP1 Expression Leads to Increased Proliferation of Human Keratinocytes and Severer Psoriasis-Like Conditions in an Imiquimod-Induced Mouse Model of Dermatitis.
Topics: Aminoquinolines; Animals; CCAAT-Enhancer-Binding Protein-beta; Cell Proliferation; Cells, Cultured; Dermatitis; Disease Models, Animal; DNA-Binding Proteins; Down-Regulation; Humans; Imiquimod; Keratinocytes; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Psoriasis; RNA Interference; Severity of Illness Index; Signal Transduction; Skin | 2015 |
Cutting Edge: PD-1 Regulates Imiquimod-Induced Psoriasiform Dermatitis through Inhibition of IL-17A Expression by Innate γδ-Low T Cells.
Topics: Aminoquinolines; Animals; Antibodies; Dermatitis; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Injections, Intraperitoneal; Interleukin-17; Keratinocytes; Mice; Mice, Inbred C57BL; Mice, Knockout; Neutrophil Infiltration; Neutrophils; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Antigen, T-Cell, gamma-delta; Signal Transduction; Th17 Cells | 2015 |
CCN1, a Pro-Inflammatory Factor, Aggravates Psoriasis Skin Lesions by Promoting Keratinocyte Activation.
Topics: Aminoquinolines; Animals; Biopsy, Needle; Cell Proliferation; Cells, Cultured; Cysteine-Rich Protein 61; Disease Models, Animal; Disease Progression; Extracellular Matrix; Female; Humans; Imiquimod; Immunohistochemistry; Inflammation Mediators; Interleukin-23; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Knockout; Psoriasis; Random Allocation; Signal Transduction | 2015 |
Klk8 is required for microabscess formation in a mouse imiquimod model of psoriasis.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Kallikreins; Mice, Knockout; Psoriasis | 2015 |
Decreased Expression of Caveolin-1 Contributes to the Pathogenesis of Psoriasiform Dermatitis in Mice.
Topics: Aminoquinolines; Analysis of Variance; Animals; Biomarkers; Biopsy, Needle; Blotting, Western; Caveolin 1; Cell Proliferation; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Humans; Imiquimod; Immunohistochemistry; Keratinocytes; Mice; Mice, Inbred C57BL; Polymerase Chain Reaction; Psoriasis; Random Allocation; Sampling Studies; Signal Transduction; STAT3 Transcription Factor | 2015 |
Activation of TLR7 increases CCND3 expression via the downregulation of miR-15b in B cells of systemic lupus erythematosus.
Topics: Adult; Aminoquinolines; Animals; Antigens, CD19; B-Lymphocytes; Cluster Analysis; Cyclin D3; Disease Models, Animal; Down-Regulation; Female; Gene Expression Profiling; Gene Ontology; Gene Regulatory Networks; Humans; Imiquimod; Lupus Erythematosus, Systemic; Mice, Inbred C57BL; MicroRNAs; Protein Interaction Maps; RNA, Messenger; Toll-Like Receptor 7; Up-Regulation | 2016 |
Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.
Topics: Aminoquinolines; Animals; Azepines; Disease Models, Animal; Imiquimod; Inflammation; Interleukin-17; Interleukin-22; Interleukins; Male; Mice; Mice, Inbred BALB C; Nuclear Receptor Subfamily 1, Group F, Member 3; Psoriasis; Signal Transduction; Skin; Triazoles | 2015 |
Suppressive effect of β, β-dimethylacryloyl alkannin on activated dendritic cells in an imiquimod-induced psoriasis mouse model.
Topics: Aminoquinolines; Animals; Cell Proliferation; Cells, Cultured; Coculture Techniques; Cytokines; Dendritic Cells; Dermatologic Agents; Disease Models, Animal; Humans; Imiquimod; Inflammation Mediators; Lymphocyte Activation; Lymphocytes; Male; Mice, Inbred BALB C; Naphthoquinones; Psoriasis; Severity of Illness Index; Skin; Time Factors | 2015 |
Using Imiquimod-Induced Psoriasis-Like Skin as a Model to Measure the Skin Penetration of Anti-Psoriatic Drugs.
Topics: Aminolevulinic Acid; Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Female; Imiquimod; Mice; Psoriasis; Skin; Skin Absorption; Tacrolimus; Tretinoin | 2015 |
Effects of Human Mesenchymal Stem Cells Transduced with Superoxide Dismutase on Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice.
Topics: Aminoquinolines; Animals; Cytokines; Dendritic Cells; Disease Models, Animal; Gene Expression; Humans; Hyperplasia; Imiquimod; Inflammation Mediators; Janus Kinases; Lymph Nodes; Lymphocyte Activation; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mitogen-Activated Protein Kinases; Mucolipidoses; Neutrophil Infiltration; NF-kappa B; Psoriasis; Reactive Oxygen Species; Severity of Illness Index; Signal Transduction; Skin; Spleen; STAT Transcription Factors; Superoxide Dismutase; T-Lymphocytes; Toll-Like Receptor 7; Transduction, Genetic | 2016 |
Dynamics and Transcriptomics of Skin Dendritic Cells and Macrophages in an Imiquimod-Induced, Biphasic Mouse Model of Psoriasis.
Topics: Aminoquinolines; Animals; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Macrophages; Mice; Mice, Transgenic; Psoriasis; Skin; Transcriptome | 2015 |
Antrodia cinnamomea Extract Inhibits Th17 Cell Differentiation and Ameliorates Imiquimod-Induced Psoriasiform Skin Inflammation.
Topics: Administration, Oral; Aminoquinolines; Animals; Anti-Inflammatory Agents; Antrodia; Autoimmunity; Cell Differentiation; Cells, Cultured; Depression, Chemical; Disease Models, Animal; Drugs, Chinese Herbal; Imiquimod; Interleukin-17; Male; Mice, Inbred C57BL; Nuclear Receptor Subfamily 1, Group F, Member 3; Phosphorylation; Phytotherapy; Psoriasis; Skin; STAT3 Transcription Factor; Th17 Cells | 2015 |
Percutaneous delivery of α-melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis.
Topics: Administration, Cutaneous; alpha-MSH; Aminoquinolines; Animals; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Ethylene Glycols; Gels; Imiquimod; Inflammation; Male; Mice; Mice, Inbred C57BL; Microdialysis; Psoriasis; Rats; Rats, Sprague-Dawley; Skin Absorption | 2016 |
Implantable synthetic cytokine converter cells with AND-gate logic treat experimental psoriasis.
Topics: Aminoquinolines; Animals; Cell Transplantation; CHO Cells; Cricetulus; Disease Models, Animal; Female; Gene Expression Regulation; Genetic Engineering; Genetic Therapy; HEK293 Cells; HeLa Cells; Humans; Imiquimod; Inflammation Mediators; Interleukin-10; Interleukin-22; Interleukin-4; Interleukins; Logic; Mice, Inbred C57BL; Psoriasis; Reproducibility of Results; Signal Transduction; Skin; Time Factors; Transfection; Tumor Necrosis Factor-alpha | 2015 |
IMQ Induced K14-VEGF Mouse: A Stable and Long-Term Mouse Model of Psoriasis-Like Inflammation.
Topics: Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Drug Eruptions; Imiquimod; Mice, Inbred Strains; Mice, Transgenic; Otitis; Psoriasis; Vascular Endothelial Growth Factor A | 2015 |
Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.
Topics: Aminoquinolines; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Caco-2 Cells; Cell Line; Crohn Disease; Dendritic Cells; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Humans; Imiquimod; Inflammation; Interleukin-1; Interleukins; Intestinal Mucosa; Keratinocytes; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Plasma Cells; Psoriasis; RNA, Messenger; Skin; Synovial Membrane; Th17 Cells | 2016 |
Imiquimod Increases Cutaneous VEGF Expression in Imiquimod-induced Psoriatic Mouse Model.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Psoriasis; Skin; Vascular Endothelial Growth Factor A | 2016 |
Immunosuppressive effect of adipose-derived stromal cells on imiquimod-induced psoriasis in mice.
Topics: Adipose Tissue; Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Immune Tolerance; Inflammation Mediators; Mice; Psoriasis; Signal Transduction; Skin; Stromal Cells; Time Factors | 2016 |
Trem-1 is not crucial in psoriasiform imiquimod-induced skin inflammation in mice.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Imiquimod; Male; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Triggering Receptor Expressed on Myeloid Cells-1 | 2016 |
Topical imiquimod yields systemic effects due to unintended oral uptake.
Topics: Administration, Oral; Administration, Topical; Aminoquinolines; Animals; Disease Models, Animal; Gastrointestinal Tract; Imiquimod; Interferon Type I; Mice; Phenotype; Psoriasis; Skin Diseases | 2016 |
Upregulation of PI3K/AKT/mTOR, FABP5 and PPARβ/δ in Human Psoriasis and Imiquimod-induced Murine Psoriasiform Dermatitis Model.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Fatty Acid-Binding Proteins; Imiquimod; Male; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; PPAR delta; PPAR-beta; Proto-Oncogene Proteins c-akt; Psoriasis; TOR Serine-Threonine Kinases; Up-Regulation | 2016 |
Periplogenin induces necroptotic cell death through oxidative stress in HaCaT cells and ameliorates skin lesions in the TPA- and IMQ-induced psoriasis-like mouse models.
Topics: Aminoquinolines; Animals; Cell Death; Cell Line; Cell Survival; Digitoxigenin; Disease Models, Animal; Female; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Necrosis; Oxidative Stress; Psoriasis; Tetradecanoylphorbol Acetate | 2016 |
Oral administration of acarbose ameliorates imiquimod-induced psoriasis-like dermatitis in a mouse model.
Topics: Acarbose; Administration, Oral; Aminoquinolines; Animals; Cell Movement; Cytokines; Dermatitis, Contact; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Neutrophils; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Skin; T-Lymphocytes, Regulatory; Th17 Cells | 2016 |
Heme oxygenase-1 induction attenuates imiquimod-induced psoriasiform inflammation by negative regulation of Stat3 signaling.
Topics: Aminoquinolines; Animals; Cell Differentiation; Cell Proliferation; Cytokines; Disease Models, Animal; Enzyme Activation; Epidermal Cells; Epidermis; Female; Gene Expression; Gene Expression Regulation; Heme Oxygenase-1; Imiquimod; Keratinocytes; Mice; Models, Biological; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Psoriasis; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Th17 Cells | 2016 |
Inhibitory Effect of Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice by Histamine H4 Receptor Agonist 4-Methylhistamine.
Topics: Aminoquinolines; Animals; Cell Movement; Cytokines; Disease Models, Animal; Female; Forkhead Transcription Factors; Humans; Imiquimod; Inflammation; Interleukin-2 Receptor alpha Subunit; Methylhistamines; Mice; Mice, Inbred C57BL; Psoriasis; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Skin; T-Lymphocytes, Regulatory; Th1 Cells | 2016 |
Therapeutic Effects of Erythroid Differentiation Regulator 1 on Imiquimod-Induced Psoriasis-Like Skin Inflammation.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents; Calgranulin A; Disease Models, Animal; Gene Expression Regulation; Imiquimod; Interleukin-17; Interleukin-22; Interleukins; Membrane Proteins; Mice; Psoriasis; Recombinant Proteins; Th17 Cells; Tumor Suppressor Proteins | 2016 |
CX3CR1 deficiency attenuates imiquimod-induced psoriasis-like skin inflammation with decreased M1 macrophages.
Topics: Aminoquinolines; Animals; Cell Count; Chemokine CX3CL1; CX3C Chemokine Receptor 1; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Interleukins; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Chemokine; Skin; Tumor Necrosis Factor-alpha | 2016 |
AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model.
Topics: Aminoquinolines; Animals; Cell Proliferation; Chemotaxis; Disease Models, Animal; Imiquimod; Immunity, Innate; Interleukin-22; Interleukins; Mice; Mice, Knockout; Psoriasis; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Antigen, T-Cell, gamma-delta; Receptors, Aryl Hydrocarbon; T-Lymphocyte Subsets; Th17 Cells | 2016 |
Oncostatin M overexpression induces skin inflammation but is not required in the mouse model of imiquimod-induced psoriasis-like inflammation.
Topics: Aminoquinolines; Animals; Biomarkers; Cell Differentiation; Cell Proliferation; Disease Models, Animal; Epidermis; Filaggrin Proteins; Gene Expression; Gene Expression Regulation; Imiquimod; Keratinocytes; Male; Mice; Mice, Knockout; Oncostatin M; Phenotype; Psoriasis; Skin | 2016 |
Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice.
Topics: Aminoquinolines; Animals; Axitinib; Dermatitis, Atopic; Disease Models, Animal; Epidermis; Humans; Imidazoles; Imiquimod; Indazoles; Mice; Pruritus; Psoriasis; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2016 |
TLR7-mediated skin inflammation remotely triggers chemokine expression and leukocyte accumulation in the brain.
Topics: Aminoquinolines; Animals; Brain; CD3 Complex; Chemokines; Chemotaxis, Leukocyte; Dermatitis; Disease Models, Animal; Doublecortin Domain Proteins; Female; Flow Cytometry; Gene Expression Profiling; Imiquimod; Interferon Inducers; Leukocytes; Membrane Glycoproteins; Mice; Microtubule-Associated Proteins; Neuropeptides; Oligonucleotide Array Sequence Analysis; Phorbol Esters; RNA, Messenger; Toll-Like Receptor 7 | 2016 |
Original Research: Different imiquimod creams resulting in differential effects for imiquimod-induced psoriatic mouse models.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Dermatologic Agents; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred BALB C; Psoriasis; Skin; Skin Cream; Treatment Outcome | 2016 |
Influence of different types of contact hypersensitivity on imiquimod-induced psoriasis-like inflammation in mice.
Topics: Aminoquinolines; Animals; Biomarkers; Cytokines; Dermatitis, Contact; Disease Models, Animal; Female; Gene Expression; Imiquimod; Mice; Psoriasis; Skin; Th1 Cells; Th17 Cells; Th2 Cells | 2016 |
NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.
Topics: Aminoquinolines; Animals; B-Lymphocytes; Disease Models, Animal; Imiquimod; Interleukin-10; Mice; Mice, Inbred C57BL; NFATC Transcription Factors; Psoriasis; Signal Transduction | 2016 |
The genetic difference between C57Bl/6J and C57Bl/6N mice significantly impacts Aldara™-induced psoriasiform dermatitis.
Topics: Aminoquinolines; Animals; Dermatitis; Disease Models, Animal; Imiquimod; Mice, Inbred C57BL; Psoriasis; Skin; Species Specificity | 2017 |
Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Bone Resorption; Disease Models, Animal; Flow Cytometry; Fluorescent Antibody Technique; Imiquimod; Interleukin-33; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis | 2016 |
The Exonuclease Trex2 Shapes Psoriatic Phenotype.
Topics: Aminoquinolines; Animals; Apoptosis; Biopsy, Needle; Case-Control Studies; Cell Survival; Cells, Cultured; Disease Models, Animal; Exodeoxyribonucleases; Gene Expression Regulation; Humans; Imiquimod; Immunohistochemistry; Keratinocytes; Mice; Mice, Knockout; Phenotype; Prognosis; Psoriasis; Severity of Illness Index; Up-Regulation | 2016 |
Reducing Flightless I expression decreases severity of psoriasis in an imiquimod-induced murine model of psoriasiform dermatitis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Carrier Proteins; Cytoskeletal Proteins; Dermatitis; Disease Models, Animal; Drug Eruptions; Female; Humans; Imiquimod; Irritants; Male; Mice, Inbred BALB C; Microfilament Proteins; Middle Aged; Psoriasis; RNA, Messenger; Toll-Like Receptor 4; Trans-Activators | 2017 |
Effects of Imiquimod on Hair Follicle Stem Cells and Hair Cycle Progression.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Cell Cycle; Cell Proliferation; Disease Models, Animal; Hair Follicle; Imiquimod; Mice; Mice, Inbred C57BL; Psoriasis; Stem Cells | 2016 |
Dual Inhibition of PI3K/Akt and mTOR by the Dietary Antioxidant, Delphinidin, Ameliorates Psoriatic Features In Vitro and in an Imiquimod-Induced Psoriasis-Like Disease in Mice.
Topics: Administration, Topical; Aminoquinolines; Animals; Anthocyanins; Antioxidants; Binding Sites; Biopsy; Chemotaxis, Leukocyte; Cytokines; Disease Models, Animal; Imiquimod; Immunomodulation; Inflammation Mediators; Mice; Models, Molecular; Molecular Conformation; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Psoriasis; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Skin; TOR Serine-Threonine Kinases | 2017 |
Intestinal Microbiota Promotes Psoriasis-Like Skin Inflammation by Enhancing Th17 Response.
Topics: Actinobacteria; Aminoquinolines; Animals; Anti-Bacterial Agents; Clostridiales; Disease Models, Animal; Female; Gastrointestinal Microbiome; Gene Expression; Germ-Free Life; Humans; Imiquimod; Interleukin-17; Lactobacillales; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Nuclear Receptor Subfamily 1, Group F, Member 3; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Skin; Species Specificity; Th17 Cells | 2016 |
Mouse model of imiquimod-induced psoriatic itch.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antipruritics; Chlorpheniramine; Disease Models, Animal; Ganglia, Spinal; Gene Expression Regulation; Histidine Decarboxylase; Imiquimod; Male; Mice; Mice, Inbred C57BL; Olopatadine Hydrochloride; Pain Measurement; Pruritus; Random Allocation; Skin; TRPV Cation Channels; Tryptophan Hydroxylase | 2016 |
Azithromycin impairs TLR7 signaling in dendritic cells and improves the severity of imiquimod-induced psoriasis-like skin inflammation in mice.
Topics: Aminoquinolines; Animals; Anti-Bacterial Agents; Azithromycin; Cell Proliferation; Cytokines; Dendritic Cells; Disease Models, Animal; Female; Humans; Imiquimod; Keratinocytes; Leukocytes, Mononuclear; Lysosomes; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Psoriasis; Signal Transduction; Skin; Spleen; Th17 Cells; Toll-Like Receptor 7 | 2016 |
Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model.
Topics: Acanthosis Nigricans; Aminoquinolines; Animals; Cell Differentiation; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cellular Senescence; Disease Models, Animal; Glucosides; Humans; Imiquimod; Immunohistochemistry; Inflammation; Interleukin-22; Interleukins; Keratinocytes; Lipids; Luteolin; Mice, Inbred C57BL; Oxidation-Reduction; Phenotype; Protein Transport; Psoriasis; Signal Transduction; STAT3 Transcription Factor | 2016 |
MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice.
Topics: Aminoquinolines; Animals; Cell Proliferation; Centella; Dermatitis; Disease Models, Animal; Female; Humans; Imiquimod; Interleukin-17; Interleukin-23; Mice; Mice, Inbred BALB C; Ointments; Psoriasis; Signal Transduction; Skin; Th17 Cells; Triterpenes | 2016 |
MicroRNA-146a suppresses IL-17-mediated skin inflammation and is genetically associated with psoriasis.
Topics: Adult; Aminoquinolines; Animals; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Imiquimod; Interleukin-17; Keratinocytes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Neutrophil Infiltration; Polymorphism, Single Nucleotide; Psoriasis; Skin; Sweden | 2017 |
Spread of Psoriasiform Inflammation to Remote Tissues Is Restricted by the Atypical Chemokine Receptor ACKR2.
Topics: Aminoquinolines; Animals; Biopsy, Needle; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Humans; Imiquimod; Immunohistochemistry; Inflammation; Keratinocytes; Mice; Mice, Inbred C57BL; Phenotype; Polymerase Chain Reaction; Psoriasis; Random Allocation; Receptors, Chemokine; Reference Values; Statistics, Nonparametric; Up-Regulation | 2017 |
Toll-like receptor 7 agonist induces hypoplasia of the biliary system in a neonatal mouse model.
Topics: Aminoquinolines; Animals; Apoptosis; Biliary Atresia; Biliary Tract; Chemical and Drug Induced Liver Injury; Cholestasis; Disease Models, Animal; DNA Nucleotidylexotransferase; Gallbladder; Imiquimod; Interferon Regulatory Factor-7; Interferon-alpha; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; RNA, Messenger; Rotavirus; Rotavirus Infections; Toll-Like Receptor 7; Tumor Necrosis Factor-alpha | 2018 |
Protective effects of agonistic anti-4-1BB antibody on the development of imiquimod-induced psoriasis-like dermatitis in mice.
Topics: Aminoquinolines; Animals; Antibodies, Monoclonal; Biopsy; Cytokines; Disease Models, Animal; Female; Imiquimod; Inflammation Mediators; Mice; Phenotype; Protective Agents; Psoriasis; Skin; Splenomegaly; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Th17 Cells; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2016 |
Improved topical delivery of tacrolimus: A novel composite hydrogel formulation for the treatment of psoriasis.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Biological Availability; Chemistry, Pharmaceutical; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Hydrogels; Imiquimod; Immunosuppressive Agents; Mice; Mice, Inbred C57BL; Polymers; Psoriasis; Skin; Skin Absorption; Solubility; Tacrolimus | 2016 |
Keratinocytes contribute intrinsically to psoriasis upon loss of Tnip1 function.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Disease Susceptibility; DNA-Binding Proteins; Female; Gene Expression Profiling; Imiquimod; Interleukin-17; Interleukin-23; Keratinocytes; Lymphocytes; Male; Mice; Mice, Knockout; Psoriasis; Transcriptome | 2016 |
Effects of Depilation Methods on Imiquimod-Induced Skin Inflammation in Mice.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Hair Removal; Imiquimod; Inflammation; Injections, Subcutaneous; Interleukin-23; Mice; Mice, Inbred C57BL; Random Allocation; Reference Values; Treatment Outcome | 2017 |
Proinflammatory effect of high-mobility group protein B1 on keratinocytes: an autocrine mechanism underlying psoriasis development.
Topics: Aminoquinolines; Animals; Autocrine Communication; Cell Proliferation; Disease Models, Animal; HMGB1 Protein; Humans; Imiquimod; Inflammasomes; Interleukin-17; Interleukin-18; Keratinocytes; Mice, Inbred BALB C; Psoriasis; Signal Transduction | 2017 |
Polyinosinic-polycytidylic acid (poly(I:C)) attenuates imiquimod-induced skin inflammation in mice by increasing cutaneous PD-L1 expression.
Topics: Aminoquinolines; Animals; B7-H1 Antigen; Cell Line, Transformed; Dermatitis; Disease Models, Animal; Humans; Imiquimod; Keratinocytes; Mice; Poly I-C; Psoriasis; Toll-Like Receptor 3 | 2017 |
IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination.
Topics: Aminoquinolines; Animals; B7-H1 Antigen; Cancer Vaccines; Cell Line, Tumor; Dendritic Cells; Disease Models, Animal; Female; Humans; Imiquimod; Immunomodulation; Immunophenotyping; Immunotherapy; Interleukin-10; Lymphocyte Activation; Melanoma, Experimental; Mice; Mice, Transgenic; Neoplasms; Phenotype; T-Lymphocytes; Vaccination; Xenograft Model Antitumor Assays | 2017 |
Decreased expression of IL-27 in moderate-to-severe psoriasis and its anti-inflammation role in imiquimod-induced psoriasis-like mouse model.
Topics: Aminoquinolines; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Imiquimod; Immunotherapy; Injections, Subcutaneous; Interferon-gamma; Interleukin-10; Interleukin-17; Interleukins; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Psoriasis; Receptors, Interleukin; Recombinant Proteins; RNA, Messenger; Severity of Illness Index; Skin; Th1 Cells; Th17 Cells | 2017 |
Involvement of high mobility group box-1 in imiquimod-induced psoriasis-like mice model.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents; Cytokines; Disease Models, Animal; Drug Evaluation, Preclinical; Glycyrrhizic Acid; HMGB1 Protein; Imiquimod; Phytotherapy; Plant Extracts; Psoriasis | 2017 |
TRIM21 is important in the early phase of inflammation in the imiquimod-induced psoriasis-like skin inflammation mouse model.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Imiquimod; Mice, Knockout; Psoriasis; Ribonucleoproteins | 2017 |
The Snowballing Literature on Imiquimod-Induced Skin Inflammation in Mice: A Critical Appraisal.
Topics: Aminoquinolines; Animals; Dermatitis; Dermatology; Disease Models, Animal; Humans; Imiquimod; Inflammation; Mice; Psoriasis; Research Design | 2017 |
Activation of Langerhans cells promotes the inflammation in imiquimod-induced psoriasis-like dermatitis.
Topics: Aminoquinolines; Animals; Antigens, CD; Antigens, Surface; Cytokines; Disease Models, Animal; Epidermal Cells; Epidermis; Flow Cytometry; Imiquimod; Langerhans Cells; Lectins, C-Type; Lymph Nodes; Mannose-Binding Lectins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Psoriasis; Tumor Necrosis Factor-alpha | 2017 |
TLR-activated plasmacytoid dendritic cells inhibit breast cancer cell growth in vitro and in vivo.
Topics: Aminoquinolines; Animals; Dendritic Cells; Disease Models, Animal; Female; Granzymes; Imiquimod; Immunotherapy, Adoptive; Interferon Inducers; Mammary Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; TNF-Related Apoptosis-Inducing Ligand; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2017 |
Anti-psoriatic potential of Solanum xanthocarpum stem in Imiquimod-induced psoriatic mice model.
Topics: Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Female; Imiquimod; Male; Mice; Plant Extracts; Plant Stems; Psoriasis; Solanum | 2017 |
Imiquimod Treatment Causes Systemic Disease in Mice Resembling Generalized Pustular Psoriasis in an IL-1 and IL-36 Dependent Manner.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Body Temperature; Disease Models, Animal; Female; Imiquimod; Inflammation; Interleukin-1; Male; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; Neutrophils; Pain Measurement; Psoriasis; Receptors, Interleukin-1 Type I; Sex Factors; Skin | 2016 |
Modeling of viral-bacterial coinfections at the molecular level using agonists of innate immunity receptors.
Topics: Aminoquinolines; Animals; Bacterial Infections; Bone Marrow; Cells, Cultured; Coinfection; Cytokines; Disease Models, Animal; Imiquimod; Immunity, Innate; Interleukin-1beta; Interleukin-6; Ligands; Lipopolysaccharides; Macrophage Activation; Macrophages; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; RNA, Messenger; Toll-Like Receptor 4; Toll-Like Receptor 7; Toll-Like Receptors; Tumor Necrosis Factor-alpha; Virus Diseases | 2016 |
Surgical Denervation in the Imiquimod-Induced Psoriasiform Mouse Model.
Topics: Aminoquinolines; Animals; Denervation; Dermatologic Surgical Procedures; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Imiquimod; Interleukin-17; Interleukin-23; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Skin; T-Lymphocytes; Toll-Like Receptor 7 | 2017 |
Isogarcinol Extracted from Garcinia mangostana L. Ameliorates Imiquimod-Induced Psoriasis-like Skin Lesions in Mice.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Female; Garcinia mangostana; Humans; Imiquimod; Interleukin-2; Interleukin-23; Mice; Mice, Inbred C57BL; Plant Extracts; Psoriasis; Skin; T-Lymphocytes, Regulatory; Th17 Cells; Tumor Necrosis Factor-alpha | 2017 |
Ccr6 Is Dispensable for the Development of Skin Lesions Induced by Imiquimod despite its Effect on Epidermal Homing of IL-22-Producing Cells.
Topics: Aminoquinolines; Animals; beta-Galactosidase; Cells, Cultured; Disease Models, Animal; Epidermis; Gene Knock-In Techniques; Homeodomain Proteins; Imiquimod; Interleukin-22; Interleukins; Mice; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, CCR6; T-Lymphocyte Subsets | 2017 |
Imiquimod Injection to Rabbit Vocal Folds: A Preliminary, Preclinical Investigation.
Topics: Aminoquinolines; Animals; Biomarkers; Disease Models, Animal; Imiquimod; Injections, Intralesional; Interferon-alpha; Laryngeal Neoplasms; Papilloma; Rabbits; Vocal Cords | 2017 |
The TLR7 agonist imiquimod induces anti-cancer effects via autophagic cell death and enhances anti-tumoral and systemic immunity during radiotherapy for melanoma.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Autophagy; Cell Death; Chemoradiotherapy; Disease Models, Animal; Imiquimod; Melanoma, Experimental; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Toll-Like Receptor 7 | 2017 |
GPR43 activation enhances psoriasis-like inflammation through epidermal upregulation of IL-6 and dual oxidase 2 signaling in a murine model.
Topics: Acetamides; Acetates; Aminoquinolines; Animals; Disease Models, Animal; Dual Oxidases; Epidermis; Imiquimod; Inflammation; Interleukin-6; Male; Mice, Inbred BALB C; Models, Biological; Psoriasis; Receptors, G-Protein-Coupled; Signal Transduction; Th17 Cells; Up-Regulation | 2017 |
Lanolin-based organogel of salicylic acid: evidences of better dermatokinetic profile in imiquimod-induced keratolytic therapy in BALB/c mice model.
Topics: Administration, Topical; Aminoquinolines; Animals; Disease Models, Animal; Drug Carriers; Excipients; Gels; Imiquimod; Keratolytic Agents; Keratosis; Lanolin; Male; Mice, Inbred BALB C; Salicylic Acid; Skin; Skin Absorption | 2018 |
Effects of Topical Application of Betamethasone on Imiquimod-induced Psoriasis-like Skin Inflammation in Mice.
Topics: Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; Betamethasone; Cytokines; Disease Models, Animal; Female; Imiquimod; Keratinocytes; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Psoriasis; RNA, Messenger; Skin; Th1 Cells; Th17 Cells | 2016 |
Psoriasis-like inflammation leads to renal dysfunction via upregulation of NADPH oxidases and inducible nitric oxide synthase.
Topics: Acetylcysteine; Aminoquinolines; Animals; Antioxidants; Buthionine Sulfoximine; Disease Models, Animal; Humans; Imiquimod; Inflammation; Kidney; Kidney Diseases; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; NADPH Oxidase 2; NADPH Oxidase 4; NADPH Oxidases; Nitric Oxide Synthase Type II; Oxidative Stress; Psoriasis | 2017 |
Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis.
Topics: Aminoquinolines; Animals; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Imiquimod; Interleukin-17; Male; Mice; Mice, Inbred Strains; Psoriasis; Sequence Analysis, RNA; Sex Factors; Skin; Species Specificity | 2017 |
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.
Topics: Aminoquinolines; Animals; Cell Differentiation; Cell Proliferation; Dermatitis, Contact; Disease Models, Animal; Humans; Imiquimod; Inflammation Mediators; Interleukin-17; Interleukin-23; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Psoriasis; Receptors, Interleukin-17 | 2009 |
Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adjuvants, Immunologic; Administration, Intravesical; Aminoquinolines; Animals; beta-Cyclodextrins; Chemistry, Pharmaceutical; Cystitis; Cytokines; Disease Models, Animal; Excipients; Female; Imiquimod; Lactic Acid; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Polyethylenes; Polypropylenes; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2010 |
Editorial comment from Dr Olbert to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Imiquimod; Membrane Glycoproteins; Mice; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2010 |
Editorial comment from Dr Arum to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Imiquimod; Membrane Glycoproteins; Mice; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2010 |
Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Antiviral Agents; Disease Models, Animal; Female; Humans; Imiquimod; Immunocompromised Host; Mice; Mice, Hairless; Skin Diseases, Viral; Vaccinia; Vaccinia virus | 2011 |
Genome-wide expression profiling of five mouse models identifies similarities and differences with human psoriasis.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Animals; Cytokines; Disease Models, Animal; Epidermis; Gene Expression Profiling; Genomics; Humans; Imiquimod; Keratinocytes; Leukocytes; Mice; Middle Aged; Mitosis; Phenotype; Psoriasis; Receptor Protein-Tyrosine Kinases; Receptor, TIE-2; Transcription, Genetic; Young Adult | 2011 |
Modulation of the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: novel therapies for squamous cell carcinoma of the head and neck.
Topics: Aminoquinolines; Analysis of Variance; Animals; Carcinoma, Squamous Cell; Disease Models, Animal; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Head and Neck Neoplasms; Humans; Imiquimod; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Receptors, Opioid; Reference Values; Squamous Cell Carcinoma of Head and Neck; Transplantation, Heterologous; Treatment Outcome; Tumor Burden; Up-Regulation | 2012 |
Anti-inflammatory and immunomodulatory effects of bortezomib in various in vivo models.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dinitrofluorobenzene; Disease Models, Animal; Drug Compounding; Drug Evaluation, Preclinical; Drug Stability; Female; Hypersensitivity, Delayed; Imiquimod; Immunologic Factors; Irritants; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Peritonitis; Psoriasis; Pyrazines; Random Allocation; Temperature; Thioglycolates | 2011 |
Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs.
Topics: Administration, Cutaneous; Aminoquinolines; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Drug Delivery Systems; Humans; Hypromellose Derivatives; Imiquimod; Immunohistochemistry; Inflammation; Methylcellulose; Mice; Mice, Inbred C57BL; Nanogels; Nanoparticles; Particle Size; Permeability; Polyethylene Glycols; Polyethyleneimine; Psoriasis; Rheology; Skin; Surface Properties; Viscosity | 2012 |
IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antigens, Differentiation; Chemokine CCL3; Dermatitis; Disease Models, Animal; Gene Expression Regulation; Imiquimod; Immunity, Innate; Interleukin-22; Interleukins; Mice; Mice, Knockout; Neutrophil Infiltration; Neutrophils; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Skin; T-Lymphocytes | 2012 |
Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques.
Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents; Autophagy; Blotting, Western; Cytokines; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Imiquimod; Immunohistochemistry; Inflammation; Inflammation Mediators; Macrophages; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; NF-kappa B; Plaque, Atherosclerotic; Rabbits; Time Factors; Toll-Like Receptor 7; U937 Cells | 2012 |
Rorγt+ innate lymphocytes and γδ T cells initiate psoriasiform plaque formation in mice.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Dendritic Cells; Disease Models, Animal; Humans; Imiquimod; Interleukin-17; Interleukin-22; Interleukins; Macrophages; Mice; Mice, Knockout; Neutrophils; Nuclear Receptor Subfamily 1, Group F, Member 3; Psoriasis; Receptors, Antigen, T-Cell, gamma-delta; Skin; T-Lymphocytes | 2012 |
Assessment of an imiquimod-induced psoriatic mouse model in relation to oxidative stress.
Topics: Aminoquinolines; Animals; Antioxidants; Disease Models, Animal; Female; Imiquimod; Mice; Mice, Inbred BALB C; Oxidative Stress; Peroxidase; Psoriasis; Reactive Oxygen Species; Skin; Superoxide Dismutase; Superoxide Dismutase-1 | 2012 |
An alternative pathway of imiquimod-induced psoriasis-like skin inflammation in the absence of interleukin-17 receptor a signaling.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Disease Models, Animal; Female; Imiquimod; Interleukin-17; Interleukin-22; Interleukin-6; Interleukins; Macrophages; Mice; Mice, Knockout; Neutrophil Infiltration; Psoriasis; Receptors, Interleukin-17; Signal Transduction; Skin | 2013 |
IL-27 activates Th1-mediated responses in imiquimod-induced psoriasis-like skin lesions.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Cells, Cultured; Chemokines; Dendritic Cells; Disease Models, Animal; Epidermal Cells; Epidermis; Female; Humans; Imiquimod; Interleukin-23 Subunit p19; Interleukins; Keratinocytes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Psoriasis; RNA, Messenger; Th1 Cells; Tumor Necrosis Factor-alpha | 2013 |
Caspase-14-deficient mice are more prone to the development of parakeratosis.
Topics: Aminoquinolines; Animals; Caspases; Cell Differentiation; Cell Proliferation; Disease Models, Animal; Genetic Predisposition to Disease; Imiquimod; Keratinocytes; Mice; Mice, Knockout; Parakeratosis; Psoriasis | 2013 |
Blockade of phosphatidylinositol 3-kinase PI3Kδ or PI3Kγ reduces IL-17 and ameliorates imiquimod-induced psoriasis-like dermatitis.
Topics: Aminoquinolines; Animals; Class I Phosphatidylinositol 3-Kinases; Class Ib Phosphatidylinositol 3-Kinase; Dermatitis; Disease Models, Animal; Female; Gene Knock-In Techniques; Humans; Imiquimod; Interleukin-17; Lymph Nodes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Psoriasis; T-Lymphocyte Subsets | 2012 |
Imiquimod does not affect shedding of viable chlamydiae in a murine model of Chlamydia trachomatis genital tract infection.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Administration, Oral; Aminoquinolines; Animals; Chlamydia Infections; Chlamydia trachomatis; Disease Models, Animal; Female; HeLa Cells; Humans; Imiquimod; Immunity, Cellular; Immunoglobulin G; Mice; Mice, Inbred BALB C; T-Lymphocytes, Helper-Inducer; Treatment Outcome; Vagina | 2003 |
[Cutaneous epithelial tumors. Molecular biology and pathogenesis-based therapy].
Topics: Adjuvants, Immunologic; Alleles; Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cerebellar Neoplasms; Disease Models, Animal; Genes, Tumor Suppressor; Hedgehog Proteins; Humans; Imiquimod; Medulloblastoma; Membrane Proteins; Mice; Mutation; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Signal Transduction; Skin Neoplasms; Trans-Activators; Transcription Factors; Tumor Cells, Cultured; Veratrum Alkaloids | 2003 |
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models.
Topics: Aminoquinolines; Animals; Cells, Cultured; Cricetinae; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Imiquimod; Interferon Inducers; Interferon Type I; Interferon-alpha; Interferons; Mice; Mice, Inbred BALB C; Motor Activity; Poly I-C; Poly U; Recombinant Proteins; Ribavirin; Survival Rate; Time Factors; West Nile Fever; West Nile virus | 2004 |
Imiquimod is a strong inhibitor of tumor cell-induced angiogenesis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bowen's Disease; Cell Line, Tumor; Disease Models, Animal; Humans; Imiquimod; Interferon-alpha; Interleukin-18; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Papillomaviridae; Papillomavirus Infections; Sarcoma; Skin Neoplasms; Tumor Necrosis Factor-alpha | 2005 |
The influence of vaginally applied imiquimod on the course of Chlamydia trachomatis serovar D infection in a murine model.
Topics: Administration, Intravaginal; Aminoquinolines; Animals; Chlamydia Infections; Chlamydia trachomatis; Disease Models, Animal; Female; Genital Diseases, Female; Humans; Imiquimod; Interferon Inducers; Mice | 2005 |
Efficacy of an immune modulator in experimental Chlamydia trachomatis infection of the female genital tract.
Topics: Adjuvants, Immunologic; Administration, Intravaginal; Aminoquinolines; Animals; Chlamydia Infections; Chlamydia trachomatis; Disease Models, Animal; Female; Genital Diseases, Female; Humans; Imiquimod; Mice; Treatment Outcome; Vagina | 2006 |
Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytokines; Disease Models, Animal; Humans; Imiquimod; Mice; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2007 |
[The effects of imiquimod on an animal model of asthma].
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Asthma; Disease Models, Animal; GATA3 Transcription Factor; Imiquimod; Interleukin-4; Male; Mice; Mice, Inbred BALB C; Rats; Rats, Sprague-Dawley; T-Box Domain Proteins; Th1 Cells; Th2 Cells | 2007 |
Efficacy of imiquimod, an immunomodulatory agent, on experimental endometriosis.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Disease Models, Animal; Endometriosis; Endometrium; Female; Imiquimod; Random Allocation; Rats; Rats, Wistar | 2008 |
Imiquimod treatment of papilloma virus and DMBA /TPA-induced cutaneous skin cancer in Mastomys coucha: an unique animal model system useful for preclinical studies.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Aminoquinolines; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Imiquimod; Murinae; Papilloma; Papillomavirus Infections; Skin Neoplasms; Tetradecanoylphorbol Acetate; Treatment Outcome | 2007 |
Effect of imiquimod as an adjuvant for immunotherapy of genital HSV in guinea-pigs.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibody Formation; Disease Models, Animal; Female; Glycoproteins; Guinea Pigs; Herpes Genitalis; Imiquimod; Immunotherapy; Random Allocation; Viral Envelope Proteins | 1995 |
Treatment of primary herpes simplex virus infection in guinea pigs by imiquimod.
Topics: Aminoquinolines; Animals; Chlorocebus aethiops; Disease Models, Animal; Drug Administration Schedule; Guinea Pigs; Herpes Genitalis; Herpes Simplex; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Imiquimod; Interferon Inducers; Molecular Structure; Vero Cells | 1999 |